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Abstract 
 
The host response to a severe burn injury is characterised by exaggerated systemic 
inflammation. Early clinical manifestations include shock, respiratory failure, renal failure 
and immunosuppression 1. The signalling pathways that propagate the inflammatory 
response are unclear but have traditionally been thought to involve overspill of 
proinflammatory cytokines 2. The importance of microvesicles, sub-cellular membrane-
bound particles, is increasingly being recognised in the context of intercellular 
communication. Although circulating microvesicles are elevated in proinflammatory states 
such as sepsis 3, their relevance to the post-burn inflammatory response has not previously 
been evaluated. 
 
We hypothesised that circulating microvesicles play a crucial role in propagating the post-
burn inflammatory response. Our overall aims were to 1) optimise protocols for the 
processing and analysis of plasma samples for microvesicle content; 2) characterise the 
circulating microvesicle profile associated with severe burn injury; 3) develop in vitro 
techniques to assess microvesicle production and function. 
 
The major findings of this work were that microvesicles derived from leukocytes, 
neutrophils, monocytes and endothelial cells were significantly elevated within 24 hours of 
burn injury. Microvesicle levels fell rapidly and were significantly decreased by day two post-
injury. Total leukocyte- and neutrophil-derived microvesicles were significantly higher in 
non-survivors of burn injury as compared to survivors. In vitro studies demonstrated that 
neutrophil microvesicle release could be elicited by incubation with opsonised heat-killed 
cells. Pilot analysis of burn patient samples, using an endothelial co-culture assay, suggested 
that microvesicles may regulate the innate immune response to burn injury. 
 
These findings indicated that circulating microvesicles are an important component of the 
post-burn inflammatory response. Their precise activity is likely to be subtype-specific but 
the association of neutrophil-derived microvesicles with patient outcome alludes to a key 
role in burn pathophysiology.   
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1.1 Burns as a clinical problem 
 
Burn injuries are a major global public health issue, resulting in over 300,000 deaths per 
year, 95% of which occur in low income countries 4. In the United States, an estimated 
450,000 patients per year require medical treatment for burns. 40,000 are admitted to 
hospital and 3,400 will die from their injuries 5,6. In Europe, the annual incidence of severe 
burns is 0.2-2.9 per 10,000 inhabitants, where a severe burn is classified as an injury 
requiring specialised inpatient care 7. In 2014, over 3,000 UK patients required hospital 
admission following burn injury 8. Although the incidence of thermal injury has been 
reduced in middle and high-income countries, by the use of safety features such as smoke 
detectors 4, the care of patients with burn injuries requires considerable resources. This is 
due to prolonged hospitalisation and rehabilitation phases of care, as well as long-term 
wound management. For example, in elderly burn patients, the median length of hospital 
admission is 26 days 7, as compared to 9.4 days for other medical conditions 9. 
 
A severe burn injury is a unique example of critical illness, where an exaggerated 
inflammatory response characterizes the early phase of the condition. This is exacerbated 
by loss of the protective cutaneous covering, necessitating repeated surgical procedures. 
Clinical manifestations include shock, respiratory failure, renal failure and 
immunosuppression 1. Burn shock is a unique combination of distributive shock and 
hypovolaemia 10. The distributive component results from widespread tissue oedema, 
distant from the site of injury. It is secondary to the systemic inflammatory response but far 
exceeds any possible beneficial effect 11. Immunosuppression is linked to the higher 
incidence of sepsis in burn patients, in comparison to that seen following other injuries. 
Burn sepsis is also associated with a higher mortality 12. 
 
This project investigated the role of sub-cellular particles known as “microvesicles” in the 
context of post-burn inflammation. The characterisation of microvesicles in burned patients 
formed the first part of the study, followed by in vitro analyses of microvesicle production 
and function. In this introductory chapter I will detail what is currently known about the 
response to a severe burn injury. I will then explain the possible relevance of microvesicles 
to this process. This will lead onto our overall hypothesis and aims. 
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1.2 Aetiology and management of burn injuries 
 
Mechanisms of thermal injury 
Burn injuries can be subdivided into thermal, electrical, chemical or radiation injuries 13,14. 
Thermal injuries are further divided into flame, scald, contact and flash burns 13 and 
constitute the largest group of injuries, for patients managed both in and out of out of 
hospital 15. The precise aetiology varies according to age, with scalds being more prevalent 
in paediatric populations and flame burns more common in adults 1,7,16. 
 
Scalds typically result from spilling hot water or being immersed in hot bathing water. They 
tend to cause superficial dermal injuries 17. Flame burns tend to be more extensive in depth 
17 and area 18. They are associated with a greater inflammatory response, increased 
hypermetabolism and worse outcomes 18. Contact burns are less common and usually affect 
a small area, although they can occasionally cause severe damage to deep structures 19,20. 
Flash burns result from sudden intense heat, for example following explosion of volatile 
compounds 21. 
 
The likelihood of electrical burns is primarily determined by the voltage, with deep burns 
being common at higher voltages (>1000 volts) 22. However, due to differing tissue 
resistances, there can be extensive muscle and bone necrosis despite relatively minor 
external burns 23. Consequently, rates of limb or digit amputation are much higher in victims 
of electrical burns than those with thermal or chemical injuries 24. Chemical burns constitute 
a small fraction of total burn cases and the number is falling, primarily due to improved 
industrial safety regulations 25. There are specific implications for injuries caused by certain 
chemicals; for example, hydrofluoric acid exposure can result in systemic toxicity that is 
disproportionate to the area of skin involved 26,27. Significant radiation burns are also 
relatively uncommon but may occur following therapeutic radiotherapy for cancer 14,28. 
 
Classification of burns 
Burn wounds are assessed according to their location, depth and the total body surface area 
(TBSA) affected. This guides initial management, particularly regarding fluid resuscitation  29 
and determines if a patient should be referred to specialist burn centre. Burns were 
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historically judged by their external appearance alone but by the 1950s, it was realised that 
the burn depth was of crucial importance 30. Deeper burns result in fewer viable ectodermal 
appendages and a prolonged healing time 31.  Clinical examination is the most commonly 
used method for depth assessment, although it is inaccurate in 20-40% of cases, with a 
tendency towards over-estimation 31–33. The current depth classification stratifies injuries as 
follows 33–37: 
 
 Superficial 
 Partial thickness 
o Superficial dermal partial thickness 
o Deep dermal partial thickness 
 Full thickness 
 
Superficial burns involve only the epidermis. Although painful, they respond to simple 
wound care and heal without scarring within seven days. They are not included when 
assessing the percentage of body surface area that is injured. Most superficial dermal burns 
will also heal spontaneously but this process takes slightly longer – up to 14 days. They are 
associated with some blistering and are very painful. Deep dermal burns preserve only the 
deeper skin structures. Blisters will develop early and skin sensation is decreased. There is 
widespread destruction of blood vessels and the capillary refill time is prolonged.  Full 
thickness burns affect both layers of skin and may extend to deeper tissues. Injured skin 
sometimes has a leathery or waxy appearance. Due to destruction of nerve endings, these 
burns are classically painless. 
 
Initial management of burn injuries 
The priorities following a burn injury are to stop the burning process; assess the patient’s 
airway, breathing and circulation; determine the severity of the burn and commence early 
fluid resuscitation 38. Most severely burned patients are intubated early to secure the airway 
and provide respiratory support. Direct airway and pulmonary inhalation injury can occur 
and is associated with significant mortality 39. Secondary tissue damage is also a risk due to 
generalised oedema, a feature of the burn inflammatory response 40. Ventilatory strategies 
typically follow the lung-protective approaches that have been adopted for other ICU 
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patients. Specific interventions such as high-frequency oscillatory ventilation (HFOV) have 
not been shown to be beneficial in the burn population 41. 
 
The cardiovascular instability evident after a major burn is the result of hypovolaemic and 
distributive shock 40,41. Hypovolaemia results from intravascular fluid loss into both burned 
and unburned tissue and this process can continue for up to 48 hours 42. Myocardial 
depression may also arise, as a consequence of increased circulating pro-inflammatory 
mediators and abnormal calcium homeostasis 10,43. Fluid resuscitation is required to mitigate 
these factors and is a crucial aspect of early burn care 44. Although a number of formulas 
exist to guide fluid administration, the Parkland formula is the most well-known 1. It uses 
the patient’s weight and burn area to calculate a total volume of fluid to be infused over the 
first 24 hours post-injury. Although under-resuscitation is now uncommon, an increasing 
concern is the administration of excessive intravenous fluid 45. This places the burn patient 
at increased risk of pulmonary oedema, limb compartment syndrome and abdominal 
compartment syndrome 46. One retrospective study in Australia confirmed that fluid 
volumes significantly exceeded Parkland targets 47 and a multi-centre investigation in the US 
associated excess fluid with increased morbidity and mortality 48. Other research has 
demonstrated increased rates of pneumonia 49 and orbital oedema 50. Novel therapies 
designed to modulate the post-burn inflammatory response may lessen the requirements 
for such aggressive fluid therapy. 
 
The final aspect of initial burn management is the early surgical excision of dead tissue. The 
benefits of primary eschar excision were recognised as early as the 1950s 30. This approach 
was not adopted initially because it was associated with physiological instability and 
increased infective complications 51.  It was not until the 1970s that perioperative care of 
the severely burned patient had reached a level where aggressive burn excision was 
possible. This progress had been accompanied by improvements in surgical techniques 52. A 
retrospective paediatric study was published in 1973, comparing primary surgical excision 
and grafting with topical dressings only 53. In the second group grafting was performed only 
after spontaneous separation of dead tissue. The authors found that mortality and wound 
healing time was lower in children undergoing early surgery. A further retrospective analysis 
from the same centre, published in 1986, argued that prompt excision in all age groups 
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contributed to improved outcome 54. The early excision of necrotic tissue has been 
supported by a number of other studies 55–58 and it is now regarded as a standard of care 59. 
Although patients with inhalational injuries historically fared less well following early 
excision  60, it is possible that modern ventilation strategies would contribute towards better 
outcomes, if such studies were repeated. 
 
The rationale for early surgery is that it removes the key driver for ongoing release of 
inflammatory mediators, i.e. necrotic burnt tissue. This is thought to attenuate the systemic 
inflammatory response, reducing the rate and duration of secondary infective and 
metabolic complications 59.  There is certainly some experimental evidence to support this 
position. A study of paediatric patients found lower levels of inflammatory mediators, 
including IL-6 and TNF-α, in patients undergoing early burn excision 61. Other paediatric 
investigations identified less muscle breakdown 62 and infection 62,63 in the prompt surgery 
cohort. A possible criticism of these studies is that because early surgery was locally 
established as best practice, it was not possible to conduct randomised trials. The 
investigators therefore relied on recruiting the control cohort from other centres, raising the 
possibility that non-surgical aspects of care, such as wound dressing, might have affected 
outcomes. However, animal models provided further evidence, demonstrating reduced 
levels of macrophage hyperactivity 64 and inflammatory cytokines 65 following early burn 
excision. If it is genuinely the case that attenuation of the post-burn inflammatory response 
leads to improved patient outcomes, then augmentation of this apparent surgical benefit 
may be possible if novel mediators can be targeted. 
 
Burn scoring systems 
As well as being crucial to the initial management of the patient, classification of burns also 
allows prognostic scoring. Accurate scoring systems facilitate decision-making, clinical 
research and quality control 66. They also provide a context for measurements of clinical 
outcomes, the focus of increasing attention in the UK 67. It has long been established that 
mortality increases with a greater area of injury and that age is also a key factor 68. The Baux 
score, described in the 1960s, used a combination of age and burn surface area to generate 
a value that approximated to the mortality rate 69.  Comprehensive improvements in burn 
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care over the intervening years has rendered this particular scoring method pessimistic 70 
and a number of alternative systems have been devised. 
 
In 1982, Tobiesen et al published the abbreviated burn severity index (ABSI) 71. The authors 
used logistic regression analysis of 1352 patients to identify three additional variables that 
could be included to improve prognostication: gender, the presence of inhalation injury and 
the presence of full-thickness burns. It proved to be accurate in both the derivation and 
validation cohorts 67,72 and remains applicable today 73,74. A retrospective analysis of 1665 
patients, published by Ryan et al in 1998 75, confirmed that increasing age, larger burn area 
and inhalation injury were all risk factors for death. 
 
More recently, McGwin et al analysed a much larger data set of 54,219 burn patients, 
collected from multiple centres, to tackle some of the perceived weaknesses of earlier 
systems 76. They developed a model that incorporated pneumonia and co-existing trauma as 
predictive variables. It was validated in a separate group of 14,442 patients and found to be 
accurate. Others have argued that the inclusion of these additional variables does not 
substantially improve mortality prediction over earlier systems and is not warranted 77. A 
further complication is that it is difficult to reliably diagnose pneumonia in ventilated 
patients 78. A simpler model was published in 2009 by the Belgian Outcomes in Burn Injury 
(BOBI) group 66. The authors modified the dichotomous approach used by Ryan et al, 
splitting age and percentage burn area into multiple categories, as with the ABSI. Although 
the 5246 patients analysed were from a single centre, the model has been externally 
validated in several cohorts 79,80, including a higher-risk ICU population 81. This scoring 
system is user-friendly and has been adopted in our centre, in conjunction with the ABSI. 
 
The scoring systems described above are relatively simple and easy to calculate. In contrast, 
the risk prediction models published for general ICU patients tend to employ larger numbers 
of physiological variables. Historically there has been some success at simplification. 
APACHE II (acute physiology and chronic health evaluation II), published in 1985, reduced 
the number of variables from the 34 used in the original APACHE to 12 82. However, 
comparison with models that use fewer variables suggests that it is the complexity of these 
systems that gives them their prognostic power 83. Increasing recognition of the 
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heterogeneity of syndromes such as sepsis is driving the use of large data sets to 
characterise disease phenotypes 84, although this approach can be problematic 85. These 
developments are likely to prove relevant to the care of patients with severe burns, due to 
the high prevalence of “ICU” conditions such as sepsis and the acute respiratory distress 
syndrome (ARDS) 86–88. 
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1.3 Local response to injury 
 
Three zones of burn intensity were proposed by Jackson in 1953: the central zone of 
coagulation, the intermediate zone of stasis and the outer zone of hyperaemia 30. The zone 
of coagulation is characterised by complete blood vessel obliteration and skin necrosis; it is 
non-viable. The hyperaemic zone comprises structurally normal skin, which is metabolically 
active. Vasodilation is present, blood flow is increased and full recovery is usual 17. The zone 
of stasis, adjacent to the area of necrosis, is viable but at risk of progression. Inflammatory 
cell infiltration, compromised perfusion and oxidative stress increase this risk 89,90. 
Consequently, a crucial part of burn care is to prevent conditions that promote progression 
of this zone over the first 48-72 hours, such as vasoconstriction and desiccation 31. Both 
early apoptosis and delayed necrosis are present in the zone of ischaemia 91. 
 
A number of inflammatory mediators are released into the surrounding tissues following a 
burn injury, including adenosine triphosphate (ATP) 92. ATP is an example of a damage-
associated molecular pattern molecule (DAMP) and as discussed below, these molecules are 
key to the innate response to tissue injury. Although inflammation promotes wound healing, 
by clearing cellular debris and protecting against pathogens, excessive inflammation can 
result in collagen degradation and keratinocyte apoptosis 90. This contributes to burn wound 
progression. 
 
The inflammatory phase of wound healing, which occurs acutely, overlaps with the 
proliferation phase, which begins after several hours but can continue for weeks 93. Burn 
depth is the major factor affecting the healing of burn wounds. Because the epidermis is 
derived from ectoderm, it is capable of regenerative healing 1. Deep dermal injuries result in 
fewer ectodermal appendages surviving and therefore slow tissue regeneration 31. Healing 
of deeper wounds depends on migration of keratinocytes from surrounding uninjured tissue 
and/or from meshed skin grafts 1. Full thickness burns result in destruction of all 
appendages and require skin grafts as they will not regenerate 42. The maturation phase of 
healing persists for months post-injury and encompasses maturation of the regenerated 
epidermis, as well as contraction of the burn wound, a myofibroblast-mediated process 93. 
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Inhalation injury 
The lungs may be injured directly by inhalation of smoke. This is predominantly a chemical 
rather than thermal effect, due to efficient heat dispersion in the upper airway 39,94. The 
initial result is an increase in bronchial blood flow, contributing to pulmonary oedema 95. 
This may play a significant role in the extension of the injury from the airways to the lung 
parenchyma and is mediated by nitric oxide 96. Reactive oxygen and nitrogen species 
contribute to tissue injury and increased pulmonary vascular permeability, leading to small 
airways obstruction. Overventilation of the non-obstructed respiratory units promotes 
further inflammation and tissue injury 96. 
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1.4 Systemic response to burns 
 
The stress response to severe burn injury is characterised by a marked inflammatory 
component 97. The acute phase starts immediately after trauma, persists for several weeks 
and its magnitude is related to the burn size 98. The inflammatory response progresses with 
time 99, contributing to remote organ damage and in severe cases leading to multiple organ 
dysfunction syndrome (MODS) 100. The long-term, chronic consequence is a persistent 
metabolic disturbance that causes a profound catabolic state 101,102. Inflammatory 
mediators, such as TNF-α, IL-1β and IL-6 are elevated in the early phase but do not 
necessarily correlate with clinical progress 103. Moreover, the pathway that leads from local 
release of mediators at the burn injury site to the development of early systemic 
inflammation remains undefined. 
 
The systemic inflammatory response syndrome 
In 1992, an American College of Chest Physicians/Society of Critical Care Medicine 
(ACCP/SCCM) consensus conference was held, with the principle aim of standardising the 
definitions of sepsis, shock and organ failure 104. Although the primary goal was to define 
the host response to infection, it was emphasised that a very similar response can result 
from a variety of insults, including trauma, pancreatitis and burns. The term “systemic 
inflammatory response syndrome” (SIRS) was proposed to describe this process. It was 
defined as the presence of two or more of the following parameters: 
 
 Core temperature > 38⁰C or <36⁰C 
 Heart rate > 90 beats/minute 
 Respiratory rate > 20 breaths/minute or PaCO2 32 mmHg 
 White cell count > 12 x 109/litre or < 4 x 109/litre 
 
The term “sepsis” was reserved for those cases where SIRS was a result of documented 
infection. Patients with SIRS were recognised to suffer from organ dysfunction to a highly 
variable degree and the term “multiple organ dysfunction syndrome” (MODS) was proposed 
to describe this disorder. It was defined as the presence of altered organ function, requiring 
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intervention to maintain homeostasis. A requirement of these definitions was that the 
organ dysfunction was a result of the systemic reaction to the initial insult 105, an important 
concept of great relevance to burns. 
 
Although widely adopted 106, the limitations of this approach to inflammation were 
recognised early on. The definitions were considered sensitive but they lacked specificity for 
any particular insult 105. More than two thirds of critically ill patients may meet the SIRS 
criteria and some argued that it was effectively useless 107.  The authors themselves 
acknowledged that the criteria were likely to evolve over time, as knowledge improved 108. 
A further conference was held in 2001, with the hope that novel biomarkers would allow 
better prognostication and diagnosis 106. Unfortunately, this did not prove to be the case 
and the definitions were left unchanged. Those involved commented that the biochemical 
features of inflammation may be fairly consistent, regardless of the initial insult. 
 
The limitations of using clinical criteria to identify inflammatory states echoes the difficulties 
experienced with ARDS, as described below. This was underscored by a recent large trial 
which demonstrated that not only are the SIRS criteria non-specific, they are also 
insufficiently sensitive for identifying serious infection 109. The most recent 2012 Surviving 
Sepsis guidelines do not actually mention SIRS in their diagnostic criteria 110 and this reflects 
an increasing recognition of the heterogeneity of sepsis 111. In burn patients, awareness of 
the ubiquity of the SIRS criteria may even distract physicians from occult infections 112. 
Elucidation of inflammatory pathways in burn patients is therefore important for two 
reasons. Firstly, it may allow identification of those patients who would benefit from 
modulation of post-burn inflammation 113. Secondly, it may facilitate recognition of serious 
infections, something that is known to be difficult in this population 87. Clinical criteria alone 
are insufficient to perform either of these roles. 
 
Cardiovascular dysfunction 
The initial clinical manifestations of the inflammatory response are generalised oedema and 
hypovolaemia 113. This necessitates aggressive fluid resuscitation as described above.  Early 
experimental physiology partly explained this by identifying increased vascular permeability, 
although it was not sufficient to account for such extensive acute oedema. Instead, 
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increased extravascular osmotic pressure was found to draw water from the intravascular 
space 114. Fluid resuscitation using intravenous colloid was historically contraindicated, as it 
was thought to worsen oedema via this osmotic “pull” 115. More recent evidence suggests 
these fears are unfounded 41. The time to peak oedema formation increases with burn size; 
animal studies suggest that after a 40% burn the peak does not arise until 12 hours 116. The 
oedema plateau is thought to occur primarily due to improved clearance, as the fluid and 
protein flux persists for several days 117. In the acute phase, burn oedema can cause life-
threatening compromise of the airway, particularly in the presence of facial or airways burns 
37. The associated hypovolaemia can be profound, causing severe cardiovascular instability if 
not treated promptly 1. 
 
Respiratory dysfunction 
Patients with severe burn injuries commonly develop respiratory dysfunction and this is the 
organ system most frequently affected, in both the early and late stages of post-burn critical 
illness 118. Burn patients are at risk from respiratory compromise due to a range insults 119. 
In addition to direct inhalational injury, as described above, the lungs can be exposed to 
large quantities of circulating inflammatory mediators, as they receive 100% of the cardiac 
output 120. However, the precise mechanisms linking thermal injury  with this remote organ 
damage are unclear 121. Neutrophil invasion is known to be a key step 122 and this process is 
mediated by CXCR2 120. Our research group has previously demonstrated that intravascular 
lung-marginated monocytes play an important role in the development of lung injury, 
following both direct pulmonary and indirect extra-pulmonary insults 123–126, although burn 
injuries were not investigated. Gut-derived factors may also be important to the 
pathogenesis 121. 
 
One manifestation of respiratory dysfunction is ARDS and this has been associated with 
burn injuries 127. The pathological hallmark of ARDS is diffuse alveolar damage (DAD) but 
identification of this requires lung biopsy or examination at autopsy 128. Attempts have 
therefore been made to diagnose ARDS using clinical criteria.  In 1994, the American-
European Consensus Conference defined ARDS as the presence of impaired oxygenation 
and bilateral pulmonary radiograph infiltrates, in the absence of left heart failure 129. 
Unfortunately, the diagnostic accuracy of this model is low and up to half of the patients 
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meeting the criteria do not have ARDS 130. The 2012 Berlin definition attempted to address 
some of the limitations of previous systems and graded ARDS into different severities 131. 
Despite these revisions, diagnostic accuracy remains poor and a direct measure of lung 
injury is lacking 132. In burn patients, the reported incidence of ARDS varies from 2-17% 88,127, 
although in those requiring mechanical ventilation, the rate may be as high as 40-50% 119,133. 
The influence on post-burn outcome is unclear. A paper based on the 1994 criteria did not 
find a significantly greater mortality in burn patients with ARDS 88 but a study using the 
Berlin definitions found that more severe ARDS was associated with an increased risk of 
death 127.  These discrepancies in incidence and outcome may reflect the poor diagnostic 
ability of the clinical criteria. 
 
Severe burns usually necessitate repeated surgical procedures and these may require 
transfusion of considerable volumes of blood products. This places patients at risk of 
transfusion-related acute lung injury (TRALI) 134. Thought to be initiated by donated anti-
leukocyte antibodies, this leads to increased microvascular permeability and pulmonary 
oedema 135.  A further concern following severe burns is the predisposition to respiratory 
infections 133. Inhalation injuries increase the risk of subsequent pneumonia and infection is 
also an independent risk factor for death 136. Multidrug-resistant organisms are isolated in a 
significant proportion of cases 137 and this is likely to be an increasing problem in the future. 
Because systemic inflammation is so prevalent, it can be difficult to identify the onset of 
new respiratory infections 138. Elucidation of inflammatory pathways could have clinical 
utility in this context, as measurement of specific mediators could potentially be used to 
exclude infection 86,139,140. 
 
Renal dysfunction 
The kidneys are also commonly affected following severe burn injuries, particularly in the 
second week post-injury 118. The risk of renal dysfunction increases with age 141 and burn 
size 142,143. The incidence of renal dysfunction reported in the literature varies from 1% to 
36%, according to the burn population studied and the criteria used 144. There is also 
variability in the published outcomes but historically, the mortality rate was over 80% in 
those patients requiring renal replacement therapy (RRT) 142,145,146. A consensus definition of 
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acute renal failure (ARF) in critically ill patients was published in 2004 147. This quantified 
renal dysfunction into five categories using the “RIFLE” criteria: 
 
 Risk 
 Injury 
 Failure 
 Loss of function 
 End-stage renal disease 
 
Several studies have subsequently applied these criteria to ascertain the incidence of acute 
kidney injury (AKI) in patients with burn injuries 141,144,148–150. The incidence found by these 
investigators varied from 24% to 53% but the rate of “failure”, requiring RRT, ranged from 
3% to 28%. Further refinements of the RIFLE criteria have been proposed by the “AKIN” and 
“KDIGO” groups 151; it is unclear what impact these systems would have on the variability of 
renal dysfunction incidence in burn patients. Importantly, the outcome of patients who are 
affected seems to be improving 149. 
 
A number of factors are thought to contribute to the pathophysiology of AKI post-burn 
injury, including pro-inflammatory mediators, sepsis and nephrotoxic drugs 144,146,150,152. 
Inadequate fluid resuscitation was considered an important cause of renal dysfunction and 
early fluid therapy has been shown to reduce mortality from ARF 153.  Other studies found, 
however, that most patients with AKI received appropriate quantities of fluid and argued 
that the inflammatory response was a more important factor 154. 
 
The incidence of AKI is highest in the most unwell patients, as determined by scores such as 
ABSI 150,155. In patients with severe burns, renal failure rarely occurs in isolation and 
frequently progresses to multi-organ failure 118,156. In addition to the circulatory, respiratory 
and renal dysfunction described above, severely burned patients are also at risk of liver, 
haematological and gastrointestinal failure 157. A concept of organ “crosstalk” is emerging, 
which suggests that injured systems, in particular the kidneys, can exacerbate inflammatory 
damage occurring elsewhere 158.  
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Hypermetabolism 
The metabolic response to trauma was first discovered by Cuthbertson in the 1930s 159. He 
found that urinary losses of nitrogen, potassium, phosphorus and sulphur were all increased 
in patients with long bone fractures, to a greater extent than would be expected by local 
tissue injury. He concluded that this represented catabolism of lean tissue and subsequent 
investigations revealed a co-existing rise in oxygen consumption. In burn patients, the acute 
systemic response to injury starts immediately after injury 10 and the clinical features are 
described above. From a metabolic viewpoint, this phase is characterised by low oxygen 
consumption, low glucose tolerance and low catabolism 101. The chronic response is 
characterised by hypermetabolism and increased catabolism. These phases have been 
described as the “ebb” and “flow” of the burn response 160. 
 
The magnitude of the hypermetabolic response is related to the size of burn injury 98. In the 
early part of this phase, the metabolic rate increases by 120-180%. This steadily decreases 
with time but hypermetabolism remains detectable at 12 months post-injury 161,162. The 
severity and duration of the hypermetabolic response is significantly longer than that seen 
following other insults 101,163. Distinctive hormonal changes occur, with increased 
catecholamine and cortisol levels, thyroid axis suppression, inappropriately low growth 
hormone secretion and reduced IGF-1 production 164,165. This drives increased proteolysis, 
lipolysis and glycogenolysis, with net nitrogen loss 98. The consequence is a prolonged 
reduction in lean body mass, with a profound loss of function that necessitates a 
considerable period of rehabilitation 102. The liver and skeletal muscle are the major sites of 
increased oxygen consumption post-burn injury 101,166. At the cellular level, mitochondrial 
dysfunction has been demonstrated in muscle tissue and may be an important factor 162. 
 
Current treatments can ameliorate some of the consequences of hypermetabolism but do 
not suspend it. Propranolol opposes the action of elevated catecholamines, decreases 
energy expenditure and attenuates muscle loss 167. Oxandrolone, an anabolic steroid, has 
been shown to improve lean body mass and reduce length of stay 168. These agents have 
been studied in patients with more severe injuries (greater than 30-40% TBSA) and are used 
in our centre for patients with a TBSA of over 40%. Non-pharmacological approaches include 
early surgery and adequate nutrition; patients with burn injuries develop specific 
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deficiencies of micronutrients such as copper and zinc 163. Some studies have suggested that 
early, aggressive nutritional support may attenuate the hypermetabolic response but the 
evidence is  inconclusive 169. 
 
The mechanisms that underlie prolonged hypermetabolism are not fully understood but are 
presumed to involve complex mediator cascades 170. Cytokines (such as TNF-α, IL-1 and IL-
6), reactive oxygen species and neutrophil-adhesion molecules are all capable of regulating 
the hypermetabolic response 163,170. This incomplete understanding may explain why 
attempts to modulate post-burn hypermetabolism have had mixed results. 
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1.5 Pathogenesis of the inflammatory response to burn injury 
 
Patients with a heterogeneous group of traumatic injuries, including burns, develop a state 
of systemic inflammation. This has been labelled SIRS, although this definition has certain 
limitations, as described above. In severe cases, this can lead to multi-organ failure and a 
number of mechanisms have been proposed to explain this process, which are thought to 
overlap 171. They include increased production of cytokines, microcirculatory dysfunction 
with impaired global oxygen delivery, dysregulated endothelial cell-leukocyte interactions 
and translocation of intestinal microflora. Before consideration can be given to the possible 
roles of microvesicles in propagating the inflammatory response to burn injury, it is 
necessary to review the current paradigm. 
 
Innate immune response 
In vertebrates, two systems constitute immunological defence: the innate immune system 
and the adaptive immune system 172,173. The innate immune system can be considered the 
first line of defence and evolved before the divergence of vertebrates and invertebrates 172. 
The cellular component of the innate system includes phagocytes (such as neutrophils, 
monocytes and macrophages) which are responsible for mediating the innate response 174. 
The complement system is the effector of the humoral innate system 175. Both the cell-
mediated and humoral components also have essential roles in regulating the adaptive 
immune response 176. 
 
The innate immune system is not completely non-specific but is able to discriminate 
between “self” and various pathogens 174. These pathogens are recognised by pattern-
recognition receptors (PRR), which are germline-encoded and limited in number. In the 
context of infection, these PRRs recognise microbial components, termed pathogen-
associated molecular patterns (PAMPs) 177. One of the best studied PAMPs is 
lipopolysaccharide (LPS), which is a vital structural component of the outer membrane of 
Gram-negative bacteria and is a potent immunostimulant 178. An important sensor for LPS is 
Toll-like receptor 4. The Toll-like receptors (TLRs), of which there are 11 in humans, are a 
major group of PRRs and are highly conserved in evolution 174. Via two signal transduction 
pathways, TLR activation leads ultimately to upregulation of nuclear factor-kappa B (NF-κB), 
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a key transcription factor. NF-κB transcribes genes that encode for inflammatory cytokines 
and chemokines, regulate expression of adhesion molecules and promote survival of 
neutrophils 179. 
 
DAMPs 
Damage-associated molecular patterns (DAMPS), also known as alarmins, are analogous to 
PAMPs but are of endogenous origin 180. They are released following cell necrosis caused by 
insults such as trauma, radiation, ischaemia and burns. They are therefore important in the 
formation of “sterile” inflammation. Apoptotic cells do not release DAMPs 181 but it is 
becoming evident that cells can secrete them under conditions of high stress 182. DAMPs 
differ from other inflammatory mediators, such as classical cytokines, because they usually 
serve essential intra-cellular functions 183. This represents a further analogy with PAMPs. 
Examples of DAMPs include galectins, annexins, heat-shock proteins and the “dual function” 
cytokines IL-1α and IL-33 181,184,185. 
 
The role of high mobility group protein B1 (HMGB1) as a DAMP has received much attention 
and it is thought to be a key mediator of inflammation 180. HMGB1 was originally discovered 
as a chromatin-binding factor that bends DNA, allowing assembly of specific protein 
complexes 186,187. It contributes to nucleosome stability and regulates a number of key 
nuclear events, including DNA repair and gene transcription 188. Extracellular HMGB1 
promotes inflammation in the context of both infectious and sterile tissue damage, acting 
synergistically with endogenous and exogenous inflammatory mediators 186. Further 
evidence of its importance was provided by the finding that the post-trauma inflammatory 
response is diminished by blocking HMGB1 activity 189. More recently, elevated HMGB1 
levels have been found in patients with burn injuries 190. This was noted early after burn 
injury and the levels in non-survivors were significantly higher than in survivors. HMGB1 
binds multiple receptors, including TLR4 but its ability to recruit leukocytes is dependent on 
formation of a heterocomplex with the chemokine CXCL12, which binds to the CXCR4 
receptor 182. 
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Cellular recruitment 
Neutrophils, monocytes and macrophages are activated by DAMPs in response to tissue 
damage 191,192. Macrophages act as sentinel cells that initiate neutrophil recruitment, by 
inducing processes such as cytokine release and increased vascular permeability 193. 
Macrophages isolated from sites of tissue damage release TNF-α, interleukin-6 (IL-6) and 
inducible nitric oxide synthase (iNOS), when exposed to hypoxia. This may be an important 
factor in macrophage activation at the local level 194. Most tissue macrophages are derived 
from circulating monocytes, although under steady-state conditions considerable local 
proliferation occurs. Following inflammatory insults there is increased dependence on 
recruitment of circulating precursors 194,195. This is dependent on chemokines such as 
monocyte chemoattractant protein-1 (MCP-1), which is elevated following thermal injury 
and may in turn be influenced by TNF-α 196,197.  
 
Neutrophils have long been considered the primary effector cell of the sterile inflammatory 
response 198. They are rapidly activated following tissue injury and their lifespan is also 
lengthened, which results in the increased presence of primed neutrophils at the site of 
inflammation 193,199. Priming of neutrophils, which has been demonstrated to occur 
following major tissue damage, results in augmented chemotaxis, adhesion, release of 
reactive oxygen species and  secretion of proteases 200–202. Priming agents, such as 
granulocyte macrophage colony stimulating factor (GM-CSF) and tumour necrosis factor-
alpha (TNF-α), are increased following trauma 191 and severe burn injuries 98. 
 
Although neutrophils contribute to wound healing, they have the potential to cause 
significant collateral tissue damage and their recruitment is tightly controlled 203,204. 
Following recognition of tissue damage by sentinel cells, such as macrophages and mast 
cells, neutrophils are recruited rapidly. The recruitment cascade involves tethering, rolling, 
adhesion and transmigration 193. A key initial step is the expression of endothelial adhesion 
molecules, including E-selectin and P-selectin, close to the area of injury 203,205. These 
mediate tethering, along with L-selectin expressed on the neutrophil surface. Rolling of the 
neutrophil along the endothelium allows it to bind with chemokines, triggering expression 
and conformational activation of integrins on the neutrophil. Interestingly, inhibition of 
neutrophil rolling in animal models of burn injury reduces subsequent oedema and tissue 
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necrosis 206. The integrins interact with endothelial ICAM-1, which arrests the neutrophil and 
permits firm adhesion. Finally, transmigration across the endothelial barrier occurs, a 
process mediated by the proteins PECAM-1 and VE-cadherin, amongst others 205. Following 
the initial neutrophil extravasation to the site of injury, there is a secondary migration of 
monocytes. This is promoted by extravasated neutrophils and is assisted to some extent by 
platelets 207,208. 
 
Cellular activity 
Once in the site of injury, primed neutrophils undergo their primary function of 
phagocytosing damaged cells and matrix proteins, along with any bacteria that may be 
present 93. Phagocytosis triggers an increase in oxygen consumption, through the activity of 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, resulting in production of 
reactive oxygen species (ROS). This is known as the neutrophil respiratory burst 209. 
Examples of ROS include the superoxide anion (O2
-), the hydroxyl radical (•HO) and 
hydrogen peroxide (H2O2). Intracellular granules also release an array of biologically active 
proteases and peroxidases, the latter requiring H2O2 as a co-substrate 
210,211. During this 
phase of activity, the neutrophils undergo a transcriptional burst that underpins their roles 
in early inflammation, resolution of inflammation and wound healing 212. 
 
The potency of the ROS and enzymes released by neutrophils means there is great potential 
for host tissue damage in inflammatory syndromes. This may occur via several mechanisms, 
including premature neutrophil activation, extracellular release of cytotoxins and failure to 
adequately terminate acute inflammation 213. Neutrophil elastase has been implicated in the 
pathogenesis of lung disorders such as emphysema and acute lung injury 214. The 
accumulation of extravascular fluid following burn injury is a particular problem and 
neutrophil-derived heparin binding protein may be a mediator of this process 215. 
 
In addition to phagocytosis, monocytes and their progeny have important roles in 
immunomodulation and antigen presentation 209. A distinction is made between “classical” 
and “non-classical” monocytes subsets. Classical or “inflammatory” monocytes differentiate 
into tissue macrophages and release inflammatory mediators. Their accumulation is slower 
than non-classical or “resident” monocytes, which perform a patrolling function 195. A 
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number of studies have demonstrated monocyte hyporesponsiveness following burn injury. 
Development of monocytes in bone marrow is disturbed in animal models of burn 216 and 
their differentiation into dendritic cells is impaired 217. Low human leukocyte antigen-DR 
(HLA-DR) expression has been found in patients with burn injuries and this correlates with 
both mortality and the risk of sepsis 218,219. In addition, there is increased appearance of 
immunosuppressive M2 monocytes post-burn injury, which increases susceptibility to 
infection. This is reversed by administration of propranolol, which suggests monocyte 
function is strongly influenced by catecholamines 220,221. 
 
Oxidative stress and nitric oxide 
ROS form continuously as a by-product of aerobic respiration and are also necessary for cell 
signalling 222,223. In health, a balance exists between the formation of ROS and their removal 
by scavenging compounds. When this reduction-oxidation (redox) balance is disturbed, by 
either excess ROS production or impaired scavenging, a state of oxidative stress occurs 224. 
Oxidative tissue damage is elicited by the uncontrolled levels of ROS, as well as by reactive 
nitrogen species (RNS) and reactive lipid species. It has been known for some time that 
oxidant-induced lipid peroxidation occurs early following burn injury, reflecting widespread 
cell membrane disruption 225.  An end product of lipid peroxidation is the formation of 
malondialdehyde (MDA). Levels of MDA rise within the first 24 hours of injury, in 
accordance with the severity of injury, with the oxidative stress persisting for weeks after 
injury 226. Increased circulating concentrations of lipid peroxides have been detected 
following burn injury 227. 
 
Numerous pathways result in ROS production but there are four main sites of ROS 
generation: mitochondrial electron transport, peroxisomal fatty acid metabolism, 
cytochrome P450 reactions and NADPH oxidase activity. The latter occurs particularly in the 
phagocytic respiratory burst, as described above 223. As well as being initiated by 
components of the innate immune response such as neutrophils, oxidative stress in itself 
amplifies the systemic inflammatory response. This is thought to be mediated by increased 
cytokine secretion, via ROS-dependent signalling pathways that activate NF-κB 227,228.  
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RNS also play a key role in post-burn oxidative stress and are produced by the reaction 
between nitric oxide (NO) and ROS 223. Increased NO production occurs following burn injury 
and this may contribute to vascular leak, as well as mediating vascular tone 229. Some 
studies demonstrate a  correlation between burn size and NO levels, although this finding is 
not universal 230.  Activity of the inducible form of nitric oxide synthase (iNOS) underlies the 
higher NO levels and iNOS has been detected in burned human skin. NO reacts with 
superoxide ion to form peroxynitrite. This may have an important direct role in inducing 
remote organ damage, such as pulmonary dysfunction 231.  When protonated, it also 
produces hydroxyl and nitrogen dioxide radicals 223. The net result is further amplification of 
oxidative stress, leading to direct cellular damage and upregulation of the inflammatory 
process. Antioxidant therapy with agents such N-acetylcysteine (NAC) results in biochemical 
and clinical evidence of oxidative stress attenuation 227,232,233. 
 
Cytokine and chemokine response 
Soluble cytokines are established as important mediators of the post-burn inflammatory 
process and have been investigated in many studies. Following initiation of the 
inflammatory cascade, a number of pro-inflammatory cytokines are rapidly upregulated 234. 
TNF-α is a potent mediator of inflammation. It activates neutrophils and macrophages, 
induces endothelial adhesion molecule expression, enhances vascular leak and is pro-
coagulant 235. It also induces secretion of secondary cytokines such as IL-1β and IL-6. IL-1β 
has potent pro-inflammatory effects and elevated levels have been detected in animal 
tissue following burn injury and non-survivors of thermal trauma 103,236–238. IL-6 induces 
production of acute phase proteins and regulates B-lymphocyte function. Early studies 
found the greatest IL-6 response in patients with larger injuries 103 and higher levels are also 
associated with the presence of post-burn sepsis 239. It is the cytokine linked most 
consistently with post-injury complications and injured skin itself seems to be a significant 
source of IL-6 240. The growth factors granulocyte colony-stimulating factor (G-CSF), 
granulocyte-macrophage colony-stimulating factor (GM-CSF) are also upregulated following 
burn injury, with levels partially influenced by burn size 98,234. G-CSF is released mainly from 
monocytes and macrophages and acts to increase neutrophil proliferation and function. 
Although it is found at significantly higher levels in non-survivors of burn injury 238, its action 
its actually thought to be protective, reducing the risk of post-burn infection 235,241.  
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The chemokine IL-8 elicits significant neutrophil accumulation at sites of inflammation and 
levels have been found to correlate with burn mortality 237,242, as is the case with monocyte 
chemoattractant protein-1 (MCP-1/CCL2) 238. MCP-1 specifically attracts monocytes and 
macrophages and is produced constitutively but is also induced by oxidative stress, growth 
factors and cytokines such as TNF-α 197,243,244. It is released by several cell types, including 
epithelial, endothelial and microglial cells. Of note, production of MCP-1 by non-
inflammatory skin cells is upregulated following burn injury 245. 
 
The large-scale post-burn upregulation of pro-inflammatory cytokines and chemokines is 
accompanied by increased production of anti-inflammatory cytokines 246. Suppression of 
immune responses is important to avoid chronic inflammation and autoimmunity 247.  
Interleukin-10 (IL-10) is the most widely studied anti-inflammatory cytokine in the context 
of burn injury. It exerts an inhibitory effect on the inflammatory response, by suppressing 
pro-inflammatory cytokine production 237,248. Several studies have demonstrated increased 
levels of IL-10 following burn injury and higher levels are also associated with a worse 
prognosis  190,234,248,249. Animal models suggest that neutrophils are the major source of IL-10 
following burn injury 250. 
 
Transforming growth factor-β (TGF-β) controls several aspects of the inflammatory response 
and accelerates wound healing 100,247,251. Levels increase following burn injury and over-
production has been linked to excessive suppression of the immune system 252,253. TGF-β 
also exerts pro-inflammatory effects post-burn, for example by inducing differentiation of 
immature T cells into inflammatory Th-17 cells 254. This dual function is not exclusive to TGF-
β, with other cytokines such as IL-6 capable of exhibiting both pro- and anti-inflammatory 
effects 255. Three further anti-inflammatory cytokines have been identified more recently: IL-
27, IL-35 and IL-37. These have been proposed as potential therapeutic targets in the 
context of inflammation 247. Cytokine inhibition has been investigated as a means of 
modulating the post-burn inflammatory response but immunotherapy has not yet 
demonstrated a clinically-relevant effect 113,248. 
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Complement 
The complement system is a key component of the innate response to both foreign and 
altered host cells 191. It is composed of a collection of plasma proteins, being produced 
mainly in the liver, and cell surface proteins 256. The complement system has four major 
functions: target recognition, opsonisation to assist phagocytosis, stimulation of 
inflammation via anaphylatoxin generation and direct cell killing by the membrane attack 
complex (MAC) 257.  The MAC forms by self-association of C5b, cleaved from C5, with C6-C9. 
Any altered host cell, debris or microorganism that lacks specific identifying molecules will 
support complement deposition, via the “alternative pathway”. This is permanently active 
and results in covalent binding of C3b, an activated form of component C3, which opsonises 
targets and recruits leukocytes 258. The alternative pathway can be amplified by properdin, 
which recognises DAMPs and PAMPs 259,260. Activation of the “lectin” and “classical” 
pathways occurs via pattern recognition molecules, such as C1q and ficolins. All three 
pathways converge at the point of C3 cleavage, which amplifies opsonisation by C3b, lyses 
cells via formation of the MAC and its insertion into target membranes, promotes 
inflammation, and activates the endothelium 256,258,261. Although MAC formation is 
conventionally considered to be a C3-dependent process, more recent evidence 
demonstrated that thrombin can act as a C5 convertase, which links complement to 
coagulation 259,262. 
 
Early complement activation has been clearly demonstrated following major injury, with the 
magnitude of activation correlating with injury severity 259,262. The alternative pathway takes 
a central role but there is also an association between thrombin generation and 
complement activation following trauma. Activation of the complement pathway following 
burn injury has been acknowledged for some time, with the first report being published in 
1963 263. Subsequent animal models of burn demonstrated that this activation occurred 
within minutes of injury and resulted in the deposition of C3 in burned tissue. Furthermore, 
this complement activation contributed to lung oedema 264,265. In vitro studies showed that 
heat-killed cells could fix C3, which in turn led to neutrophil recruitment 266. In burn 
patients, complement has been shown to influence neutrophil function post-burn 267,268 and 
circulating C3 levels inversely correlate with injury severity, consistent with its deposition in 
injured tissue 269. 
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Inflammation and coagulation 
Systemic inflammatory states are frequently accompanied by simultaneous activation of the 
coagulation system. This close functional linkage can be traced back to the early stages of 
evolution and is preserved throughout vertebrates 270. Interestingly, the pattern recognition 
molecules of the innate immune system, such as C3, function in a similar manner to contact 
factors of the coagulation cascade. Increasing recognition of the interface between 
inflammation and coagulation generated a great deal of interest, particularly in the context 
of sepsis, where physiologic anticoagulants were found to be depleted 271. Unfortunately, 
attempts to modulate this hypercoagulable state have not proved successful, despite the 
early promise of activated protein C 272. 
 
Given the close physiological relationship of inflammation and coagulation, as well as the 
activation of clotting associated with major trauma 273, it was assumed that severe burn 
injuries would also be associated with a hypercoagulable state 274. Several investigations 
have supported this assumption, with both hypercoagulability and hyperfibrinolysis 
identified early after burn injury 274–276. Furthermore, the magnitude of the clotting 
activation was found to be related to organ dysfunction and clinical outcome. In contrast, 
more recent evidence suggests that burn patients have normal coagulation parameters on 
admission, becoming hypercoagulable during recovery 277. This discrepancy highlights the 
importance of delineating the specific pathways that are activated as part of the 
inflammatory response to burn injury. 
 
Post-burn immunosuppression 
Severe burn injury results in profound alterations to the host response to pathogens and 
infectious complications remain a major cause of death in this population 278. This can partly 
be attributed to loss of skin, which acts as the primary barrier to microorganisms. However, 
burn patients also exhibit classical signs of immunosuppression, such as loss of delayed 
hypersensitivity reactions, prolonged allograft survival and reduced T-cell proliferation 279. 
This has been termed the compensatory anti-inflammatory response syndrome (CARS) and 
is described as a systemic deactivation of the immune system, in an attempt to restore 
homeostasis from a severely inflamed state 280. CARS was first described by Bone in 1996 
and resulted from a reappraisal of sepsis pathophysiology. This was prompted by the failure 
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of a number of sepsis trials that attempted to modulate inflammatory mediators 281. He 
hypothesised that some survivors of the initial inflammatory insult develop an excessive 
anti-inflammatory response, resulting in immunosuppression. A final stage of “immunologic 
dissonance” was posited, whereby the imbalance between pro- and anti-inflammatory 
mechanisms became persistent. 
 
The concept of immunosuppression following an inflammatory insult was not new, having 
been reported for several decades in patients sustaining burn injuries, as well as major 
trauma 280. Lymphocyte dysfunction was recognised early on to be a key factor in this 
immunosuppression and evidence in the 1980s suggested this was due to upregulation of 
“suppressor” T cells in the post-burn period 282,283. T cells are critical to the adaptive immune 
response and a crucial subtype is T helper cells (Th), which are classically generated by 
antigen-presenting cells (APCs), such as macrophages and dendritic cells 284. A number of 
studies identified a characteristic switch, from Th1 to Th2 activity, following burn and major 
trauma. The resulting bias away from cell-mediated immunity and towards humoral 
immunity is thought to predispose burn patients to secondary sepsis 173,253. 
 
A newly discovered Th subset, known as Th17 cells, has also been linked to post-burn 
immunosuppression. These are generated in animal models of burn injury and are 
antagonistic to Th1 cells 
285. Furthermore, the Th17 effector cytokines IL-17 and IL-22 have 
been detected at increased levels at the site of burn injury 284. Some discrepancies exist, 
however, with an investigation of burn patient samples failing to identify increased Th17 
production 286. 
 
Defective CD3 signalling may underlie some of the T cell alterations present following burn 
injury 278,287 and increased levels of MCP-1 have also been implicated 288. A number of 
alterations to effectors of the innate immune system are also likely to contribute to post-
burn immunosuppression. Monocyte deactivation or hypo-responsiveness is thought to be 
an important factor, as discussed above 216. Impaired dendritic cell differentiation has also 
been demonstrated 289. Further investigation of the inflammatory pathways that mediate 
these responses may generate novel targets for modulation, with the ultimate aim of 
reducing infectious complications post-burn.  
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1.6 Microvesicles 
 
Microvesicles (MVs) are small, functionally-active, membrane-bound structures that are of 
emerging importance in the pathogenesis of systemic inflammation 290,291. They are derived 
directly from the plasma membrane of activated or dying parent cells 292. Microvesiculation 
is a ubiquitous cellular mechanism but it increases under conditions of stress.  Importantly, 
the released vesicles retain proteins and lipids characteristic of parent cells 293. Following 
preliminary studies in the 1940s, the presence of cell-derived vesicles was first confirmed by 
Wolf in 1967, using electron microscopy 294. Wolf termed them “platelet dust” and this 
“dust” was thought to account for the pro-coagulant activity of cell-free serum 295. Although 
platelets are the main source in health, erythrocytes, leukocytes and endothelial cells also 
release microvesicles 296. 
 
Definitions 
The most widely used collective term for cell-derived, phospholipid bilayer-bound structures 
is “extracellular vesicles” 294,297,298. Occupying the size range between molecules and cells, 
this broad population is thought to consist of a number of distinct subtypes, with varying 
physicochemical characteristics 299. However, the nomenclature relating to these subtypes is 
ambiguous and inconsistent 292,294,300. The three major types referred to in most publications 
are as follows 292,294,297,298,301: 
 
 Exosomes 
 Microvesicles 
 Apoptotic bodies 
 
Multiple other terms have been used in the literature, including ectosomes, microparticles, 
membrane particles, exosome-like vesicles, shedding vesicles and apoptotic vesicles 292,299. 
For the purposes of this thesis, we will refer to the three major types of vesicles listed 
above. Exosomes are the smallest subtype, with a diameter of 50-100nm – similar to 
viruses. They are released from all cells, with production increased by cell activation 298. 
Classically, they are thought to form within multivesicular endosomes, which then fuse with 
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the plasma membrane, resulting in exosome release. An alternative pathway of release is 
thought to exist, with exosomes budding directly from the plasma membrane 294. 
 
This latter method of formation and release is also thought to occur with microvesicles, the 
next major category of extracellular vesicles. These have a diameter of 100-1000nm, 
(comparable to bacteria) and are released only in response to cell activation or stress 297,298. 
Many publications use the term “microparticles” instead of microvesicles and they are 
largely interchangeable, although some authors use “microvesicles” as a collective term for 
both exosomes and shedding vesicles 292,302. We will refer to microvesicles in this thesis 
because the term “microparticle” can also apply to non-biological structures, such as those 
used for drug delivery. Apoptotic bodies are the largest type of extracellular vesicle, with a 
diameter of 1-5μm, which overlaps the size range of platelets. Unsurprisingly, they are 
released by cells undergoing apoptosis and a distinguishing feature is that they contain 
nuclear components. They are therefore capable of transferring genes to other cells 298,301. 
 
It is important to note at this stage that there is considerable overlap of the characteristics 
of these three types of extracellular vesicles, including size. There is currently no consensus 
on the markers that can be used to distinguish the origin or biogenesis of extracellular 
vesicles once they have left the cell 303. Different separation protocols may allow enrichment 
of one subtype over another but any preparation will be heterogeneous. The introduction of 
artefacts, by processes such as fixation for electron microscopy, will also influence the 
accuracy of vesicle classification 299. Because microvesicles are thought to be produced 
primarily in response to cell activation or stress, this subtype will be the focus of our 
investigations. In practice, current technologies do not allow them to be studied in isolation. 
 
Role of microvesicles in inflammation 
It is only recently that the key function of MVs in intercellular communication has been fully 
appreciated 304. The ability of MVs to package and deliver signals between cells may have 
important inflammatory and immuno-modulatory effects 305. In patients with sepsis, 
elevated levels of functionally-active leukocyte-derived MVs have been described 306. Major 
trauma has also been associated with increased MV release 307. In contrast, despite the 
profound systemic inflammation in patients with burn injuries, there are no studies to date 
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that have evaluated microvesicles in this condition. An increasing body of evidence suggests 
that microvesicles have fundamental roles in mediating the different phases of systemic 
inflammation. 
 
As discussed earlier, the release of DAMPs in response to tissue injury is crucial to initiation 
of the inflammatory response. Evidence suggests that the activity of DAMPs such as HMGB1 
is dependent on the formation of complexes with other DAMPs or cytokines, with vesicular 
structures providing a vehicle for the assembly and delivery of these complexes to remote 
targets 183,308. Other DAMPs associated with vesicular structures include heat-shock proteins 
and S100 proteins 297. 
 
A number of investigations also support a key role for microvesicles in propagating the 
inflammatory response. Macrophages release MVs in response to activation of purinergic 
P2X7  receptor (P2X7R) and TLRs 
309,310. Phospholipids delivered by these MVs are capable of 
activating other macrophages, in a NF-κB-dependent process. A similar autocrine process 
may occur between monocytes 311 and in the context of non-sterile inflammation 177,312,313. 
Another means by which microvesicles can mediate intercellular communication is by the 
packaging of cytokines, such as TNF-α 314. IL-1β has significant pro-inflammatory effects and 
the release of IL-1β-enriched microvesicles is recognised to be a key pathway by which this 
molecule is secreted 315. IL-18, which induces the synthesis of inflammatory cytokines and 
upregulates adhesion molecule expression, also associates to microvesicles 316. P2X7R 
appears to be important to the release of both IL-1β- and IL-18-enriched microvesicles 317. 
 
Microvesicle-mediated endothelial activation 
We have seen that following recognition of tissue damage, the endothelial adhesion 
cascade is important for recruiting neutrophils and monocytes to the site of injury. In vitro 
investigations has demonstrated that microvesicles released by neutrophils are capable of 
potentiating this process, leading to inflammatory gene expression, IL-6 release and 
upregulation of adhesion molecules 318. Procoagulant responses in the endothelium are also 
enhanced by this signalling pathway 319. Further investigations have suggested that 
neutrophil-derived microvesicles contain myeloperoxidase and are capable of injuring 
endothelial cells 320. Monocyte-derived MVs have also been shown to activate and injure 
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endothelial cells, in addition to mediating procoagulant effects 302,321,322. Taken together, 
these studies support the idea that leukocyte-derived microvesicles make a key contribution 
to the widespread endothelial dysfunction that is associated with systemic inflammation. 
 
MVs released by endothelial cells are also involved in leukocyte-endothelial crosstalk. They 
are capable of activating monocytes and modulating their procoagulant activity 323,324. 
Maturation of dendritic cells and production of inflammatory cytokines is induced by 
endothelial MVs 325. In addition, endothelial MVs exhibit autocrine effects, eliciting 
inflammatory responses and dysfunction in nearby endothelial cells and pericytes 326–328. 
MVs derived from platelets may modulate the interaction between leukocytes and 
endothelial cells 329.  Clinical studies have demonstrated elevated levels of endothelial MVs 
in a number of disease states associated with dysregulated endothelial function. These 
include sepsis 330 acute coronary syndromes 331, atherosclerosis 332 and pulmonary 
hypertension 333. They may therefore have value as prognostic markers 332,334. 
 
Immunomodulation by microvesicles 
The biological actions of MVs are diverse and include effects which are immunosuppressive 
and potentially protective 3,335. Neutrophil-derived MVs, for example, have been found to 
downregulate inflammatory activity in macrophages, dendritic cells and natural killer cells 
336–340. In vitro analysis of endothelial cells demonstrated decreased survival when MV 
production was inhibited 341. One possible mechanism for this protective MV effect is the 
delivery of functional microRNA to recipient cells 342. In patients with sepsis, high levels of 
endothelial MVs have been associated with increased survival 343. These investigations 
underscore the fact that microvesicles represent a heterogeneous population. Their precise 
role in mediating inflammation in vivo is likely to depend both on their composition and site 
of action 344. 
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1.7 Analysis of microvesicles 
 
Detection of MVs is problematic, owing to their small size and low refractive index 345. A 
number of techniques have been used in their detection but the most commonly used is 
flow cytometry, being used by 75% of departments processing clinical samples 346. This is an 
optical method that is able to collect both light scatter and fluorescence information for 
each “event” detected. The benefits of flow cytometry include high sample turnover rate, 
enumeration of large number of events and the detection of two or more antigens 
simultaneously. Unfortunately, most cytometers are designed to study larger structures and 
have a sensitivity limit of around 300-500nm, excluding a significant proportion of 
extracellular vesicles. It is also somewhat subjective and difficult to automate 347,348. Flow 
cytometric MV analysis will be discussed in more detail in chapter three, in conjunction with 
the pre-analytical aspects of investigating microvesicles. 
 
It is difficult to visualise particles of less than 1μm using conventional optical microscopy, 
with the resolution limit of the best microscopes lying at around 200nm. Furthermore, 
enumeration of particles using this technique is laborious and impractical 347,348.  A more 
useful method is electron microscopy, of which there are two types: transmission electron 
microscopy (TEM) and scanning electron microscopy (SEM) 349. TEM uses a similar principle 
as light microscopy, transmitting a beam of electrons (instead of photons) through a thin 
specimen, which is then focused to create an image. TEM has a higher resolution of around 
1nm 345 - this is sufficient to resolve internal morphological features 347. The fixation 
techniques required may alter this morphology, however. It is also only capable of providing 
semi-quantitative information. The resolution of SEM is less than that of TEM but it provides 
three-dimensional images 349. 
 
Enzyme-linked immunosorbent assays (ELISAs) have also been used for MV analysis, albeit 
much less extensively than flow cytometry. ELISAs are purported to generate reproducible 
results 350,351 but they require the presence of a specific target that can be captured by the 
assay. A common approach is to use annexin V, which binds to phosphatidylserine on the 
MV surface. Unfortunately, a large proportion of MVs fail to bind annexin V 352. 
Furthermore, ELISAs do not provide any information regarding vesicle size. 
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A more recent method of analysing MVs is nanoparticle tracking analysis (NTA). This uses a 
combination of light microscopy and video software to track the Brownian motion of 
individual vesicles 353. The sensitivity limit of this technique varies according to the refractive 
index of the particle being analysed. For extracellular vesicles, which have a low refractive 
index, the limit is around 50nm, i.e. significantly lower than the limit of flow cytometers 354. 
NTA may not be as accurate as the current generation of flow cytometers, does not allow 
multi-parameter fluorescence detection and is relatively slow. Consequently, flow 
cytometry is still considered superior for clinical research 345 and is the method we used in 
our investigations. 
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1.8 Hypothesis and aims 
 
The principal aim of this project was to investigate the microvesicle profile associated with 
the post-burn inflammatory response. We hypothesised that due to widespread tissue 
injury and inflammatory cell activation, severe burn injury would produce an acute, 
significant and potentially specific pattern of MV release, generating targets for subsequent 
analysis. We also hypothesised that changes in the MV profile may reflect evolution of the 
inflammatory response. 
 
In order to test these hypotheses, it was first necessary to optimise our sample processing 
and flow cytometry protocols. This work is described in chapter three. We applied these 
protocols in a clinical observational study, comparing blood sampled from burn patients, 
sepsis patients and healthy volunteers. The results of this analysis are described in chapter 
four. To conclude our project, we investigated the burn-related conditions necessary to 
generate MVs in vitro and  developed an assay relevant to microvascular inflammation, to 
assess the role of microvesicles in the propagation of organ injury. This assay was then 
applied to samples taken from burn patients. These investigations constitute chapter five. 
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Chapter 2 
Materials and Methods 
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2.1 Equipment and software 
 
Equipment Application Supplier 
Cyan ADP Analyser Flow cytometry Beckman-Coulter, High Wycombe, UK 
Eppendorf 5417R microcentrifuge Centrifugation Eppendorf, Hamburg, Germany 
Heraeus Multifuge 3 S-R Centrifugation Thermo Fisher Scientific, Waltham, USA 
Leucosep Tube 163 290 Whole blood separation Hugo-Sachs Elektronik, March, Germany 
Nuaire DH autoflow incubator Cell culture Nuaire Group, Caerphilly, UK 
Nylon cell strainer (40μm) BAL fluid filtration BD Falcon, New Jersey, USA 
 
Table 2.1 Equipment 
 
Equipment Application Supplier 
FlowJo v10.0.7 Flow cytometry analysis Flowjo, LLC, Ashland, OR, USA  
Graphpad Prism 6 for Windows Plotting / statistical analysis GraphPad, La Jolla, CA, USA 
Summit v4.3.04 Flow cytometry acquisition  Beckman-Coulter, High Wycombe, UK 
 
Table 2.2 Software  
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2.2 Materials 
 
Reagent Application Supplier 
Adenosine triphosphate (ATP) Cell stimulation Tocris Bioscience, Bristol, UK 
Bovine serum albumin (BSA) Buffer/media constituent Sigma Aldrich, St Louis, USA 
Calcein AM Cytoplasmic staining Invitrogen, Paisley, UK 
Calcium ionophore A23187 Cell stimulation Tocris Bioscience, Bristol, UK 
Cell dissociation solution Cell harvesting Sigma Aldrich, St Louis, USA 
CFDA-SE Cytoplasmic staining Thermo Fisher Scientific, Waltham, USA 
DMEM F12 media Cell culture Invitrogen, Paisley, UK 
Eagle’s MEM media Cell culture Sigma Aldrich, St Louis, USA 
EGM-MV Cell culture Lonza, Basel, Switzerland 
EDTA Buffer constituent Sigma Aldrich, St Louis, USA 
Foetal calf serum (FCS) Buffer constituent Sigma Aldrich, St Louis, USA 
Hanks Balanced Salt Solution (HBSS) Buffer Sigma Aldrich, St Louis, USA 
Human albumin solution (HAS) Media constituent Baxter, Newbury, UK 
K-SFM media Cell culture Invitrogen, Paisley, UK 
Lipopolysaccharide (LPS) Cell stimulation Autogen Bioclear, Calne, UK 
Phorbol myristate acetate (PMA) Cell stimulation Tocris Bioscience, Bristol, UK 
Phosphate buffered saline (PBS) Buffer Invitrogen, Paisley, UK 
Sodium azide Buffer constituent Sigma Aldrich, St Louis, USA 
Staphylococcus aureus Cell stimulation Invitrogen, Paisley, UK 
Triton Detergent lysis Sigma Aldrich, St Louis, USA 
Trypsin-EDTA Cell harvesting Lonza, Basel, Switzerland 
Trypsin Neutralizing Solution Cell harvesting Lonza, Basel, Switzerland 
Zymosan Cell stimulation Invitrogen, Paisley, UK 
 
Table 2.3 Reagents and pharmacological agents 
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Equipment Application Constituents 
Flow wash buffer (FWB) Flow cytometry PBS, 2% FCS, 0.1% sodium azide, 5mM EDTA 
 
Table 2.4 “In house” buffers 
 
Flow cytometry 
Antibodies were fluorophore conjugated and anti-human. Table 2.1 below contains details 
of the antigen, fluorophore and manufacturer for each antibody.  
 
 Antigen Fluorophore Clone Manufacturer 
 CD45 AF 647 HI30 BioLegend, San Diego, USA 
 CD14 PE HCD14 BioLegend, San Diego, USA 
 CD11b AF 647 M1/70 BD Horizon, Oxford, UK 
 CD66b PE G10F5 BioLegend, San Diego, USA 
 CD105 PE 43/A3 BioLegend, San Diego, USA 
 PE-Cy7 43/A3 BioLegend, San Diego, USA 
 CD62e PE HAE-1f BioLegend, San Diego, USA 
 CD106 APC STA BioLegend, San Diego, USA 
 C3c FITC Polyclonal Thermo Fisher Scientific, Waltham, USA 
 
Table 2.5 Flow cytometry antibodies 
  AF 647 – Alexa Fluor 647 
PE – Phycoerythrin 
  PE-Cy7 – Phycoerythrin-Cyanine 7 
  APC – Allophycocyanin 
  FITC – Fluorescein isothiocyanate  
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2.3 Blood processing and cell isolation 
 
Blood collection 
Informed consent or assent was obtained for all participants. For microvesicle analysis, 18ml 
of venous or arterial blood was collected into lithium heparin Vacutainers and processed 
immediately. For leukocyte isolation, 18ml of venous blood was collected into EDTA 
Vacutainers and processed immediately. For serum preparation, 18ml of venous blood was 
collected into clot activator Vacutainers. 
 
Preparation of plasma and serum 
To prepare platelet-rich plasma (PRP), whole blood was centrifuged at 200g for 10 minutes. 
The supernatant (PRP) was collected immediately. To prepare platelet-poor plasma (PPP), 
PRP was centrifuged for a further 20 minutes at 1500g. For serum preparation, clotted 
whole blood was centrifuged at 1400g for 5 minutes. The supernatant was collected and 
centrifuged at 20,000g for 10 minutes to yield serum (supernatant). 
 
Peripheral blood mononuclear cell (PBMC) isolation 
PBMCs were isolated from healthy volunteers by density gradient centrifugation of whole 
blood. This was performed using Leucosep tubes (Greiner Bio-One) and Histopaque-1077 
(Sigma), according to the manufacturers’ instructions. After separation, PBMC were washed 
in 10ml sterile PBS and centrifuged for 10 minutes at 250g. This was repeated twice, before 
the cells were resuspended in HBSS and counted using flow cytometry. Cells were kept on 
ice until used. 
 
Neutrophil isolation 
Following PBMC separation, the neutrophil- and erythrocyte-rich pellet was recovered 
aseptically, mixed gently with ice-cold sterile 6% dextran solution, and allowed to sediment 
for 30 minutes. The neutrophil-rich, erythrocyte-depleted upper layer was aspirated and 
centrifuged to pellet the cells. Residual erythrocytes were lysed using ice-cold sterile water 
for 20 seconds, before isotonicity was restored by adding one volume of 10x PBS to 9 
volumes of cell suspension. The neutrophils were then washed twice in 10ml of cold HBSS, 
centrifuged at 250g for 10 minutes and counted using flow cytometry.  
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2.4 Cell culture 
 
Cells were cultured in 175cm2 flasks, at 37⁰C, in 95% air / 5% CO2. Media were changed 
every 48 hours. Where Trypsin-EDTA was used for harvesting, cells were observed using a 
microscope until detached. Trypsin Neutralizing Solution (TNS) was then added 
immediately. Wash steps were performed using fresh medium and cells were centrifuged at 
250g for 5 minutes unless otherwise stated. 
 
RAW 264.7 mouse macrophage cell line 
RAW 264.7 cells (Sigma) were cultured in DMEM F12 media. Once confluent, cells were 
harvested with cell dissociation solution (CDS), washed in PBS and centrifuged. Cells were 
resuspended in HBSS and counted using the flow cytometer. For subculturing, one quarter 
of the cells were transferred to fresh culture flasks. For seeding into plates, 2 x 106 cells 
were added to wells (growth area 9.5cm2) then incubated in fresh media at 37⁰C until 
confluent. 
 
HK-2 human kidney epithelial cell line 
HK-2 cells (ATCC) were cultured in K-SFM media. For subculturing, 80% confluent cells were 
harvested using Trypsin-EDTA. One quarter of the washed cells were transferred to fresh 
culture flasks. For experiments, cells were detached using CDS, washed in PBS and 
centrifuged. Cells were resuspended in HBSS and counted using the flow cytometer. 
 
BJ Human fibroblast cell line 
Fibroblasts (BJ, ATCC) were cultured in Eagle’s MEM / 10% foetal calf serum. For 
subculturing, confluent cells were harvested using Trypsin EDTA. One quarter of the washed 
cells were transferred to fresh culture flasks. For experiments, cells were detached using 
CDS, washed in PBS and centrifuged. Cells were resuspended in HBSS and counted using the 
flow cytometer. 
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Primary human endothelial cells 
Primary human pulmonary microvascular endothelial cells (HPMECs, Promocell) were 
cultured in EGM-MV medium. For cell passaging and plate seeding, cells were harvested 
using Trypsin-EDTA. Cells were washed in fresh medium and centrifuged at 250g for three 
minutes, then seeded at confluence (2x105 / well) into 24 well plates. 
 
PBMC-endothelial cell co-culture experiments 
Following stimulation (see below), endothelial cells were detached using cell dissociation 
solution, then diluted in FACS wash buffer (FWB), before centrifugation at 200g for 5 
minutes. The cell pellet was resuspended in 120μl of FWB and stained with fluorescent 
antibodies raised against identification marker and relevant activation markers. After 
staining and washing, the samples were analysed by flow cytometry. Cell adhesion 
molecules levels were expressed as MFI of stained cells with background values subtracted. 
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2.5 Microvesicle preparation 
 
Neutrophil and PBMC preparations were resuspended in Eppendorf tubes in HBSS / 0.5% 
Human Albumin Solution (HAS), at 1 x 107 cells per ml. Cells were rested for one hour at 
37⁰C, before incubating with the relevant stimulant for a further hour at 37⁰C. Incubations 
were performed under sedimenting (static) or suspension (rotating) conditions. The 
microvesicles were isolated by centrifuging the cells at 200g for 10 minutes, before 
collecting the supernatant. Microvesicles were analysed as described below. 
 
For incubation of PBMC-endothelial co-culture with microvesicles, the cell-free supernatant 
was centrifuged for 30 minutes at 20,000g to pellet microvesicles, which were then 
resuspended in 200μl 0.5% HAS/EBM. The microvesicles were added to the endothelial cell-
PBMC co-culture and incubated for 4 or 16 hours. Endothelial cells were retrieved and 
analysed as above. 
 
Opsonisation of particulate stimulants 
Cells or microbial particles were opsonised by suspension in 500μl of serum and incubation 
in the rotator for one hour at 37⁰C. The stimulant was then washed to remove residual 
serum, before being added to the leukocyte preparation. 
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2.6 Flow cytometry 
 
Flow cytometry acquisition was performed using a Cyan ADP flow cytometer, with Summit 
software (version 4.3.04). Acquired microvesicle and cell data was analysed using FlowJo, 
version 10.0.7. 
 
Microvesicle analysis 
Microvesicle samples (10μl) were incubated with 10μl of antibodies (see Table 2.1) for 30 
minutes at 23⁰C, and then diluted with 1ml of filtered PBS. 500μl was removed from each 
sample and added to 5μl of Triton X-100 10%. 10μl of counting beads were added to each 
sample before data acquisition. 
 
Cell analysis 
Endothelial cells (50μl) were incubated with 50μl of antibodies for 30 minutes at 4⁰C, and 
then washed with 4ml of wash buffer (WB), before centrifugation at 200g for 5 minutes. Cell 
pellets were resuspended in 400 μl of WB before flow cytometry data acquisition.  
 
Cytometric bead array 
Soluble cytokines, chemokines and growth factors were measured using a cytometric bead 
array kit (BD CBA Soluble Flex Set System) as per manufacturer’s instructions.  Standards, 
capture beads and phycoerythrin (PE) detection reagents were prepared prior to performing 
the assay. Human platelet-poor plasma was prepared as below. 50µl of 10 serially-diluted 
standards were added to 10 tubes. 50µl of each sample was added to the appropriate assay 
tubes. 50µl of capture beads were added to each tube, before incubation at room 
temperature for one hour. 50µl of detection reagent was then added to each tube before 
incubation for a further two hours. Samples were washed with 1ml of wash buffer, and 
centrifuged at 200g for 5 minutes. The supernatant was discarded before the sample was 
resuspended in a further 300µl of wash buffer. Data was acquired using a Cyan ADP and 
analysis was performed using FCAP Array software. 
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2.7 Statistical analysis 
 
Means and standard deviations are provided for parametric data. Means are shown where 
all data points are displayed. A t-test was used to compare two groups of data. For three or 
more groups, a one-way analysis of variance (ANOVA) was used with Dunnett’s multiple 
comparison test (if comparing groups to a control) and Tukey’s multiple comparison test (if 
comparing each group to all others). Paired values were compared using a paired t-test. 
Nominal variables were compared with Fisher’s exact test and Pearson’s correlation 
coefficient was used to measure correlations. 
 
For non-parametric data, medians and interquartile ranges are provided. Medians are 
shown where all data points are displayed. The Mann-Whitney test was used to compare 
two groups of data. For three or more groups, the Kruskal-Wallis test was used with Dunn’s 
multiple comparison test. Paired values were compared using the Wilcoxon signed rank test 
and Spearman’s correlation coefficient was used to measure correlations. Normality was 
assessed using the D'Agostino-Pearson omnibus test. 
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Chapter 3 
Optimisation and validation of flow cytometry protocols for analysing microvesicles  
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Summary 
 
The most commonly used method for quantifying and characterising microvesicles is flow 
cytometry. However, these small particles lie at the detection limits of conventional flow 
cytometers, in the range where optical and electronic noise become problematic. A number 
of attempts have been made to standardise microvesicle analysis, but there is no 
universally-approved approach. Individual cytometers also vary in their size detection 
threshold and resolution. Before analysing samples from burn patients, we sought to 
establish the capabilities and limitations of our cytometer and to optimise methods for 
processing and storing samples. 
 
Calibrated sizing beads were used to determine the physical characteristics of the cytometer 
when investigating small particles. After optimising machine setup, including 
troubleshooting signal distortions produced by mismatched sheath and sample fluid 
composition, we evaluated different approaches to the detection and analysis of 
microvesicles generated in vitro. Our initial findings suggested that it was better to 
discriminate microvesicles from background noise on the basis of fluorescence, rather than 
size. Fluorescence triggering for acquisition of heterogeneous microvesicle populations 
requires generic stains to label microvesicles according to common biochemical properties.  
We evaluated two cytoplasmic dyes that have previously been used in cell proliferation 
studies. The second of these, calcein-AM, showed promise with isolated microvesicles, but 
when used to study plasma samples, this dye increased background noise without 
increasing microvesicle detection. We eventually concluded that for microvesicles in plasma 
samples, side scatter was the best discriminator.  Further steps were then taken to exclude 
artefact, including detergent lysis of microvesicles and reference to a biological size 
standard from ionophore-stimulated platelets. 
 
The optimised cytometry protocol was then used to study sample processing. We found that 
the centrifugation steps described in many publications led to an unacceptable loss of 
microvesicles. We also confirmed that freezing of platelet-rich plasma had a minimal effect 
on non-platelet microvesicles. By this stage we were satisfied that we had evaluated and 
optimised all the components necessary for a patient sample protocol.  
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3.1 Background 
 
Flow cytometers are designed to measure laser light scattered by a cell at two distinct 
angles, whilst simultaneously measuring fluorescence emission signals 355. Cells are drawn 
from a sample tube and are constrained as they pass the sensing laser by a cylinder of 
sheath fluid. This process is known as hydrodynamic focussing 356. Light is reflected in all 
directions. The forward scatter light, correlating to cell size, is collected at narrow angles. 
The side scatter light, reflecting structural complexity, is collected at wide angles in 
conjunction with fluorescence signals. The information then undergoes computer analysis. 
The process is summarised in figure 3.1 below. 
 
 
Figure 3.1 Schematic of typical flow cytometer 
1: Side scatter detector 2-4: Fluorescence emission detectors 357 
 (reproduced with permission) 
 
Flow cytometry is the most widely-used technique for analysing microvesicles because it 
allows simultaneous multi-parametric analysis of thousands of particles per second 358. 
However, its use can be problematic and lacks standardisation 347–349,359,360. For example, the 
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relationship between forward scatter and size breaks down as the particle size approaches 
the laser wavelength of 400-500nm 361. Before we could begin investigating microvesicles 
from patients with burn injuries, we sought to develop an optimised flow cytometry 
protocol. There were two separate issues to consider: firstly, the intrinsic analytical 
capabilities and limitations of our particular cytometer, a Beckman Coulter Cyan ADP. 
Secondly, the pre-analytical factors relevant to human samples. 
 
Flow cytometry-based microvesicle analysis 
The diameter range of microvesicles is often reported as between 100nm and 1μm 348, 
although this range does vary, with some authors including particles up to 1.5μm 362. Others 
argue that the lower size limit is arbitrary and advocate inclusion of all particles below a 
certain size 360. Regardless of the precise values chosen, most cytometers have a threshold 
for detection of around 400-500nm; detection is possible below this value but unreliable 
360,363,364. The absolute limit of sensitivity is around 300nm, or 150nm where the cytometer 
has been designed specifically for microvesicles 345,353. Therefore, when using flow 
cytometry for microvesicle analysis, a certain proportion of the population of interest will be 
missed. 
 
When assessing the capabilities of a flow cytometer, consideration should be given to the 
standard used for calibration. Fluorescent beads of specific sizes are often utilised and have 
been proposed as a means for comparing results from different centres, using different 
machines 365. The location of these beads on a cytometry scatter plot can be used to define 
a size-restricted group of events commensurate with microvesicles. The assumption in this 
process is that all particles of a given size will scatter laser light to the same degree. 
Unfortunately, polystyrene beads have a higher refractive index than particles of a cellular 
origin 366 and will scatter more light than similarly-sized microvesicles. Silica calibration 
beads may mitigate this problem to some degree, as their refractive index more closely 
matches that of microvesicles 364, although these were not available commercially to us. 
Therefore the most appropriate use of calibration beads would be to ensure consistency 
between samples, with a precise cut-off ideally referenced to a biological standard. 
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The next issue to consider is the choice of a “threshold” or trigger. When analysing cells, 
usual practice is to select a forward scatter value that lies between the population of 
interest and the noise floor. The cytometer will then record every event above this value. 
Noise can represent small particles in the sample solution and sheath fluid. It also originates 
from low level signals in the cytometer electronics and stray light detected by the optics 367 
– this will be present regardless of actual particle content.  Microvesicles lie very close to or 
within the noise floor, meaning the smallest microvesicles may be unresolvable from noise 
on physical characteristics alone 368. Raising the threshold to exclude noise excludes 
particles of interest. Because of this dilemma, a number of authors have advocated the use 
of alternative triggers, such as fluorescence, to improve discrimination of microvesicles from 
noise 349,368–370. 
 
A further potential source of error is the co-detection of immune complexes. These are 
protein aggregates, consisting of antibodies and bound antigen, that have physiologic but 
also pathophysiologic roles 371 and pose a particular problem when derived from 
fluorescence-conjugated antibody probes. The biophysical properties of microvesicles 
overlap with those of immune complexes and they cannot be distinguished by 
centrifugation or light scattering. This contrasts with particles such as lipoproteins, which 
are significantly smaller 372. For this reason, several papers have suggested the use of 
detergent to lyse microvesicles, leaving insoluble protein complexes intact 372–374. These 
events can then be excluded from the final microvesicle count. 
 
Sample processing 
A number of pre-analytical factors are also thought to affect microvesicle counts. The 
overall aim of sample processing is to minimise ex-vivo or post-harvest production of 
microvesicles, whilst retaining the greatest possible yield from the system being analysed. 
An important part of minimising post-sampling microvesicle release is to remove cells as 
rapidly as possible. One approach used for blood samples is to perform a two-stage 
centrifugation, at ~200g and ~1500g 375–377. The lower speed centrifugation removes 
leukocytes and erythrocytes, whilst the medium speed centrifugation reduces platelet 
contamination. However, this is another area with a lack of standardisation. Some authors 
argue a further centrifugation, at a medium speed, is needed to produce platelet-free 
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plasma (PFP) 377. Others suggest a high speed of 13000g can be used for shorter periods 378, 
which conflicts with data indicating that larger microvesicles are lost at speeds as low as 
1200g 379. 
 
The storage of samples is another key question, of particular relevance to studies involving 
patient samples. Complete processing and analysis of samples from patients recruited 
outside normal working hours is not always possible. This is particularly relevant with 
conditions that require emergency treatment, such as burn injuries. Therefore it is 
advantageous if samples are amenable to basic processing and storage, with analysis being 
performed at a later date. Adequate sample storage would also facilitate multi-centre 
studies, by avoiding the need for multiple analysers, with each requiring independent 
calibration 365. The light scatter parameters of microvesicles are not thought to be altered by 
freezing 333 but the optimal storage protocol is not clear. Freezing platelet-rich plasma (PRP) 
is certainly a problem when analysing platelet microvesicles, because the cellular source is 
by definition still present in the fluid. A considerable increase in platelet ‘microvesicle’ 
counts is therefore seen in freeze-thawed platelet-rich plasma 378. This effect has also been 
described with platelet poor plasma (PPP) 378,380, although some studies found PPP to be 
unaffected 359. In contrast, leukocyte and endothelial microvesicle counts have not been 
shown to change after a freeze-thaw cycle with plasma depleted of cells 380.  
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3.2 Aims 
 
The aims for this chapter were as follows: 
 
1. Determine the optimal flow cytometry set up and protocol for analysing 
microvesicles on a Cyan ADP cytometer 
2. Develop a sample processing and storage protocol suitable for studying 
microvesicles from patient samples 
 
3.3 Protocols 
 
Cell culture and stimulation 
RAW 264.7 cells (murine monocyte-macrophage cell line) were cultured in flasks and wells 
as described in chapter two. For stimulation, cells were washed with PBS, then stimulated 
for 30 minutes with either ATP (3mM) or ATP + A23187 (3mM + 10μM).  The fluid from each 
well was aspirated and centrifuged in microfuge tubes at 200g for 10 minutes, to pellet cells. 
Microvesicles were analysed in the supernatant. 
 
Blood collection 
For analysis of circulating microvesicles, 20ml of blood was obtained from volunteers who 
had given informed consent, or assent in the case of patients unable to give consent. The 
blood was collected into lithium heparin Vacutainers and processed immediately. 
 
Microvesicle staining 
A 10µl volume of the microvesicle preparation was incubated with PE or APC-conjugated 
monoclonal antibodies, specific to the cell surface marker to be analysed, for 30 minutes at 
room temperature. Antibody volumes were titrated to maximise separation between 
negative and positive events (logarithmic scale). The total staining volume was 20µl and 
filtered PBS was added where necessary to ensure constant volume. Staining was 
terminated by diluting samples with 1ml of filtered PBS. 
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3.4 Results – Flow cytometry optimisation 
 
Sensitivity of Cyan ADP Flow Cytometer as determined by fluorescent beads is improved 
with fluorescence trigger but discriminatory power is lost in the sub-500nm size range 
Our first task was to establish the intrinsic characteristics and capabilities of our flow 
cytometer, in the size range at which we would expect to find microvesicles. A commonly 
described method is to use calibrated fluorescent beads to define the forward scatter 
resolution limit, which is the most appropriate parameter to use when defining microvesicle 
size 365. 
 
Spherotech polystyrene fluorescent beads (20μl), ranging in size from 220nm to 1.3μm, 
were suspended in 400μl of distilled water. Accucheck counting beads (20μl), with an 
approximate size of 6.36 and 6.4μm, were also included for comparison. Cytometry data 
was acquired for a fixed period of 60 seconds, at a speed calibrated to ensure constant flow. 
Forward and side scatter voltages were based on normal settings for cell acquisition and the 
threshold set initially to the lowest value (0.01%). 
 
Size calibration and counting beads were acquired with a forward scatter trigger and 
evaluated on forward scatter vs side scatter plots (figure 3.2A). 6μm, 1.3μm and 880nm 
beads were successfully detected and could be discriminated from each other. However, it 
was not possible to detect a distinct population of 490nm or 220nm beads. In contrast, 
using a fluorescence trigger enabled the detection of discrete populations of 490nm and 
220nm beads (figure 3.2B). Their positions on the scatter plot suggest that these beads are 
obscured by noise when a forward scatter trigger is used. 
 
The ability of the Cyan flow cytometer to discriminate on forward scatter alone was then 
evaluated (figure 3.3). This was important because we could not reliably predict the extent 
to which genuine microvesicles would vary in their side scatter. When using a forward 
scatter trigger, only the 6μm and 1.3μm beads were distinct, with the 880nm beads 
blending into the noise signal (figure 3.3A). When using a fluorescence trigger, it was also 
possible to discern the 880nm beads, although the 490nm beads and 220nm beads did not 
have discrete forward scatter signals (figure 3.3B). 
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Figure 3.2 Analysis of forward scatter and side scatter of sizing beads using a Cyan 
ADP cytometer 
Fluorescent beads of size 490nm and 220nm were obscured by noise when 
using a forward scatter trigger (A). Fluorescence trigger (channel 1) allows 
detection and discrimination of all bead populations (B)  
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Figure 3.3 Analysis of forward scatter of sizing beads using a Cyan ADP cytometer 
Cyan can only detect discrete forward scatter signals for 1.3μm and 6μm 
beads when forward scatter trigger is used (A). Fluorescence trigger also 
allows discrimination of forward scatter signal for 880nm beads (B). Y axis is 
adjusted to demonstrate bead peaks. Noise is therefore off-scale but distinct 
bead peaks not visible when scale increased  
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Forward scatter events in microvesicle size range are affected by sheath fluid with 
mismatched refractive index 
It became apparent in our early experiments that the forward scatter signal of small 
particles was often distorted and shifted away from zero. An example of the scatter plots 
obtained is shown in figure 3.4A. Because the affected area of forward scatter would 
typically be excluded when analysing cells, this phenomenon would normally be overlooked. 
However, we did not detect the distortion when the sizing beads were studied (figure 3.4A), 
which were resuspended in distilled water, whereas our in vitro microvesicle samples were 
resuspended in a physiological saline (PBS). Because the sheath fluid being used at this point 
was also distilled water, we suspected that an interaction between the sheath fluid and 
sample fluid was occurring. Investigations of small particles have previously demonstrated 
that a mismatch in refractive indices, between sheath and sample fluids, distorts forward 
scatter 381. The effect was maximal with the smallest particles but affected cells up to 5μm 
in diameter, well in excess of the size range we were focusing on. We concluded that using 
sheath solutions with matched refractive indices was critical for all further microvesicle 
analyses. All subsequent work was performed with a commercial isotonic sheath solution 
(Isoflow, Beckman Coulter). 
 
Before analysing a batch of samples, we acquired scatter data using filtered PBS for at least 
10 minutes. By plotting time against forward scatter, it was possible to confirm that the 
forward scatter signal was stable. If water had previously been used for sheath fluid, we 
found stabilisation to occur after approximately 9 minutes after switching to Isoflow. A plot 
demonstrating this effect is shown in figure 3.4B.   
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Figure 3.4 Effect of mismatched sheath fluid on forward scatter 
Forward scatter noise is shifted away from baseline when refractive index of 
sheath fluid does not match that of sample (A). Substituting unmatched 
sheath fluid (water) for matched Isoflow results in forward scatter noise 
returning to baseline. This process takes approximately 9 minutes (B) 
    
67 
 
A combination of surface labelling and fluorescence trigger allows detection of RAW 264.7 
cell microvesicle response to stimulation 
Our initial bead data had suggested that a fluorescence trigger could be useful for reducing 
background noise. We next sought to establish if a fluorescence trigger would enable our 
cytometer to detect microvesicles generated in vitro, from the RAW 264.7 murine 
monocyte-macrophage cell line. Local experience showed these cells produce significant 
quantities of microvesicles when stimulated with ATP and calcium ionophore. 
 
RAW 264.7 cells were cultured and stimulated with ATP and ionophore A23187. Released 
microvesicles were stained with allophycocyanin (APC)-conjugated anti-CD11b antibodies 
then diluted with PBS. Analysis was performed using a fluorescence trigger (channel 8, APC) 
set to the minimum value (0.01%). Microvesicles were defined as all events with a forward 
scatter value smaller than that of the 1.3μm beads described earlier. Unstained and stained 
samples were compared. 
 
The absolute numbers of microvesicles detected were relatively low, when unstained 
samples were analysed (figure 3.5). There was an increase in counts seen following 
stimulation with ATP + A23187 (924 ± 1291 to 1674 ± 2237 MV μl-1) but this was not 
significant. In contrast, the stained samples yielded a significant increase in microvesicle 
counts following stimulation with ATP alone (8599 ± 265 to 18794 ± 6466 MV μl-1) and ATP + 
A23187 (38149 ± 8102 MV μl-1). These results demonstrated that by using a fluorescence 
trigger, it was possible to clearly identify microvesicles with only a relatively low background 
event counts. However, this technique was dependent on fluorescent labelling and 
detection could not be based upon an intrinsic auto-fluorescence signal alone.  
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Figure 3.5 Comparison of auto-fluorescence and surface marker labelling when using a 
fluorescence trigger to detect RAW cell microvesicles 
Use of fluorescent CD11b antibody in conjunction with fluorescence trigger 
allows detection of increased RAW cell microvesicle levels following 
stimulation with ATP + A23187. Absolute numbers are lower and significant 
post-stimulation increase is not detected by use of auto-fluorescence only 
(unstained samples) 
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Cytoplasmic staining of RAW 264.7 microvesicles with calcein-AM allows detection of 
greater numbers of microvesicles than staining with CFDA-SE 
Although the combination of surface marker labelling and a fluorescence trigger could be 
useful for analysing microvesicles in single-cell preparations, it would not be valid for fluids 
with multiple cell types, such as human plasma. Such an approach could be affected by 
weak or variable surface marker expression on cells and their subsequent packaging into 
microvesicles. Identification of microvesicles with generic markers based on their physical 
and/or biochemical properties could potentially overcome this limitation. Our first 
candidate was a cytoplasmic dye: carboxyfluorescein diacetate succinimidyl ester (CFDA-SE). 
This is converted by intracellular esterases to carboxyfluorescein succinimidyl ester (CFSE), 
which is fluorescent 382. CFDA-SE is conventionally used for cell proliferation assays 382–384 
but has also been used for tracking the uptake of microvesicles 385,386. 
 
When parent RAW cells were stained pre-stimulation (ATP + A23187) with CFDA-SE, a 
marked increase in microvesicle response was detectable (1425 ± 988 to 30078 ± 2423 MV 
μl-1) (figure 3.6A). However, when the microvesicles were stained directly, the number of 
post-stimulation microvesicles detected was much smaller (6962 ± 5004 MV μl-1) (figure 
3.6B). 
 
Staining of parent cells would not be an appropriate technique for staining circulating 
microvesicles that had already been released in vivo. As direct MV staining with CFDA-SE 
was sub-optimal, we evaluated an alternative cytoplasmic dye, calcein acetoxymethyl ester 
(calcein-AM). Calcein-AM is similar to CFDA-SE, in that it is converted to a fluorescent form 
by intracellular esterases. However, it does not covalently link to intracellular molecules 
382,387 and also exhibits less dye leakage than CFSE 388,389. Before testing calcein-AM with 
human samples, we investigated its behaviour with RAW microvesicles. 
 
RAW cells were stimulated as above. The resultant microvesicles were stained directly with 
calcein-AM and fluorescent anti-CD11b antibodies. When using calcein-AM (20nM) and a 
fluorescence trigger, a clear CD11b+ microvesicle population was detectable. The number of 
microvesicles detected using 200nM calcein-AM was markedly increased (figure 3.6C).  
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Figure 3.6 Effect of cytoplasmic staining on detection of RAW microvesicles when 
using fluorescence trigger 
CFDA-SE (5μm) staining of parent RAW 264.7 cells, prior to stimulation, leads 
to greater microvesicle detection (A) than is the case when RAW microvesicles 
are stained directly (B) 
 
Clear population of CD11b+ RAW microvesicles is detectable using direct 
calcein-AM stain (20nM). Microvesicle detection is enhanced by higher 
concentration of calcein-AM (200nM) (C)  
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Investigation of calcein-AM as a generic marker for plasma microvesicles  
We next investigated calcein-AM as a generic staining method in platelet rich plasma. 
Although not previously described, we considered that this method might be an ideal 
approach for identifying microvesicles in burn patients. We speculated that plasma would 
be a significant source of small non-vesicular particles, such as immune complexes and 
other protein aggregates. By preferentially staining vesicles of cellular origin with a relatively 
inert, non-protein-binding cytoplasmic dye such as calcein-AM, we hoped a fluorescence 
discriminator could be used to maximise the microvesicle count, whilst minimising noise. 
 
Blood was sampled as above and centrifuged to pellet cells. Plasma was collected and 
analysed immediately. Samples were stained with a combination of calcein-AM (200nM), 
anti-CD42b and annexin V-APC. Annexin V binds to phosphatidylserine, which is externalised 
during microvesicle formation 377,390.  CD42b (glycoprotein 1b alpha), is widely used as a 
platelet surface marker 343,391–395. As a comparator, we also assessed side scatter as the 
trigger parameter. This has lower levels of background light detection than forward scatter 
368, with the potential for improved resolution, as evidenced by our earlier sizing bead 
analysis. Although the exact side scatter value will not reflect the size of microvesicles 396, 
using this parameter as the trigger had the potential for reducing noise 367. Repeat sample 
acquisitions were performed, using fluorescence (FITC) and side scatter triggers separately. 
Microvesicles were defined as events positive for annexin V and CD42b, with a forward 
scatter less than 1.3μm sizing beads. 
 
When using the combination of calcein-AM staining and a fluorescence trigger, it was 
possible to identify separate platelet and platelet microvesicle populations (figure 3.7A). 
However, by using a side scatter trigger, it was possible to detect a higher number of 
platelet microvesicles, despite a lower overall number of events (figure 3.7B). We attributed 
this to relatively weak calcein-AM staining of microvesicles, as well as staining of non-
vesicular plasma constituents, i.e. the side scatter trigger had greater sensitivity and 
specificity for microvesicles. We therefore concluded that side scatter was a more suitable 
trigger parameter to use for analysing microvesicles in plasma.  
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Figure 3.7 Comparison of fluorescence trigger and side scatter trigger for detecting 
platelet microvesicles stained with cytoplasmic and surface dyes 
Flow cytometry plots of platelet microvesicles (AV+/CD42b+) in human 
plasma. Microvesicle detection is lower when using direct calcein-AM stain 
and fluorescence trigger (A) than when using side scatter trigger (B), despite 
more events being detected overall 
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Platelet microvesicles are sensitive to lysis with Triton X-100 
Next we investigated methods to verify identification of events as microvesicles. The 
presence of immune complexes in the fluid being analysed may lead to overestimation of 
microvesicle numbers 372. Self-aggregation of fluorescent antibodies may also form protein 
complexes that can mimic vesicular events 298. Some authors therefore advocate the use of 
a detergent lysis step, to differentiate insoluble protein aggregates from genuine 
microvesicles 300,373,397. 
 
We tested this procedure by adding Triton X-100 (TX-100), a non-ionic surfactant, to the 
microvesicle samples after they had been analysed. Addition of TX-100 (final concentration 
0.1%) to plasma samples resulted in the disappearance of virtually all annexin V+/CD42b+ 
events (figure 3.9 A and B). We concluded these represented genuine platelet microvesicles. 
This was also the case when TX-100 was added to samples containing RAW cell-derived 
microvesicles. The small number of detergent-insoluble events remaining can be subtracted 
from the total gated event count, to give a final microvesicle count. 
 
 
 
Figure 3.8 Effect of Triton X-100 detergent on platelet microvesicles 
Majority of Annexin V+ / CD42b+ events (A) are lysed by Triton X-100 
detergent (B), indicating they are genuine platelet microvesicles  
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Calibration of the forward scatter size gate using platelet microvesicles 
We next sought to establish a biological reference point so that a forward scatter value 
could be set to define microvesicles accurately. Sizing beads have conventionally been used 
for this purpose, however as explained above, some beads scatter more light than similarly-
sized membrane-bound particles 366. One approach is to create artificial phospholid vesicles 
of known diameter 364.  A more relevant method is to stimulate plasma to generate a 
population of microvesicles, which can then be compared to sizing beads. This technique 
has been used previously, with calcium ionophore A23187 as the stimulant 380. 
 
Platelet-rich plasma was stimulated with A23187 (10μM) for 30 minutes. The plasma was 
then stained as above to analyse platelet microvesicle content. In unstimulated plasma, the 
smallest platelets coincided with the forward scatter value of 1.3μm sizing beads (figures 
3.9A and C respectively). Following stimulation of plasma, a microvesicle population became 
evident, the upper forward scatter limit of which also corresponded to 1.3μm sizing beads 
(figure 3.9B and C).  The microvesicle population was both annexin V+ / CD42b+ and TX-100-
sensitive. We were therefore confident that these were the expected platelet microvesicles. 
We concluded that the 1.3μm beads were an appropriate means to define a microvesicle 
scatter gate for future experiments. 
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Figure 3.9 Flow cytometry plots demonstrating calibration of microvesicle gate 
(A)  Human platelet-rich plasma, with platelet population indicated 
(B)  Following stimulation of plasma with A23187, a platelet microvesicle 
population is visible 
(C)  Upper forward scatter limit of the microvesicle population corresponds 
to 1.3μm sizing beads  
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Microvesicle background fluorescence as determined by matched isotype controls 
Antibody isotype controls have traditionally been used in flow cytometry to distinguish 
“fluorescent-positive” from “fluorescent-negative” populations 398. Staining with isotype 
controls of irrelevant specificity indicates the component of the fluorescence signal emitted 
by cells due to Fc receptor or non-specific antibody binding 399, in addition to the intrinsic 
auto-fluorescence of the cell. However, isotypes controls exhibit limitations and drawbacks. 
They are secreted by abnormal “hybridoma” cells and subtle differences in immunoglobulin 
structure can exist, despite being matched for subclass. Errors can also be introduced by 
differences in manufacturing protocols, fluorophore-antibody conjugate ratios and antibody 
concentrations. The appropriateness of isotype controls for cellular analysis has 
consequently been questioned 398–400. 
 
When analysing microvesicles, these issues become more significant. Because of a smaller 
surface area, antibody binding to microvesicles is much less than that to cells. Considerable 
variations in the binding of isotype controls have been demonstrated and this would have a 
disproportionate effect on microvesicle quantification 400. These problems may be 
exacerbated by the issues of their broad size range and overlap with machine noise. We 
therefore did not routinely use isotype controls in our quantification of microvesicles. 
However, it was important to demonstrate the absence of significant non-specific antibody 
binding. 
 
Plasma samples were analysed for CD45+ (protein tyrosine phosphatase receptor type C), 
CD66b+ (CEACAM8) and CD105+ (endoglin) microvesicles. Triton X-100 detergent was then 
added to each sample, to identify non-vesicular events. The results were compared to 
plasma samples stained with matched isotype controls. Because of low numbers of 
microvesicles in healthy volunteers, this was necessarily performed on samples from burn 
patients. The number of fluorescent-positive events identified by isotype controls was low in 
each case (figure 3.10). We concluded that non-specific antibody binding was not a 
significant contribution to microvesicle fluorescence in our samples.  
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Figure 3.10 Cytometry plots of burn patient plasma samples labelled with antibodies to 
cell-surface markers and matched isotype controls 
Detergent-sensitive CD45+ (A), CD66+ (B) and CD105+ (C) microvesicle 
populations are demonstrated above red cut-off line. Staining with isotype 
controls does not demonstrate significant non-specific antibody binding  
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3.5 Results – Effect of sample processing and storage 
  
Centrifugation protocols that deplete platelets also result in significant loss of 
microvesicles 
Several sources advocate multiple plasma centrifugation steps, of increasing speed, to 
remove as many platelets as possible 359,377. One argument for this is to minimise generation 
of microvesicles from residual platelets when a sample is freeze-thawed 380,401. However, 
other investigations have found that even a moderate speed centrifugation will result in 
some microvesicle loss 378. We therefore investigated the effect of different centrifugation 
speeds on the microvesicle levels detected by our flow cytometer. 
 
Healthy volunteer blood was centrifuged at 200g for 10 minutes to generate platelet-rich 
plasma (PRP). This was the minimum speed we could use to obtain a sufficient yield of 
plasma from whole blood. A further centrifugation at 1500g for 20 minutes was performed 
to generate platelet-poor plasma (PPP). PRP and PPP were analysed for platelet microvesicle 
content. Samples were used immediately after venepuncture to minimise ex vivo 
microvesicle production from platelets and events were size-gated to minimise the inclusion 
of platelets in the microvesicle counts. A second analysis was performed using neutrophil 
microvesicles generated according to the protocols developed in chapter 5. 400μl of 
neutrophil microvesicles (cell-free, mean 27,000 MV μl-1) were added to 600μl of 
ultracentrifuged fresh human serum. This was centrifuged at 200g for 10 minutes, with half 
of the supernatant undergoing a further centrifugation at 1500g for 20 minutes. 
 
The second centrifugation step resulted in a significant reduction of both platelet (figure 
3.11A) and neutrophil (figure 3.11B) microvesicle counts. We therefore concluded that 
microvesicle levels and composition in PPP were unlikely to reflect those circulating in vivo 
and that PRP was a more suitable plasma preparation to investigate.  
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Figure 3.11 Effect of serial centrifugations on microvesicle counts  
Platelet-derived (A) (n=5) and neutrophil-derived (B) (n=4) microvesicle counts 
are significantly reduced when centrifugation at 200g for 10 minutes is 
followed by further centrifugation at 1500g for 20 minutes 
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Leukocyte microvesicle detection levels in platelet plasma are minimally changed by one 
freeze-thaw cycle 
Storage of microvesicles would have considerable advantages for studying patients with 
burn injuries. Such patients are admitted on an emergent basis and samples cannot always 
be collected during daylight hours. Presentation to non-specialist hospitals is also relatively 
rare. A reliable storage method would also facilitate multi-centre studies 365. Several 
publications have shown that freezing of PRP and PPP increases platelet microvesicle counts 
333,378,380. Leukocyte and endothelial cell microvesicle counts have been shown to be stable 
after a freeze-thaw cycle 380, although this analysis was performed using PPP. Given the 
deleterious effects of higher centrifugation speeds as highlighted above, it was important to 
confirm that storage of PRP had no effect on detection of non-platelet microvesicles. 
Because of the very low circulating levels in healthy volunteers, this analysis necessarily 
included samples from patients. 
 
PRP was prepared as before and aliquots were frozen at -80°C.  Fresh samples were 
analysed for leukocyte microvesicle content. Leukocyte microvesicles were defined using a 
similar method for platelet microvesicles, but CD45 was used as the surface marker. 
Neutrophil microvesicles were defined as CD11b+ / CD66b+. Frozen samples were thawed at 
room temperature before analysis using the same procedure; these results were then 
compared to the matched fresh sample. 
 
The appearance of leukocyte (CD45+), monocyte-macrophage (CD45+ / CD14+) and 
neutrophil (CD11b+ / CD66b+) microvesicle populations were similar, when fresh and 
frozen-thawed samples were compared (figure 3.12, A and B). In contrast, platelet 
microvesicles are clearly altered by the freezing process, with a disappearance of AV- 
platelets and consequent loss of distinction between platelets and microvesicle populations. 
It appeared that freeze-thawing results in most platelet (CD42b+) events binding AV, 
presumably due to loss of membrane integrity and access of AV to the phosphatidylserine-
rich inner face of the plasma membrane. 
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Figure 3.12 Effect of freeze-thaw cycle on leukocyte and platelet microvesicle plots 
Plasma CD45+ / CD14+ (A) and CD11b+ / CD66b+ (B) microvesicle flow 
cytometry plots are similar when fresh and frozen-thawed samples are 
compared. AV+ / CD42b+ microvesicle plots are different when fresh and 
frozen-thaw samples are compared, with complete loss of platelets (C)  
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The total leukocyte microvesicle counts were minimally affected by the freeze-thaw cycle, 
with only minor increase or decreases in numbers observed (figure 3.13A). This was also the 
case for monocyte-macrophage microvesicles (figure 3.13B) and neutrophil microvesicles 
(figure 3.12C). 
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Figure 3.13 Effect of freeze-thaw cycle on leukocyte microvesicle counts 
Total leukocyte (CD45+) (A), monocyte-macrophage (CD45+/CD14+) (B) and 
neutrophil (CD11b+/CD66b+) (C) microvesicle counts in platelet-rich plasma 
were minimally affected by one freeze-thaw cycle (n=5)  
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3.6 Discussion 
 
In order to analyse microvesicles from patient samples, we undertook a series of flow 
cytometry-oriented optimisation and validation studies. Despite its versatility and precision 
for cell analysis,  there is no universal standardised approach to using flow cytometry for 
microvesicle analysis, although this is an active and advancing aspect of research in this field 
303,346,365,402. We therefore sought to apply some of the techniques used by other 
researchers to our flow cytometer set up (BC Cyan ADP) to generate a robust, reliable 
method of analysing microvesicles, whilst identifying potential limitations. 
 
First, we used calibrated sizing beads to establish some baseline characteristics of our 
cytometer. We found that when using a forward scatter trigger, we could detect and 
discriminate beads of 1.3μm. However, the forward scatter signal of smaller beads merged 
with background noise. When utilising a fluorescence trigger, this noise was reduced and it 
was possible to discern the beads of size 880nm. By incorporating the side scatter signal, the 
490nm and 220nm beads could also be discriminated from each other. The cytometer 
behaviour observed here was largely to be expected. It is known that as particle size 
decreases, light scatter decreases in a non-linear fashion 347,368. This explains why it was not 
possible to detect separate forward scatter signals for the smallest beads, even when noise 
was reduced by using a fluorescence trigger. 
 
The performance of newer cytometers, for example the Gallios (Beckman Coulter) is 
improved by analysing forward scatter light over a relatively wide angle 346,358. Cytometers 
that are designed specifically to analyse small particles, such as the A50 (Apogee), can 
distinguish beads of 100nm diameter 358,392. However, our preliminary results did show that 
our cytometer was capable of detecting particles in the size range of microvesicles. They 
also demonstrated that background noise could be reduced considerably by avoiding use of 
forward scatter as an event acquisition trigger.  
 
Having established that sheath-sample fluid refractive index matching was essential to avoid 
distortion of forward scatter, our next set of experiments assessed the feasibility of using a 
fluorescence trigger to detect microvesicles. This was an approach suggested by several 
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sources 349,367–370. We began by investigating microvesicles released by RAW 264.7 cells, a 
murine leukaemic monocyte macrophage cell line. When fluorescent antibodies to CD11b 
were combined with a fluorescent trigger, the detection of microvesicles increased 
dramatically. This demonstrated the principle of using a dye to amplify an intrinsic property 
of the microvesicles. However, for it to be applicable to human samples, we needed a 
generic label that could be used for heterogeneous microvesicle populations. CFDA-SE was 
evaluated in the first instance, a cytoplasmic dye converted to a fluorescent form (CFSE) by 
intracellular esterases. We found that if the parent cells were stained prior to stimulation, a 
large increase in RAW microvesicle count could be detected following stimulation. However, 
this effect was markedly reduced when the microvesicles were stained directly. The reason 
for this was unclear. It is known that CFSE has a cytotoxic effect 403,404 but if this induced 
microvesicle release it might be expected in the unstimulated as well as stimulated cells. 
Another possible cause is that only a protein-conjugated form of CFSE (CFR2) is fully 
retained in the cytoplasm; this conjugation may not occur to the same extent in vesicles, 
due to selective packaging of contents.  
 
We next trialled calcein-AM (C-AM), which had theoretical advantages over CFDA-SE in that 
it does not rely on protein binding and is retained in the cytoplasm to a greater extent 387–
389. Unfortunately, we could not demonstrate a benefit of using a C-AM/fluorescence trigger 
combination, when compared to a forward scatter trigger. In fact, the use of both 
parameters as a discriminator proved problematic, due to the sheer number of events 
detected. This could only be avoided by raising the threshold value, which is in itself an 
issue, as genuine particles of interest can be excluded 368.  In contrast, the use of a side 
scatter trigger enabled the consistent acquisition of data from plasma samples, without 
compromising the microvesicle count.  Furthermore, the side scatter trigger resulted in a 
greater signal to noise ratio. A major advantage of the side scatter trigger is that it provides 
an intrinsic detection signal, minimally affected by the type of microvesicle or biological 
fluid. It also removes the need for a dedicated labelling step. We therefore concluded that 
side scatter was the best initial discriminator for analysing plasma samples with our Cyan. 
The principle remains promising however, and colleagues in our research group have had 
success using PKH26, a lipophilic dye 382, for in vitro investigations. 
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In order to distinguish microvesicles from non-vesicular particles, such as immune 
complexes, we investigated a detergent lysis method using TX-100. This procedure had 
previously been described 372. The vast majority of the population we had identified as 
microvesicles proved sensitive to lysis, increasing our confidence in our results. A further 
advantage of this step was that it provided a suitable background fluorescence level for 
each antibody combination, as well as allowing subtraction of false positive events from the 
microvesicle total. A common approach when performing conventional flow cytometry is to 
use isotype control antibodies, to establish the non-specific background signal. However, 
this technique can represent a major source of error if used with microvesicles. Because the 
frequency of microvesicle antigens is low and varies randomly, variations in isotype binding 
can significantly affect microvesicle quantification 400. Our analysis of burn patient samples 
did not reveal significant background fluorescence following labelling with isotype controls. 
 
Because microvesicles, unlike cells, do not form a discrete population of similar dimensions 
on a flow cytometry plot, it is necessary to use a cut-off value of some sort. This is 
commonly performed by using polystyrene sizing beads 365. However, these refract light to a 
greater extent than membrane-bound particles 366. We therefore created a biological 
standard by stimulating platelets to generate microvesicles, as described by Ayers et al 380, 
the upper limit of which matched the forward scatter of 1.3μm beads. This was 
advantageous as it would not be practical to generate the microvesicle population for every 
experiment. 
 
The only way to reliably differentiate microvesicles from small platelets on the basis of size 
would be to reduce the forward scatter value we were using as a cut-off, sacrificing 
sensitivity for specificity. As an additional discriminator, platelet-specific surface markers are 
commonly used in combination with annexin V 359,365,378,392 and this was the approach we 
used. Annexin V binds to phosphatidylserine, externalised during the vesiculation process 
390. However, some studies have suggested that only a minority of platelet microvesicles 
bind annexin V 352. Therefore, the numbers of platelet microvesicles are likely to be 
underestimated if small platelets are excluded with any degree of confidence. The problems 
faced when quantifying platelet microvesicles continue when the effect of centrifugation is 
considered. As discussed above, depletion of platelets from plasma is advocated to 
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minimise ex vivo microvesicle production. However, we found that even the production of 
PPP, which requires less centrifugation than PFP, removed the majority of microvesicles. 
This was consistent with other published data 378. We concluded that none of the plasma 
preparations described was likely to yield representative microvesicle counts. One caveat is 
that platelet microvesicles from inflamed patients might be smaller and sediment at higher 
centrifugal forces, which could allow greater separation using centrifugation. Freeze-thaw 
analysis of ionophore stimulated-plasma could be used to test this idea. In contrast to 
platelets, leukocytes are separated from plasma by low-speed centrifugation. Ex vivo 
leukocyte microvesicle production should therefore be minimised, whilst preserving 
microvesicle yield. 
 
The last issue we addressed in this chapter was the storage of microvesicles. Leukocyte 
microvesicles have previously been shown to tolerate a freeze-thaw cycle when stored in 
PPP 380 but we wanted to confirm that this would be the case when PRP was stored. 
Endothelial cell microvesicle counts have also been shown to be minimally changed by 
freezing 380. Endothelial cells circulate at very low levels, with a mean level of 0.4 per 
millilitre in health, vs 7 x 106 leukocytes per millilitre 405. There is therefore minimal 
potential for ex vivo endothelial microvesicle generation. 
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Chapter 4 
Circulating microvesicles in patients with burn injuries 
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Summary 
 
The period following a severe burn is characterised by marked systemic inflammation. 
Microvesicles are thought to play a key role in propagating the inflammatory response 
associated with other conditions such as sepsis but they have not been investigated in 
patients with burn injuries. We sought to establish whether microvesicle release by 
leukocytes and endothelial cells, as part of the inflammatory response to burn injury, would 
be altered in comparison to that seen in healthy volunteers. We also sought to identify any 
changes in microvesicle profile over the days following burn injury. 
 
Blood samples were taken from patients admitted to the Burn Intensive Care Unit, within 24 
hours of injury. Samples were also taken from healthy volunteers (negative controls) and 
patients with severe sepsis (positive controls). Plasma was obtained by centrifugation and 
stored for subsequent analysis. An optimised flow cytometry protocol was used to quantify 
microvesicles derived from leukocytes, neutrophils, monocytes/macrophages and 
endothelial cells. Clinical information including laboratory blood results, severity of illness 
scores and outcome data was also recorded. 
 
On day zero, elevated circulating levels of all microvesicle populations were evident in burn 
patients, in comparison to healthy volunteers. These counts then decreased rapidly over the 
subsequent 48 hours. Leukocyte counts did not correlate with microvesicle levels and 
decreased at a slower rate following injury, implying that increased microvesicle numbers 
are not a simple reflection of leukocytosis. A strong correlation was found between total 
leukocyte microvesicle levels and the ABSI and BOBI injury severity scores. Leukocyte-
derived microvesicles were also significantly elevated in non-survivors of burn injury. 
 
The results suggested that leukocyte and endothelial cell-derived microvesicles may be 
important to the systemic inflammatory response that occurs following a severe burn. They 
provide targets for investigation in mechanistic studies and show potential for use as 
prognostic markers in burn patients. 
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4.1 Background 
 
The systemic inflammatory response precipitated by a severe burn leads to widespread 
vascular leak, hypermetabolism, hypercatabolism and a propensity towards multi-organ 
failure 113,406. This inflammatory response is thought to be mediated at least in part by 
circulating cytokines 103,234,239,248. An accumulating body of evidence supports the idea that 
in other inflammatory conditions, such as sepsis, microvesicles play a key role in the 
immuno-vascular response 3,318,319,329. However, the production of microvesicles following 
severe burns or contribution to post-burn inflammation has not previously been 
investigated. 
 
Following tissue damage such as that caused by burn, endogenous DAMPs are released, 
which activate resident macrophages 193. This initiates recruitment of neutrophils to the site 
of damage, followed by secondary recruitment of circulating monocytes 191,192,207,208. 
Endothelial activation, which upregulates surface adhesion molecules, is key to the 
recruitment of inflammatory leukocytes 203,205. These processes are mediated by cytokines 
and chemokines such as TNF-α, IL-6 and MCP-1, which are elevated following burn injury 
194,196,197. Microvesicles are elicited by multiple inflammatory stimuli, including DAMPS and 
cytokines, and therefore their release from myeloid leukocytes and endothelial cells should 
be expected in the acute post-burn phase.  The potential sources of circulating leukocyte 
and endothelial microvesicles in burn patients can be categorised into two groups. Firstly, 
the areas of ischaemic and inflamed tissue that surround coagulated necrotic tissue – 
Jackson’s zones of stasis and hyperaemia 17. Secondly, remote organ systems injured by (and 
perpetuating) the systemic inflammatory response – in particular, the cardiovascular 
system, lungs and kidneys 118. 
 
Leukocyte-derived microvesicles, circulating at low levels in health, have been found at 
elevated levels in patients with other inflammatory conditions such as sepsis and major 
trauma 313,330,385,407. In vitro studies have suggested these microvesicles can act as 
inflammatory mediators; neutrophil-derived microvesicles for instance activate endothelial 
cells 318,319. Monocyte-derived microvesicles have been shown to exhibit autocrine 
activation of monocyte/macrophages 311 and increase nitrosative stress in endothelial cells 
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408. It was therefore relevant to the post-burn inflammatory response and organ dysfunction 
to establish if these populations could be detected in patients with burn injuries. 
 
Endothelial microvesicles have also been associated with inflammation, both as mediators 
and markers 334,409. In the context of end-stage renal failure, elevated microvesicle levels 
were associated with clinical and experimental evidence of endothelial dysfunction 410. 
Endothelial microvesicles are also capable of inducing pulmonary inflammation by initiating 
a cytokine cascade 411. In vitro studies have suggested that they can act as paracrine 
mediators, inducing an inflammatory response in “naïve” endothelium 326. This was found to 
be a p38-dependent process. It is not clear, however, that elevated levels of endothelial 
microvesicles are associated with a poorer outcome in patients. In severe sepsis, increased 
counts correlated with improved survival 343 and some argue endothelial microvesicles may 
have protective effects 412. 
 
As part of this observational study, we also recorded clinical data, including outcome and 
severity of illness scores. A number of clinical scoring systems have been devised for 
patients with burn injuries. The abbreviated burn severity index (ABSI) is in widespread use 
and is based on a combination of five variables 72. Although published in 1982, recent 
reviews have established that it remains methodologically sound and  robust as a predictive 
tool 67,73,80. A more recent system was developed by the Belgian Outcome in Burn Injury 
(BOBI) group. This has been validated externally 79 and is also robust 67. Both of these 
systems use hospital mortality as their outcome. 
 
We included in our analysis samples from healthy volunteers and patients with severe 
sepsis. We expected to find low levels of circulating leukocyte and endothelial microvesicles 
in healthy participants 3,334,413 and this was our negative control group. In contrast, elevated 
levels of both populations were expected to be found in sepsis patients 330,343 and this group 
served as a positive control.  
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4.2 Aims 
 
The specific aims in this chapter were as follows: 
 
1. To characterise leukocyte and endothelial-derived microvesicle populations in 
patients with severe burn injuries 
2. To relate the microvesicle analysis to clinical data including severity of illness 
scores and patient outcomes 
 
4.3 Protocols 
 
Patient selection 
Our study was approved by a local research ethics committee (NRES Committee London – 
Camden & Islington, reference 12/LO/1543) and our Department of Research & 
Development (reference C&W12/101). All participants were over 18 years of age and were 
excluded if pharmacologically immunosuppressed pre-injury, or known to be infected with 
blood-borne viruses. A prospective power calculation was not possible because the “effect 
size” was unknown and previous research  led us to suspect microvesicle counts would not 
be normally-distributed 414. However, based on our admission rates, we expected that it 
would be possible to recruit 15-20 burn patients during the study. All patients admitted to 
the Burns Intensive Care Unit at Chelsea and Westminster Hospital were screened for 
eligibility. Patients were excluded if they had injuries judged too extensive for active 
treatment.  
 
Healthy volunteers were recruited from laboratory staff at Imperial College London and 
from clinical staff at Chelsea and Westminster Hospital Intensive Care Unit. Volunteers were 
excluded if they were suffering from intercurrent illness or if they had undergone 
venesection within seven days. Patients with severe sepsis, as defined by the American 
College of Chest Physicians/Society of Critical Care Medicine (ACCP/SCCM) Consensus 
Conference Committee, were recruited from the General Intensive Care Unit at Chelsea and 
Westminster Intensive Care Unit.  
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Sampling 
Initial sampling of burn patients occurred within 24 hours of injury. Further samples were 
taken on days two and five. Blood (18mls) was obtained from arterial cannulas, or central 
venous catheters if arterial blood was unavailable. A single sample was taken from the 
healthy volunteers and severe sepsis patients, who were sampled within 48 hours of 
identification of sepsis. The sepsis group included both community and hospital-acquired 
infections, with variable prodrome duration. Blood was transferred into lithium heparin 
Vacutainers and processed immediately for storage at -80⁰C. Samples were subsequently 
analysis. 
 
Analysis 
Thawed platelet-rich plasma (PRP) was stained with fluorescent antibodies, using the 
protocol explained in chapter 3, in the following combinations: 
 
1. CD45-APC / CD14-PE 
2. CD11b-APC / CD66b-PE 
3. CD105-PE 
4. CD106-APC / CD62e-PE 
 
Fluorophores were limited to PE and APC to standardise sensitivity and minimise spectral 
overlap. 
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4.4 Results 
 
Patient demographics and baseline characteristics 
Details of the burn injuries group are shown in table 4.1. The parameters included are those 
required to calculate the Abbreviated Burn Severity Index (ABSI) and Belgian Outcomes in 
Burn Injury (BOBI) scores. Burn patients were recruited to the study as soon after admission 
as possible and all participants were sampled within 24 hours of injury. However, as the 
majority of patients were transferred from other hospitals, a short delay was unavoidable. 
The mean time from injury to sampling was 11 ± 4.9 hours. 
 
A total of 16 burn patients were recruited during the study, with a median burn size of 28% 
of Total Body Surface Area (TBSA). The median ABSI value was 8, corresponding to a 
predicted mortality of 30-50% 73. Actual hospital mortality for the cohort was 31%, with all 
five deaths occurring in ICU following a planned withdrawal of care. Significant differences 
between survivors and non-survivors were observed for age and the presence of inhalation 
injury. 
 
Table 4.2 demonstrates the clinical data for patients with severe sepsis. A total of 15 
participants were recruited. 53% had a pulmonary source of infection, with most of the 
remainder having an abdominal source. The median Acute Physiology and Chronic Health 
Evaluation (APACHE) II score was 21, equivalent to a predicted mortality of 30-40% 415. 
Actual hospital mortality was 33%. There were no statistically significant differences 
between the burn and sepsis patients in terms of age, gender, ICU length of stay, hospital 
length of stay, or mortality rates.  
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 Burn Patients 
All 
(n = 16) 
Survivors 
(n = 11) 
Non-survivors 
(n = 5) 
p 
 Male sex, n (%) 11 (69) 7 (64) 4 (80) 1 
 Age, mean ± SD (years) 47 ± 23 38 ± 19 66 ± 20 0.02 
 Inhalation injury present, n (%) 8 (50) 3 (27) 5 (100) 0.03 
 Full thickness burn present, n (%) 11 (69) 6 (55) 5 (100) 0.12 
 Burn TBSA %, median (IQR) 28 (18-36) 30 (18-35) 25 (16-39) 0.98 
 ABSI, median (IQR) 8 (7-8) 7 (6-8) 10 (8-12) 0.03 
 BOBI, median (IQR) 3 (1-5) 2 (1-3) 6 (5-7) 0.001 
 Days in ICU, median (IQR) 15 (7-37) 15 (4-32) 12 (5-79) 0.98 
 Days in hospital, median (IQR) 42 (18-77) 54 (27-96) 12 (5-79) 0.22 
 
Table 4.1 Demographics data for burn patients 
SD – standard deviation; TBSA – Total Body Surface Area; IQR – interquartile 
range; ABSI – Abbreviated Burn Severity Index; BOBI – Belgian Outcome in 
Burn Injury 
 
Sex, presence of inhalation injury and presence of full thickness burn were 
compared with Fisher’s exact test. Ages were compared using unpaired t test. 
TBSA, ABSI, BOBI and lengths of stay were compared using Mann-Whitney 
test  
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 Sepsis Patients All (n = 15) 
 Male sex (%) 9 (60) 
 Age, mean ± SD (years) 58 ± 16 
 Source of sepsis, n (%)  
     Pulmonary 
     Abdominal 
     Soft tissue 
8 (53) 
6 (40) 
1 (7) 
 APACHE II, mean ± SD 20 ± 9 
 Days in ICU, median (IQR) 11 (7-22) 
 ICU mortality, n (%) 4 (27) 
 Days in hospital, median (IQR) 34 (23-145) 
 Hospital mortality, n (%) 5 (33) 
 
Table 4.2 Demographics data for sepsis patients 
SD – standard deviation; APACHE II - Acute Physiology and Chronic Health 
Evaluation II; IQR – interquartile range 
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Circulating leukocyte-derived microvesicle populations are elevated in patients with 
severe burn injuries 
Given the onset of the post-burn inflammatory response is known to be rapid 406,416 and our 
interest in the role of MV in propagation of systemic inflammation, our initial focus was the 
acute post-burn phase. Leukocyte-derived microvesicles were quantified within 24 hours of 
burn injury. Sampling, processing, storage and analysis were performed using the protocols 
described in chapter 3. The results were compared to those from healthy volunteers and 
patients with severe sepsis. 
 
Patients with burn injuries had significantly elevated levels of total leukocyte-derived 
(CD45+) microvesicles within 24 hours of admission compared to healthy volunteers (Fig 
4.1A). However, levels of CD45+ microvesicles in sepsis patients were not significantly 
different from those in burns patients. Neutrophil-derived (CD11b+/CD66b+) microvesicles 
were elevated in burn patients and sepsis patients compared to healthy volunteers (figure 
4.1B), with no significant difference between the burn and sepsis groups. By contrast, 
monocyte/macrophage-derived (CD45+/CD14+) microvesicles in burn patients were 
significantly higher than in both the healthy volunteer and the sepsis groups (figure 4.1C). 
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Figure 4.1 Comparison of circulating leukocyte microvesicle levels in healthy 
volunteers, patients with burn injuries and patients with severe sepsis 
Blood was sampled from burn patients within 24 hours of injury and from 
sepsis patients within 48 hours of identification of sepsis 
 
(A)  Circulating leukocyte (CD45+) microvesicle levels are significantly 
elevated in patients with burn injuries, in comparison to healthy 
volunteers (HV). Levels in patients with severe sepsis are not 
significantly different from those found in burn patients 
(B)  Circulating neutrophil (CD11b+/CD66b+) microvesicle levels are 
significantly elevated in patients with burn injuries and severe sepsis, 
in comparison to healthy volunteers (HV). Levels found in burn 
patients are not significantly different from those found in sepsis 
patients 
(C)  Circulating monocyte/macrophage (CD45+/CD14+) microvesicle levels 
are significantly elevated in patients with burn injuries, in comparison 
to both healthy volunteers (HV) and patients with severe sepsis 
  
Kruskal-Wallis test with Dunn’s multiple comparisons test 
*p<0.05 
**p<0.01 
  ****p<0.0001 
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Leukocyte-derived microvesicle levels in burn patients are similar in arterial and venous 
circulations 
Animal and human studies suggest that clearance of microvesicles occurs rapidly, which 
implies that microvesicles are continuously produced 393,417,418. Uptake is primarily 
performed in the liver and spleen by macrophages 419,420. Production of microvesicles, in the 
context of burns, may occur at sites of injury but also in remote organs such as the lungs. 
Microvesicle levels may therefore vary according to sampling site. Paired samples of arterial 
and venous blood were taken simultaneously from burn patients, within 24 hours of injury. 
Leukocyte-derived microvesicles were subsequently quantified. 
 
No significant differences were found between arterial and venous samples, in terms of 
total leukocyte-derived, neutrophil-derived or monocyte/macrophage-derived microvesicles 
(figure 4.2A-C). This suggested that the circulating microvesicle counts reflected a steady-
state between production and uptake that was relatively consistent throughout the 
circulation. 
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Figure 4.2 Comparison of post-burn leukocyte microvesicle counts in paired arterial 
and venous samples 
Blood was sampled simultaneously from indwelling arterial and central 
venous catheters, within 24 hours of burn injury 
 
No significant difference in leukocyte (A), neutrophil (B) or 
monocyte/macrophage (C) microvesicle levels, between arterial and venous 
samples 
 
Wilcoxon matched-pairs signed rank test 
(n=6)  
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Circulating leukocyte-derived microvesicle levels decrease by day two post-injury 
Having identified increased quantities of circulating leukocyte-derived microvesicles in the 
first 24 hours following burn injury, we next sought to characterise changes in this profile 
over time.  Studies investigating temporal changes in cytokine levels tend to show an early 
peak after burn injury with a decrease over time 103,421, although this is not universal 406. In 
contrast, some clinical parameters such as temperature and leukocyte count remain 
persistently elevated for at least 20 days post-injury 422. 
 
To evaluate early post-burn microvesicle kinetics, repeat blood samples were taken where 
possible. Paired analyses of samples from day zero and day two post-burn (n=8) indicated 
that the numbers of leukocyte-derived microvesicles declined significantly in all 
subpopulations. The median total leukocyte-derived MV count reduced from 2711 (1335-
2977) MV μl -1 to 617 (327-983) MV μl -1 (figure 4.3A). Median neutrophil-derived MV levels 
reduced from 989 (450-2686) MV μl -1 to 325 (110-520) MV μl -1 (figure 4.3B). The median 
monocyte/macrophage MV count fell from 223 (158-996) MV μl -1 to 60 (3-185) MV μl -1 
(figure 4.3C). Total leukocyte and neutrophil cell counts were also significantly lower at day 
two post-burn. However, the magnitude of reduction was much smaller in each case; mean 
leukocyte cell counts fell from 18.8 ± 8.5 x106 ml -1 to 14 ± 6.2 x106 ml -1 (figure 4.4A) and 
neutrophil counts decreased from 14.6 ± 6.9 x106 ml -1 to 10.8 ± 5.4 x106 ml -1 (figure 4.4B) 
Circulating monocyte counts were not significantly lower at day two (Figure 4.4C). 
 
Samples were also available from day five post-injury but due to the relatively low n number 
of 5, these were not included in the statistical analysis. Median levels of CD45+ and 
CD45+/CD14+ microvesicles were the same at day five as day two, whereas median 
CD11b+/CD66b+ microvesicle counts were further reduced at day five (data not shown). 
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Figure 4.3 Change in circulating leukocyte microvesicle levels over time following burn 
injury  
  Blood was sampled on day zero (n=8) and day two (n=8) 
 
(A)  Significant decrease in leukocyte (CD45+) microvesicle levels by day 
two post-burn injury 
(B)  Significant reduction in neutrophil (CD11b+/CD66b+) microvesicles by 
day two post-burn injury 
(C)  Significant decrease in monocyte/macrophage (CD45+/CD14+) 
microvesicles by day two post-burn injury 
 
Wilcoxon matched-pairs signed rank test 
*p<0.05 
**p<0.01  
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Figure 4.4 Change in leukocyte cell counts over time following burn injury 
Cell counts were recorded from clinical laboratory analysis of blood sampled 
on day zero (n=8) and day two (n=8) post-injury 
 
(A)  Significant reduction in total leukocytes by day two post-burn 
(B)   Significant reduction in neutrophils by day two post-burn 
(C)  Similar levels of monocytes at day zero and day two 
 
Paired t test 
  
109 
 
Circulating endothelial cell-derived microvesicle populations are elevated in patients with 
severe burn injuries 
We next investigated endothelial cell-derived microvesicles because of evidence linking 
them to endothelial dysfunction in sepsis 343, trauma 423 and related organ dysfunction 
410,411. In addition to mediating pro-inflammatory states, they may also have clinical utility as  
biomarkers  332,334,409. 
 
Because of the known heterogeneity in endothelial microvesicle surface molecule 
expression 331,334,424, antibodies to three separate markers were selected: CD105 (endoglin), 
CD62e (E-selectin) and CD106 (VCAM-1). CD105 is constitutively expressed by endothelial 
cells 425, whereas CD62e (E-selectin) and CD106 (VCAM-1) are upregulated following 
endothelial activation 418,426. 
 
CD105+ microvesicles were found to be significantly elevated in burns patients, in 
comparison to both healthy volunteers and patients with severe sepsis (figure 4.5A). In 
contrast to the uniformly low leukocyte microvesicle levels in healthy volunteers, levels of 
CD105+ in some individuals were higher than the patient group mean values. Levels of 
CD62e+ and CD106+ microvesicles were significantly higher in burn patients, as compared to 
healthy volunteers but were not significantly different from sepsis patients (figure 4.5B and 
4.5C respectively).  
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Figure 4.5 Comparison of circulating endothelial levels in healthy volunteers, patients 
with burn injuries and patients with severe sepsis 
Blood was sampled from burn patients within 24 hours of injury and from 
sepsis patients within 48 hours of identification of sepsis 
 
(A) Circulating CD105+ microvesicle levels are significantly elevated in 
patients with burn injury, in comparison to both healthy volunteers 
and patients with severe sepsis 
(B) Circulating CD62e+ microvesicle levels are significantly elevated in 
patients with burn injury, in comparison to healthy volunteers. Levels 
found in patients with severe sepsis are not significantly different from 
those found in burn patients 
(C) Circulating CD106+ microvesicle levels are significantly elevated in 
patients with burn injury, in comparison to healthy volunteers. Those 
found in patients with severe sepsis are not significantly different from 
those found in burn patients 
 
Kruskal-Wallis test with Dunn’s multiple comparisons test 
*p<0.05 
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Circulating endothelial cell-derived microvesicles rapidly decrease post-burn injury 
As was the case with circulating leukocyte microvesicles, endothelial microvesicles also 
decreased by day two post-burn. This reduction was statistically significant in the case of 
CD105+ microvesicles, (figure 4.6A). The reduction in CD62e+ and CD106 microvesicle 
counts was less consistent and not statistically significant (figure 4.6B and C respectively). 
 
Levels of the three endothelial microvesicle populations were similar at day five (n=5) to 
those found at day two (data not shown). Circulating endothelial cells were not quantified. 
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Figure 4.6 Change in circulating endothelial microvesicle levels over time following 
burn injury 
  Blood was sampled on day zero (n=8) and day two (n=8) post-burn 
 
(A)  Significant decrease in CD105+ microvesicle levels by day two 
(B)  Statistically non-significant reduction in CD62e+ microvesicles by day 
two 
(C)  Statistically non-significant reduction in CD106+ microvesicles by day 
two 
 
Wilcoxon matched-pairs signed rank test 
*p<0.05 
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Levels of circulating leukocyte-derived microvesicles do not correlate with circulating 
leukocytes 
The elevation of leukocyte-derived circulating microvesicle levels may simply be a reflection 
of the increased numbers of circulating leukocytes in severe burns injury, as found here and 
in previous studies 198,217,219,422,427,428. We therefore compared leukocyte and microvesicle 
counts to establish if there was a direct relationship. Total leukocyte numbers were 
compared to CD45+ microvesicles, neutrophils to CD11b+/CD66b+ microvesicles and 
monocytes to CD45+/CD14+ microvesicles, in burns and sepsis patients. Correlation was 
determined using Pearson’s or Spearman’s correlation coefficient, as appropriate. 
 
In the burns group no significant correlation was found between leukocytes and CD45+ 
microvesicles (figure 4.7A), neutrophils and CD11b+/CD66b+ microvesicles (figure 4.7B), or 
monocytes and CD45+/CD14+ microvesicles (figure 4.7C). Analysis of the severe sepsis 
group generated the similar findings (figure 4.8A-C). Therefore, the increased microvesicle 
levels in both disease states were not merely results of leukocytosis and instead were likely 
to indicate enhanced microvesicle production by cells in response to the burn injury. 
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Figure 4.7 Comparison of cell and microvesicle counts on day zero post-burn injury 
No significant correlation found between leukocyte and CD45+ microvesicle 
counts (A), neutrophil and CD11b+/CD66b+ microvesicle counts (B), or 
monocyte and CD45+/CD14+ microvesicle counts (C) 
 
Correlation determined using Pearson’s correlation coefficient (A) and 
Spearman’s correlation coefficient (B and C) 
(n=16)  
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Figure 4.8 Comparison of cell and microvesicle counts in patients with severe sepsis 
No significant correlation found between leukocyte and CD45+ microvesicle 
counts (A), neutrophil and CD11b+/CD66b+ microvesicle counts (B), or 
monocyte and CD45+/CD14+ microvesicle counts (C) 
 
Correlation measured using Spearman’s correlation coefficient (A and B) and 
Pearson’s correlation coefficient (C) 
(n=15)  
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Circulating leukocyte-derived microvesicle levels correlate with the ABSI and BOBI burn 
severity scores 
Microvesicles have been proposed for use as biomarkers across a range of diseases 
303,353,429–431 but they have not previously been investigated in burn patients. Our objective 
was to test whether there was any relationship between circulating microvesicle levels and 
conventional means of quantifying burn severity. We therefore compared the %TBSA, ABSI 
and BOBI with each patient’s initial microvesicle counts. 
 
No significant correlation was identified between any microvesicle population and %TBSA. 
An example of the correlation analysis is shown for total leukocyte (CD45+) microvesicles vs 
%TBSA in figure 4.9A. A significant, strong correlation was found between CD45+ 
microvesicles and the ABSI score (r=0.63, p<0.01) (figure 4.9B).  A significant strong 
correlation was also identified between CD45+ microvesicles and the BOBI score (r=0.67, 
p<0.01) (figure 4.9C). No significant correlations were found between these scores and 
other leukocyte or endothelial microvesicle populations (data not shown). 
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Figure 4.9 Correlation between microvesicle counts and indices of burn injury 
(A)  No correlation was found between circulating CD45+ microvesicle 
levels and percent of Total Body Surface Area (TBSA) burned 
(B)  Significant, strong correlation between circulating CD45+ microvesicle 
levels and Abbreviated Burn Severity Index (ABSI) score 
(C)  Significant, strong correlation between circulating CD45+ microvesicle 
levels and Belgian Outcomes in Burn Injury (BOBI) score 
 
Correlation measured using Pearson’s correlation coefficient (A) and 
Spearman’s correlation coefficient (B and C) 
**p<0.01 
   (n=16)  
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Circulating leukocyte microvesicle levels are reduced in survivors of severe burn injuries 
To complete our analysis we compared microvesicle levels with actual mortality. This is an 
approach that has been taken with numerous biomarkers in burn patients 237,416,432–434. The 
positive correlation between leukocyte microvesicles and ABSI/BOBI scores suggested these 
microvesicles may be increased in non-survivors of burn injury. All burn patients were 
followed to hospital discharge or death. Patients were classified as survivors or non-
survivors accordingly. Levels of each microvesicle population, as measured in samples taken 
on day zero, were compared between each group. 
 
Total leukocyte (CD45+) microvesicles were significantly elevated in non-survivors as 
compared to survivors (figure 4.10A). Neutrophil (CD11b+/CD66b+) microvesicles were also 
significantly increased in the non-survivors group (figure 4.10B). A statistically non-
significant increase in monocyte/macrophage (CD45+/CD14+) microvesicles was identified 
(figure 4.10C). No differences were found in CD105+ or CD62e+ endothelial microvesicle 
levels (figure 4.11A and B). In non-survivors, there was a non-statistically significant increase 
in CD106+ endothelial microvesicle levels (figure 4.11C).  
 
We performed a similar analysis using the data obtained from patients with severe sepsis. In 
non-survivors, we identified statistically non-significant increases in total leukocyte and 
neutrophil microvesicles (data not shown).  
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Figure 4.10 Comparison of leukocyte microvesicle counts in survivors and non-survivors 
of burn injury 
(A)  Circulating CD45+ microvesicles are significantly elevated in non-
survivors 
(B)  Circulating CD11b+/CD66b+ microvesicles are significantly elevated in 
non-survivors 
(C)  Non-significant increase in CD45+/CD14+ microvesicles in non-
survivors 
 
Mann-Whitney test (A and C) 
Unpaired t test (B) 
*p<0.05 
**p<0.01 
(n=11 (survivors), n=5 (non-survivors)) 
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Figure 4.11 Comparison of endothelial microvesicle counts in survivors and non-
survivors of burn injury 
No statistically significant difference in CD105+ (A), CD62e+ (B) or CD106+ (C) 
endothelial microvesicle counts, between survivors and non-survivors. 
 
Unpaired t test (A and C) 
Mann-Whitney test (B) 
(n=11 (survivors), n=5 (non-survivors)) 
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Circulating leukocyte microvesicle levels are predictive of mortality of patients with burn 
injuries 
Accurate prediction of the risk of death associated with burn injuries facilitates clinical 
decision-making and stratification for research purposes 66. The best performing prediction 
models at present are the ABSI and BOBI score, which are composites of clinical data such as 
burn area and age 66,67,73,79,80. Given that numbers of total leukocyte microvesicles were 
markedly elevated in patients who did not survive their injuries, we reasoned that specific 
microvesicle values might be used to predict death. 
 
Burn patients were classified as before as survivors or non-survivors. A receiver operating 
characteristic (ROC) curve was constructed, using the day zero CD45+ and CD11b+/CD66b+ 
microvesicle counts as a discriminator. For comparison, ROC curves were also constructed 
using the same patients’ ABSI and BOBI values. Accuracy of each test for predicting death 
was measured by the area under the ROC curve, with 1 representing a perfect test and 0.5 a 
test that performs no better than a random classifier 435. 
 
In our population, the initial CD45+ microvesicle count performed well as a predictor of 
death, with an area under the curve (AUC) of 0.89 (95% confidence interval 0.72-1, p=0.01). 
A cut-off value of 7253 CD45+ MV μl-1 yielded a specificity of 0.9 and sensitivity of 0.6 
(likelihood ratio 6.6). The CD11b+/CD66b+ count also performed well, with an AUC of 0.85 
(95% confidence interval 0.64-1, p=0.02) (figure 4.12A). The ABSI score demonstrated 
comparable performance, with an AUC of 0.85 (95% CI 0.62-1, p=0.03). The BOBI score 
displayed excellent predictive ability, with an AUC of 0.96 (95% CI 0.88-1, p=0.004) (figure 
4.12B).  
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Figure 4.12 Receiver-operator characteristic (ROC) curves for mortality prediction in 
patients with burn injuries  
(A)  Good prediction of mortality by day zero circulating CD45+ and 
CD11b+/CD66b+ microvesicle levels 
(B)  Good prediction of mortality using ABSI score; excellent prediction of 
mortality using BOBI score 
 
AUC = Area Under the Curve. 95% confidence intervals in parentheses 
*p<0.05, **p<0.01  
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4.5 Discussion 
 
Quantification of circulating microvesicles 
The primary aim of this study was to characterise the leukocyte and endothelial microvesicle 
profile associated with severe burn injuries. These findings were then compared to clinical 
data to assess the potential significance of microvesicles as mediators of burns 
pathophysiology. For the first time, we have demonstrated that levels of circulating 
leukocyte and endothelial microvesicles are increased significantly in patients with severe 
burns. The preliminary findings indicate that microvesicles could be an important 
component of the inflammatory response to acute severe burn injury and have potential 
value as prognostic markers. 
 
It is important to first consider whether our burn population was representative of Burn ICU 
patients in general. By comparing our patients to larger cohorts and published 
epidemiology, the applicability of any findings can be judged. A preponderance of male 
patients was noted, which was consistent with data from both the UK 15 and Europe 7. The 
age distribution was also consistent, with the majority of patients falling within the 0-49 
years category 436. The median burn injury area in our cohort was 28% TBSA (range 11 to 
59%). Although the precise definition of a “severe” burn injury varies 7, this is above the 
threshold of 15-20% TBSA at which shock can develop 47. The mortality predicted by the 
burn severity scores showed good agreement with actual mortality. We concluded that the 
patients we had recruited were reasonably representative of “severely burned” patients in 
general. 
 
Patients with severe sepsis were included as a positive control and reference group because 
previous investigations have associated this syndrome with increased levels of leukocyte 
and endothelial microvesicles 3,330,343. Recruitment was opportunistic and was not designed 
to capture a group that was representative of all severe sepsis patients. However, 
comparison of our patients with those of other sepsis studies allows our microvesicle 
analysis to be placed in context and some judgement of wider applicability to be made. The 
age, male preponderance, APACHE II score and mortality rate of participants was similar to 
recent data from UK ICUs 437. The mortality rate was also similar to international data 438, 
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although it was higher than recent figures from Australia 109,439. ICU and hospital lengths of 
stay were longer in our cohort than in the UK and Australian studies 109,437,439. Lengths of 
stay are affected by illness severity but can also be influenced by institutional factors 440. 
Overall, the demographic data did not suggest our severe sepsis group was markedly 
different from those investigated in larger studies. 
 
The elevation in levels of circulating leukocyte microvesicles in patients with severe burns is 
consistent with the upregulation demonstrated in other systemic inflammatory states 330. In 
the sepsis group, total leukocyte microvesicle counts were not significantly different from 
burn patients and a similar range of values was evident. Total leukocyte (CD45+) 
microvesicle numbers were of a similar magnitude to those of neutrophil microvesicles, 
suggesting that this was the predominant cellular origin of CD45+ microvesicles. CD45 is also 
expressed on lymphocytes 441 and lymphocyte activation has been demonstrated following 
burn injury 442, although the response is relatively slow 443. This is a microvesicle population 
which could be evaluated in future studies. 
 
Increased neutrophil mobilisation from bone marrow and recruitment to sites of 
inflammation occurs rapidly following tissue injury  193,199. Neutrophils have been shown to 
release microvesicles in vitro in response to multiple inflammatory stimuli 444.  The 
neutrophil-derived circulating microvesicles in burn patients may therefore originate 
directly from burned tissue, specifically the viable zones of stasis and hyperaemia 17 . They 
could also originate from areas of remote organ damage, such as the lungs and kidneys. 
Multiple organ dysfunction is often evident following burn injuries and this has been linked 
to neutrophil sequestration 118,445. However, the acute increases seen within 24 hours of 
admission, before significant organ injury has developed, argues in favour of a primary 
(burn) injury site of origin. In the sepsis patient group, where the course and stage of 
inflammation is less defined, the elevated circulating neutrophil levels may reflect 
generation at the site of infection 385 but also vascular sites of neutrophil sequestration and 
infiltration in remote organs 446. 
 
The potential function of these neutrophil-derived microvesicles in the context of burn 
injuries is less clear. There is certainly some in vitro evidence that neutrophil microvesicles 
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can mediate an inflammatory effect, either through a direct action on endothelial cells 318–
320,447 or by adhering to other mediators such as monocytes 448. Furthermore, analysis of 
burn-activated neutrophils showed them to be capable of increasing endothelial 
permeability 449. However, other studies have suggested neutrophil microvesicles have 
immunomodulatory effects  338,450,451 and may in fact help to preserve vascular integrity 452. 
 
The increased levels of CD14-expressing microvesicles observed in burn patients was a 
potentially significant finding. This population is likely to be derived mainly from classical 
subset CD14+ monocytes and tissue macrophages, although CD14 is also expressed at low 
levels by non-myeloid cells 453. There is evidence to suggest that monocyte-derived 
microvesicles are capable of mediating endothelial dysfunction 302,321,454. Vesicles released 
by macrophages have also been shown to stimulate an inflammatory response 177. The 
higher levels in burn patients as compared to sepsis patients should be interpreted with 
caution. In burn patients, the time of injury is usually established to within a few minutes. In 
contrast, sepsis is known to be a heterogeneous syndrome where the time of onset, prior to 
identification, is unknown 455. It is important to note that previous investigations identified a 
rapid reduction of neutrophil microvesicle counts in sepsis patients but found monocyte 
microvesicle levels to be sustained for longer 330. This suggests that the timing of sampling, 
in relation to the initial insult, cannot fully explain the differences between burn and sepsis 
patients. The next step would be to investigate a more stringently selected sepsis cohort, 
perhaps focusing on a single source and narrower time window. If our provisional result was 
replicated it would support the notion that the roles of microvesicles in mediating these 
inflammatory states are distinct. 
 
The rapid decline in leukocyte-derived microvesicles after burn injury was also a noteworthy 
result, particularly when compared to the corresponding leukocyte counts, as it cannot be 
explained solely by changing numbers of circulating leukocytes. One possible explanation for 
this finding is that the early excision of burned tissue is removing the stimulus for 
microvesicle production. Another possibility is that reduced microvesicle production by 
leukocytes reflects a developing state of “immunoparalysis”. In this model, a pro-
inflammatory state is followed by an exaggerated anti-inflammatory response, resulting in 
deactivation of monocytes and neutrophils 313. This phenomenon has been described in the 
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context of major trauma 456, sepsis 457 and ARDS 458. Monocyte hyporesponsiveness in 
particular has been demonstrated following burn injuries 216,219. The net result is that the 
patient is more susceptible to subsequent infections 191,219,456. The decreases we have 
shown in this study will need to be confirmed in a larger patient group, as serially-sampled 
patients were limited in number. If the frequency and duration of sampling can also be 
increased, it may ultimately prove possible to associate specific microvesicle profiles with 
major clinical events. For example, a lull in microvesicle release at 24-48 hours, followed by 
a subsequent large peak in production, may reflect secondary sepsis. 
 
The lack of correlation between circulating leukocyte counts and microvesicle levels could 
be explained by our hypothesis that a major site of microvesicle production in burn patients 
is injured tissue. Neutrophil recruitment and monocyte influx is known to occur in burned 
tissue 197,445. An additional factor is that there may be varying rates of microvesicle 
clearance. Microvesicles have been shown to have a short half-life in the circulation 418, 
which implies that the results we obtained reflect a balance of continuous production and 
removal 417. If the clearance capacity of individual patients varies or was temporarily 
overloaded, for example due to altered macrophage function 459, this would also affect 
circulating microvesicle counts. From a methodological point of view, the fact that 
microvesicle and circulating leukocyte counts do not correlate argues against post-sampling 
ex vivo microvesicle release being a significant factor. 
 
Our investigations also revealed significantly elevated levels of endothelial cell microvesicles 
in burn patients. The difference in comparison to healthy volunteers was less stark than that 
seen with leukocyte-derived microvesicles but was significant for all three surface markers 
analysed. The results support the idea that endothelial microvesicles could be used as 
markers of endothelial dysfunction in burns, as has been proposed for other diseases 331,333. 
The fact that we detected a reduction in endothelial microvesicles by day two, suggests they 
could have sufficient sensitivity for this purpose. It would be interesting to directly compare 
temporal changes in endothelial microvesicles following burn injury, with the profiles of 
soluble inflammatory mediators. There is also scope for expanding the panel of surface 
markers used to quantify endothelial markers, to include PECAM-1 (CD31) 413, ICAM-1 
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(CD54) 461 and  VE-cadherin (CD144) 391. In vitro studies suggest these could be used to 
identify phenotypically distinct endothelial microvesicles 424. 
 
We did not set out to analyse platelet microvesicles in our study because we hypothesised 
that leukocyte and endothelial sources would be most likely to reflect the intravascular 
inflammatory response, local or systemic. Furthermore, because of the methodological 
issues described in the previous chapter, we did not consider their quantification to be 
sufficiently accurate. Nevertheless, there is some evidence platelet microvesicles contribute 
to inflammatory processes, in addition to their pro-coagulant activity 462,463. Further 
refinements in cytometry technique might allow more reliable analysis in the future. 
Although erythrocyte microvesicles may be an important to blood transfusion 464–466, they 
have not been shown to mediate inflammatory processes and were not analysed here. 
 
Comparison with severity of illness and clinical outcomes 
Previously published work has correlated microvesicle levels with severity of illness in a 
wide variety of disease states, including sepsis 343, trauma 467, ARDS 414 and  pulmonary 
hypertension 333. In burn patients, a number of clinical scoring systems have been devised. 
The simplest is the percentage of the patient’s skin affected by burn (TBSA). It has long been 
recognised as a key factor in patient mortality 67 and it forms a major part of burn scoring 
systems 66,72. The ABSI is in widespread use and it remains methodologically sound and  
robust as a predictive tool 67,73,80. A simpler and more recent scoring method, adopted by 
our burns unit BOBI system. This has been validated externally 79 and is also robust 67. Both 
of these systems use hospital mortality as their outcome. 
 
A number of correlations between microvesicle levels and clinical parameters were found. A 
strong correlation was found between total leukocyte (CD45+) microvesicle levels and the 
validated burn severity scores, which predict the risk of death for each patient. In contrast, 
microvesicle levels did not correlate with burn area alone. There is a degree of biological 
plausibility to this finding, as the factors that constitute the burn severity scores could 
theoretically also influence circulating microvesicle levels. The burn area, burn depth and 
presence of inhalational injury all reflect the extent of injured tissue. Alternatively, 
advanced age may reduce the ability to clear microvesicles, which would increase their 
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numbers as discussed above. It is unclear how gender would affect microvesicle levels but 
this factor is not included in the BOBI score and is allocated a low weighting in the ASBI 
value 80. However, the same arguments could be applied to the other microvesicle 
populations and they did not correlate strongly with the burn severity scores.  The reason 
for this is unclear and is worthy of further investigation. 
 
The next step of our analysis was to compare microvesicle levels with actual mortality. This 
is an approach that has been taken with numerous biomarkers in burn patients 237,416,432–434. 
When the burn patients were subdivided into survivors and non-survivors, a clear pattern 
emerged, with leukocyte microvesicles being significantly elevated in those patients who 
died before hospital discharge. The greatest difference was seen with neutrophil 
microvesicles but there was also a significant difference when total leukocyte microvesicle 
counts were analysed. Monocyte-macrophage microvesicles were also increased in non-
survivors but this difference was not statistically significant. For the reasons outlined above, 
this is a plausible result, with the factors known to influence mortality, such as burn area 
and age 73, also having the potential to affect microvesicle levels. 
 
It is not yet certain that microvesicles would contribute to the pathophysiology of SIRS in 
severe burns, and if so by what mechanism 412. It is possible that they directly mediate 
remote organ inflammation and dysfunction. An alternative explanation is that higher initial 
microvesicle production increases the risk of subsequent immune dysfunction. Neutrophil 
microvesicles have antibacterial effects 468, so if microvesicle production or availability is 
diminished post-burn, the risk of secondary infection may be increased. For comparison, no 
significant differences in leukocyte, neutrophil or monocyte counts were found between 
survivors and non-survivors. 
 
We used the strong association between higher leukocyte microvesicle counts and mortality 
to guide our final analysis. Construction of receiver operating characteristic (ROC) curves 
suggested that leukocyte- and neutrophil-derived microvesicles might be useful as 
discriminators to predict mortality. Their performance was comparable to the validated ABSI 
and BOBI prediction systems and superior to other novel biomarkers described in the 
literature, such as neutrophil extracellular traps (NETs) 434. An obvious caveat is that the 
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groups we analysed (survivors / non-survivors) contained low numbers of patients. 
However, if this finding can be validated in a larger cohort, leukocyte-derived microvesicles 
may represent a clinically useful prognostic marker for burn patients. 
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Chapter 5 
Investigation of microvesicle production and pro-inflammatory activity 
 in relation to heat injury in vitro 
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Summary 
 
The analysis of samples from burn patients in the previous chapter had demonstrated 
significantly elevated levels of circulating microvesicles. These were derived predominantly 
from neutrophils but we also detected monocyte/macrophage-derived microvesicles, as 
well as a population from endothelial cells. We speculated that a potential trigger for 
leukocyte microvesicle release may be their direct interaction with burned tissue, following 
their recruitment to the site of injury. We also hypothesised that the microvesicles 
produced locally by recruited leukocytes might contribute to systemic inflammation by 
mediating endothelial dysfunction. 
 
To address these questions in human cells in vitro, we first developed an optimised system 
for microvesicle production. We chose to focus on neutrophil MV production because of the 
relative abundance of neutrophils during the early stages of local inflammation and our 
observation of high levels of neutrophil-derived MV in burn patient plasma. Isolated 
neutrophils were stimulated with defined agonists previously shown to induce MV, 
including phorbol myrisate acetate (PMA), zymosan and a calcium ionophore (A23187). We 
initially saw a negligible MV response, however following assessment of different 
stimulation conditions, we found that significant quantities of microvesicles could be elicited 
by maintaining neutrophils in suspension throughout the 37⁰C incubation period.  
 
Demonstration that neutrophil microvesicle production was elicited by opsonised 
particulate stimulants led us to consider opsonisation of heat-injured cells as a model to 
investigate neutrophil microvesicle release at the burn injury site. We performed pilot 
studies in which serum-opsonised heat-treated epithelial cells were co-incubated with 
neutrophils in suspension culture. This method produced a significant release of 
microvesicles. 
 
The second aim of our in vitro experiments was to test the activity of burn-relevant 
microvesicles in vitro. We used PBMC-endothelial cell co-culture as in vitro model to assess 
MV-induced microvascular inflammation. Incubation with microvesicles from A23187-
stimulated neutrophils led to a significant upregulation of E-selectin on endothelial cells. We 
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then assessed the activity of MV derived from a human skin explant model of burn injury, 
and demonstrated a clear upregulation E-selectin expression. In contrast, incubation with a 
mixed population of microvesicles, isolated from burn patient plasma, led to 
downregulation of both E-selectin and VCAM-1 expression. 
 
We concluded that heat-injured cells could elicit a microvesicle response from neutrophils 
and this may be one pathway responsible for the microvesicle populations seen in burn 
patients. We also concluded that microvesicles from sources relevant to burn injury are 
capable of influencing endothelial activation, potentially contributing to the development of 
systemic inflammation and organ injury after severe burn injury.  
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5.1 Background 
 
Our investigations to this point had shown that circulating leukocyte- and endothelial cell-
derived microvesicles are significantly elevated following severe burn injury. The most 
abundant microvesicles were those derived from neutrophils. We also identified a 
significantly elevated population of monocyte/macrophage-derived microvesicles, in the 
same range or higher than that seen in patients with severe sepsis. Leukocyte microvesicles 
were therefore prime candidates for further evaluation in the context of systemic 
propagation of burn inflammation. 
 
In vitro interaction between thermal injury and leukocyte microvesicle production 
Our initial priority was to explore the experimental conditions that would reproducibly 
generate leukocyte microvesicles in vitro. The importance of this was twofold. Firstly, to 
investigate the mechanisms linking thermal injury to leukocyte activation and microvesicle 
release. Secondly, to provide a reliable source of microvesicles, to develop assays for 
measuring microvesicle inflammatory activity, including those derived from patient plasma. 
Our initial focus was neutrophil MV production because of the relative abundance of 
neutrophils during the early stages of local inflammation and our finding of high levels of 
neutrophil-derived MV in burn patient plasma. 
 
A range of defined stimuli have been shown to promote neutrophil microvesicle release in 
vitro, such as formyl-methionyl-leucyl-phenylalanine (fMLP) 336,444, phorbol myristate 
acetate (PMA) 469 and calcium ionophore (A23187) 320. However, such stimuli may not be 
relevant to burn wound microenvironment, an important consideration as the type of 
stimulus may be key to determining the phenotype of elicited MV. A large neutrophil 
microvesicle response can be generated by Staphylococcus aureus particles, if opsonised by 
incubating with normal serum 468. This finding is relevant to burns because previous studies 
of the burn wound microenvironment have suggested that activation and chemotaxis of 
neutrophils by heat-killed fibroblasts is a complement-dependent process 266. A number of 
other studies have highlighted the role of complement in the response to burn injuries 
6,94,470–473 and separately, complement activation products have been demonstrated to play 
a role in microvesicle induction 474. We therefore reasoned that opsonisation of heat-killed 
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cells may be necessary to generate a significant microvesicle response in neutrophils. To our 
knowledge, the effect of heat-damaged cells on leukocyte microvesicle production has not 
previously been investigated. 
 
Endothelial dysfunction following severe burn injury 
Endothelial dysfunction is known to be a key component of the innate immune response to  
severe infection and major trauma. Although the initial insult is very different, endothelial 
dysfunction is also evident following severe burns. This leads to widespread leak of fluid and 
proteins into the interstitium 475, a procoagulant state 275 and vasoplegia 476. This is 
exacerbated by leukocyte adhesion and activation in the microvasculature 477.  The potential 
interaction between leukocyte microvesicles and endothelial cells was therefore of 
considerable interest. The concept of leukocyte-derived microvesicles contributing to an 
inflammatory state, by way of endothelial dysfunction, is not new. Neutrophil-derived 
microvesicles have previously been shown to activate 318,319 and injure 320 endothelial cells in 
vitro. Monocyte-derived microvesicles have been found to induce loss of endothelial cell 
integrity and apoptosis 302.  Microvesicles released into the circulation following burns may 
therefore play an important role in the propagation and/or the amplification of systemic 
inflammation and organ injury. A basic pathway consistent with burn pathogenesis can be 
envisaged, whereby inflammatory leukocytes are recruited to heat-injured tissue, leading to 
their activation and release of microvesicles. These microvesicles in turn activate remote 
endothelial cells, contributing to organ inflammation and injury. To address these concepts 
we aimed to develop protocols that would lead ultimately to an in vitro bioassay system for 
assessing the pro-inflammatory of circulating patient-derived MV in burn and other pro-
inflammatory conditions.   
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5.2 Aims 
 
1. Investigate methods for in vitro microvesicle generation, relevant to burn injury 
2. Optimise assays using in vitro-generated microvesicles to measure their effect on 
microvascular inflammation in the context of systemic inflammation 
3. Apply the vascular inflammation assay to evaluate burn patient microvesicles 
 
5.3 Protocols 
 
Leukocyte isolation 
Density gradient centrifugation of whole blood was used to isolate peripheral blood 
mononuclear cells (PBMCs). Neutrophils were isolated from the resultant cell pellet by 
dextran sedimentation. For experiments involving total leukocytes, dextran-sedimentation 
of whole blood was performed. Further details of these methods are given in chapter two.  
 
Microvesicle generation 
The leukocytes were resuspended in 0.5% Human Albumin Solution (HAS) to a volume of 
450μl, such that the neutrophil concentration was 1x107 ml-1. Cells were rested for one hour 
at 37⁰C, before incubating with 50μl of stimulant for a further hour at 37⁰C.  The 
microvesicles were then isolated by centrifugation and analysed as described above. 
Stimulants (bacteria or cells) requiring opsonisation were resuspended in serum and 
incubated on a rotator as described earlier. 
 
Leukocyte-endothelial co-culture 
Primary human pulmonary microvascular endothelial cells (HPMECs) were seeded as 
described in the methods chapter. They were co-cultured with PBMCs for one hour at 37°C, 
the PBMCs having been resuspended in 200µl of 0.5% human albumin solution/endothelial 
basal medium (HAS/EBM). The co-culture was then stimulated with microvesicles for 16 
hours. Following stimulation, endothelial cells were recovered and stained with antibodies 
specific for E-selectin (CD62e) and VCAM-1 (CD106). 
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5.4 Results – Generation of neutrophil microvesicles in vitro 
 
Initial evaluation of microvesicle release from in vitro stimulated neutrophils 
We performed pilot experiments, consisting of stimulation of primary human neutrophils, to 
ascertain if our optimised flow cytometry protocol was able to replicate results published by 
other authors. PMA was chosen in the first instance, as this has previously been shown to 
generate a significant microvesicle response from neutrophils 468. Neutrophils were isolated 
from whole blood and stimulated with PMA at a final concentration of 1μM. Microvesicles 
were collected from cell supernatants and stained with PE-conjugated anti-CD66b 
monoclonal antibody. Baseline levels of CD66b+ microvesicles were low and there was only 
a small increase in count following PMA stimulation (figure 5.1). 
 
 
Figure 5.1 Minimal increase in neutrophil-derived microvesicle release following PMA 
stimulation of neutrophils in static environment Unpaired t test (n=2) 
 
Given the minimal increase in neutrophil microvesicle release elicited by PMA stimulation, 
we next investigated the effect of zymosan particles, to see if a greater response could be 
elicited. Zymosan (yeast wall extract) is an established tool for generating sterile 
inflammation and has been shown to increase microvesicle production from neutrophils 340. 
However, the results were unclear, with low CD66b+ microvesicle counts despite clear 
evidence of cell activation (upregulated CD11b expression). We concluded that this 
stimulation environment, despite prior optimisation of our flow cytometry protocol, was not 
sufficient to replicate the microvesicle response demonstrated in other studies 340,468.  
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Optimal microvesicle release from neutrophils requires maintenance of cells in suspension 
We next investigated experimental conditions that might influence neutrophil activation 
and MV production. Neutrophils are known for the ease by which they can become 
activated as a result of in vitro isolation methods 478,479. Early activation could theoretically 
affect the subsequent microvesicle response to stimulation. To eliminate the prolonged 
isolation procedure as a factor contributing to low microvesicle production, we elected to 
truncate the cell separation and stimulate neutrophils in a mixed leukocyte preparation. A 
further consideration was that during the rest and stimulation incubations, a significant 
amount of cell sedimentation was observed. A potential consequence was cell-cell contact-
dependent activation, which may have adversely affected MV release. We therefore 
investigated stimulation of cells in suspension, to ensure thorough mixing of cells 
throughout the stimulation phase. 
 
Mixed leukocytes were prepared as above, before stimulation with opsonised S. aureus 
(OSA) particles (5 x 107 in 50μl HBSS) or calcium ionophore A23187 (10μM). These stimuli 
have previously been shown to be effective inducers of neutrophil microvesicle release 
320,468. The stimulation was performed in either static or rotated Eppendorfs. As before, 
static stimulation did not lead to significant increases in neutrophil microvesicle counts 
above baseline (1063 ± 1099 MV μl-1) (Figure 5.2A). However, after rotated stimulation, 
there was a significant increase in microvesicle levels with both opsonised S. aureus (2239 ± 
1352 to 8954 ± 286 MV μl-1, p<0.001) and A23187 (19160 ± 774 MV μl-1, p<0.0001) (Figure 
5.2B). 
 
In order to confirm that opsonisation was an important factor in the rotated stimulation 
environment, we also evaluated the effect of non-opsonised S. aureus (NOSA) on the mixed 
leukocyte preparation. The neutrophil microvesicle counts generated by NOSA stimulation 
were not significantly higher than baseline levels (data not shown). This was consistent with 
the literature 468.  
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B 
 
Figure 5.2 Effect of continuous rotation on neutrophil microvesicle release 
(A)  No significant increase in neutrophil microvesicle release, in response 
to stimulation by opsonised S. aureus (OSA) and A23187, in static 
environment 
(B)  Significant increase in microvesicle release, in response to OSA and 
A23187, in rotating environment 
  
***p<0.001, ****p<0.0001 
   One-way ANOVA with Dunnett’s multiple comparisons test (n=3)  
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Isolation of neutrophils from other leukocyte sub-populations does not affect their 
production of MV 
The next task was to investigate the effect of rotated stimulation on purified neutrophils, as 
we had suspected the isolation procedure may have affected their capacity to produce 
microvesicles. A pure neutrophil preparation facilitates elucidation of the direct neutrophil-
specific pathways, while mixed leukocyte stimulation may be complicated by cross-
regulation of microvesicle release. 
 
Neutrophils were isolated as before and stimulated in the rotating incubator with opsonised 
S. aureus and A23187, in the same manner as that used for mixed leukocytes. Neutrophil 
numbers were the same in all treatments and experiments were run separately. No 
significant differences in neutrophil microvesicle levels were found between the mixed 
leukocyte and neutrophil preparations, as shown in figure 5.3. This applied to all three 
treatments, with reasonably low variability seen in both methods. We therefore concluded 
that modulation by other leukocytes was unlikely in this system and that provision of “pure” 
neutrophil-derived MV for activity assays was optimal using isolated neutrophils. 
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Figure 5.3 Comparison of neutrophil microvesicle release from mixed leukocytes and 
purified neutrophil preparations 
Rotated suspensions of mixed leukocytes and purified neutrophils yield similar 
numbers of neutrophil microvesicles when stimulated with opsonised S. 
aureus (OSA) and A23187 
   
  Unpaired t test (separate test for each treatment) 
(n=3)  
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Development of a cell-based model of burn-injury and complement activation 
Our experiments with purified neutrophils had demonstrated significant quantities of 
microvesicles, provided the stimulation was performed whilst the cells were mixed 
continuously. They also confirmed that opsonisation of S. aureus particles produced 
increased microvesicle generation, suggesting the importance of complement deposition as 
a co-stimulus. We hypothesised that heat injury of host cells, leading to fixation and 
activation of complement 266,470, may provide a stimulus for neutrophil microvesicle 
production post-burn injury. 
 
We first evaluated the effect of heat treatment on complement activation, as one potential 
mechanism by which opsonisation may induce or enhance MV production. Heat injury and 
complement activation has previously been modelled using human kidney cells 470 and with 
the HK-2 human kidney epithelial cell line available, these cells were selected for pilot 
experiments. A severe burn will lead to widespread skin epithelial damage, so this choice 
was of relevance to burn injury. 
 
HK-2 cells (1.6x106) were incubated in 100μl HBSS at 37 or 80⁰C, for 15 minutes, based on 
previously published methods 266. After centrifugation, the epithelial cells were resuspended 
in fresh human serum or HBSS and incubated at 37⁰C, for one hour. To assess surface 
complement activation, the cells were washed and stained with anti-C3c. The geometric 
mean fluorescence intensity (gMFI) of viable non-opsonised HK-2 cells was 203, rising to 537 
for viable opsonised cells. Non-opsonised heat-killed cells demonstrated a gMFI of 1634, 
rising to 8065 for heat-killed opsonised cells (see appendix). These results suggested 
increased complement activation on heat-killed cells and was consistent with work 
previously performed on kidney epithelial cells 470, as well as fibroblasts 266. We also 
investigated shorter, more clinically-relevant heat exposure times and found that one 
minute at 80⁰C was sufficient for a large increase in C3c deposition over baseline levels, with 
no further increase in complement activation with longer heating periods (data not shown). 
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Stimulation of neutrophils with heated-injured and opsonised HK-2 cells induces 
microvesicle release 
To determine if heat-injured cells stimulate neutrophil microvesicle release and if this is 
enhanced by opsonisation, neutrophils were incubated with treated kidney cells in 
suspension.  HK-2 cells (1x106) were heated for two minutes and serum-opsonised using the 
above method. After washing and resuspension, 50μl of heated-opsonised cells (approx. 
5x105) were added to the neutrophils and incubated for one hour.  
 
Stimulation of neutrophils with the opsonised non-heated epithelial cells resulted in a 
significant increase in microvesicle release (1401 ± 811 to 5167 ± 1177 MV μl -1, p<0.01) 
(Figure 5.4). However, the response seen after stimulation with the heated-opsonised cells 
was significantly greater again (8731 ± 1690 MV μl -1, p<0.05). Without opsonisation, heat-
injured cells did not induce significant MV release from neutrophils (2073 ± 811 MV μl -1, 
p<0.001) suggesting that opsonisation and/or complement activation may be a key factor in 
neutrophil MV release following burn injury in vivo. 
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Figure 5.4 Neutrophil microvesicle release in response to stimulation with opsonised 
heat-killed HK-2 kidney epithelial cells 
Neutrophil microvesicle release is significantly increased over baseline by 
incubation with both opsonised heat-killed (80⁰C) and opsonised viable (37⁰C) 
kidney epithelial cells. Increase is significantly higher in response to opsonised 
heat-killed cells, than in response to both opsonised viable cells and non-
opsonised heat-killed cells 
 
*p<0.05 
**p<0.01 
***p<0.001 
One-way ANOVA with Tukey’s multiple comparison test 
(n=3) 
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5.5 Results – Development of in vitro assay of microvesicle inflammatory activity 
 
Treatment of PBMC-endothelial cell co-cultures with neutrophil microvesicles induces 
upregulation of endothelial cell adhesion molecule expression 
We used pulmonary microvascular endothelial cells as an in vitro indicator of vascular 
inflammation, with the addition of PBMCs to evaluate endothelial cell activation in the 
presence of capillary-sequestered leukocytes 126. Our previous experiments had shown that 
the most productive and reliable microvesicle response was generated by stimulation with 
calcium ionophore (A23187) and therefore this was used for the initial experiments. 
 
The neutrophils were stimulated with A23187 as above and microvesicle numbers were 
determined from the cell-free supernatant by flow cytometry. Supernatant from three 
Eppendorfs (13.5 x 107 neutrophils in total) was pooled and centrifuged at 20,000g for 30 
minutes. Pelleted microvesicles were resuspended in 200µl of 0.5% HAS/EBM and added to 
HPMEC-PBMC co-cultures, that were pre-equilibrated for one hour in 200µl of 0.5% HAS-
EBM. Controls included microvesicles from the same number of unstimulated neutrophils 
(13.5 x 107), as well as 10μl of supernatant obtained from pelleting the microvesicles. This 
was included as a control to assess the effect of any residual A23187 or soluble mediators 
associated with the microvesicle pellet. After incubation for 16 hours, media was aspirated 
from wells, centrifuged and frozen for future analysis. Endothelial cells were retrieved by 
non-enzymatic detachment, washed, stained and analysed for the presence of the 
activation markers E-selectin (CD62e) and VCAM-1 (CD106). 
 
Due to variation in baseline expression of VCAM-1 and E-selectin, we normalised the data 
from different experiments, using values from unstimulated co-cultures as baseline values. 
Following incubation with microvesicles from stimulated neutrophils, there was a significant 
increase in E-selectin expression (fold-change in gMFI 6.0 ± 4.9, p<0.01) (figure 5.5A). In 
contrast, an increase was not seen following incubation with the A23187-treated neutrophil 
MV-free supernatants, which argued against the upregulation being triggered directly by the 
soluble stimuli (fold-change 0.90 ± 0.14). The neutrophil microvesicles released 
spontaneously were associated with only a modest increase in E-selectin expression (fold 
change 1.9 ± 1.1). 
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This overall pattern was replicated when CD106 expression was assessed (figure 5.5B). 
There was a non-statistically significant upregulation following incubation with microvesicles 
from stimulated neutrophils (fold-change 3.3 ± 3.1, p=0.05). Again, there was no increase in 
expression following incubation with the supernatant (fold change 0.83 ± 0.16) and only a 
modest upregulation with the spontaneously-released microvesicles (fold-change 1.3 ± 
0.85).  
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B 
 
Figure 5.5 Stimulation of endothelial co-culture with neutrophil microvesicles 
(A)  Stimulation of endothelial cell (EC)-PBMC co-culture with neutrophil 
microvesicles (MV) leads to significant upregulation of E-selectin 
(CD62e) expression by endothelial cells 
(B)  Statistically non-significant VCAM-1 (CD106) upregulation 
 
SN=supernatant. **p<0.01. One-way ANOVA with Dunnett’s multiple 
comparison test. (n=4-6)  
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Detergent-sensitive microvesicle population can be generated by heat treatment of 
human skin explant 
Having established the co-culture model of intravascular inflammation for assessing 
microvesicle function in vitro, we next investigated microvesicles generated using a human 
skin explant model of burn injury. These are highly relevant to burn injury and the 
microvesicles generated were an ideal candidate to test in the co-culture system. 
Optimisation of murine skin microvesicle generation was conducted within the group by 
Umar Katbeh, as part of a PhD thesis. Significant skin MV release could be induced by 
incubation with a combination of ATP (6mM) and ARL 67156 (1mM), a selective ecto-ATPase 
inhibitor. The optimal duration of skin heating, which generated a comparable level of 
microvesicles, was found to be 10 seconds, at 95⁰C (figure 5.5A). These protocols were 
adapted for human skin explants and used for the work described here, which was 
conducted jointly. 
 
Commercially-supplied skin samples, approximately 25cm2 in area, were taken from 
volunteers undergoing panniculectomy. These were delivered to the laboratory within 18 
hours of excision. Subcutaneous fat was removed from the skin, in sterile conditions, before 
biopsies of a standardised diameter (8mm) were taken. Each piece of skin was then 
immersed in sterile PBS at 95⁰C for 10 seconds to produce a thermal injury response that 
included oedema, as evidenced by substantial uptake of explant medium and weight 
increase (data not shown). After incubation at 37⁰C for 2 hours, the fluid from each well was 
collected and centrifuged at 200g for 10 minutes, to pellet any cells or large debris. The 
supernatant contained a detergent-sensitive, annexin V+ / SytoRNA+ microvesicle 
population (figure 5.5B). The precise cellular source of these microvesicles was 
undetermined. Untreated control skin did not yield a similar microvesicle population (figure 
5.5C). 
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Figure 5.5 Generation of skin-derived microvesicles 
(A) Significant microvesicle (MV) release elicited by incubation of murine 
skin with ATP/ARL. Similar levels of microvesicles are released by heat 
treatment of skin for 5 and 10 seconds, at 95⁰C. MV levels are 
expressed per cm2 of skin sample. (n=4) 
(B) Large numbers of detergent-sensitive microvesicles are released 
following 10 second 95⁰C heat treatment of human skin samples 
(C) Minimal levels of detergent-sensitive skin microvesicles are released 
following incubation of human skin samples at 37⁰C 
 
***p<0.001 
****p<0.0001 
One-way ANOVA with Dunnett’s multiple comparison’s test  
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Stimulation of endothelial cell-PBMC co-culture with microvesicles from heat-injured 
human skin causes upregulation of endothelial cell adhesion molecules 
To assess skin microvesicle activity, cell-free supernatant was collected as above. This was 
centrifuged (20,000g / 30 minutes) to pellet microvesicles, which were then resuspended in 
200μl HAS/EBM. The microvesicles were added to the endothelial cell-PBMC co-culture and 
incubated for 16 hours. Endothelial cells were retrieved and analysed as above. 
 
In response to stimulation with the heat-injured skin-derived microvesicles, there was a 
significant increase in E-selectin (CD62e) expression by endothelial cells (fold-change 3.3 ± 
0.33, p<0.01) (figure 5.6A). However, significant changes were not seen following 
stimulation with either the microvesicles from untreated skin, or the heated skin 
microvesicle supernatant.  A small increase in VCAM-1 (CD106) expression was also found 
following stimulation with the heated skin microvesicles (figure 5.6B). However, this did not 
reach statistical significance. Taken together with the neutrophil MV experiments, it 
appeared that E-selectin was a more sensitive marker of endothelial activation at the 16 
hour time-point in this co-culture assay.  
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Fig 5.6 Stimulation of endothelial co-culture with skin-derived microvesicles 
(A)  Stimulation of endothelial cell-PBMC co-culture with heated skin 
microvesicles leads to significant upregulation of E-selectin (CD62e) 
  (B)  VCAM-1 (CD106) expression in response to same stimuli 
 
**p<0.01 
One-way ANOVA with Dunnett’s multiple comparisons test (n=2) 
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Microvesicles isolated from burn patients downregulate endothelial cell adhesion 
molecule expression in vitro 
Further optimisation of the co-culture system demonstrated that endothelial cell adhesion 
molecule expression was maximal at four hours. This was conducted within the group by 
Nikhil Tirlapur, as part of preliminary work towards a PhD thesis. We used this protocol to 
assess the activity of circulating microvesicles isolated from patients within 24 hours of burn 
injury. In this pilot study, samples from the patients with the six highest CD45+ microvesicle 
counts (in platelet-rich plasma) were analysed to maximise the likelihood of detecting 
microvesicle activity. Platelet-poor plasma (PPP) was used to minimise the effect of platelets 
on the co-culture. PPP was generated by an initial 200g / 10 minute centrifugation, followed 
by a 1500g / 20 minute centrifugation, prior to storage. After being thawed, the PPP was 
filtered, before centrifugation at 20000g to pellet the microvesicles, before resuspension in 
400μl of 0.5% HAS/EBM. The PBMC-endothelial co-culture was then stimulated with the 
burn patient MV and MV-free supernatants, for four hours. 
 
In contrast to the upregulation demonstrated in previous experiments, incubation with burn 
patient microvesicles resulted in a significant downregulation of endothelial adhesion 
molecules. The shorter incubation protocol was more consistent in terms of endothelial cell 
adhesion molecule expression, enabling data to be expressed as gMFI. E-selectin (CD62e) 
expression was reduced from a baseline gMFI of 93.7 ± 7.1 to 75.6 ± 18.2 (p<0.05) (figure 
5.7A). VCAM-1 (CD106) expression also decreased, from a gMFI of 1385 ± 110, to 1154 ± 170 
(p<0.01) (figure 5.7B). These findings are likely to represent attenuation of the endothelial 
adhesion molecule upregulation that results from the presence of PBMC alone. Significant 
downregulation was not found following incubation with the cell and MV-free supernatant, 
arguing against a significant contribution from soluble mediators. 
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Figure 5.7 Incubation of endothelial co-culture with burn patient-derived microvesicles 
Incubation of PBMC-endothelial co-culture with microvesicles (MV) isolated 
from burn patients leads to significant downregulation of endothelial E-
selectin (CD62e) (A) and V-CAM1 (CD106) (B) expression. MV-free 
supernatant (SN) does not cause significant downregulation. 
 
*p<0.05 
**p<0.01 
One-way ANOVA with Dunnett’s multiple comparisons test (n=6)  
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5.6 Discussion 
 
In vitro generation of neutrophil-derived microvesicles 
The overall objective in this chapter was to test our hypothesised role for microvesicles in 
burn-related inflammation, using in vitro models. In particular, we were interested in 
neutrophil microvesicle production as our in vivo studies had identified significantly elevated 
levels of this subpopulation, following burn injury. Our first specific aim was to investigate 
whether thermal damage would initiate microvesicle release from neutrophils in vitro. To do 
so, we had to be sure that we were stimulating the neutrophils in an optimised 
environment. 
 
We conducted a pilot experiment, using PMA as the stimulant but we were unable to elicit a 
notable increase in microvesicle production. This was followed by further attempts at 
producing a microvesicle response, using zymosan, opsonised S. aureus and the calcium 
ionophore A23187. These stimuli have all previously been shown to stimulate microvesicle 
release from neutrophils 320,468,469. Furthermore, the mechanisms by which these stimuli act 
are thought to be distinct: PMA is a protein kinase C activator 480, A23187 increases calpain 
activity via calcium influx 481–483, whilst zymosan and S. aureus can stimulate neutrophils 
once opsonised by complement and immunoglobulins 484,485. Additionally, there is evidence 
that non-opsonised zymosan can stimulate neutrophils in a protein tyrosine kinase-
dependent pathway 485. Consequently, we felt there was sufficient diversity in the stimuli to 
suggest that a generic factor was preventing us from detecting a microvesicle response. A 
consistent phenomenon in these early experiments was a degree of cell settling, during the 
rest and stimulation phases. We therefore compared the effect of a rotated stimulation to a 
static stimulation, to achieve a homogeneous suspension. As seen above, we found that this 
dramatically increased the number of microvesicles detected, following both S. aureus and 
ionophore stimulation. 
 
Although brief mention is made of linear agitation in the methods of some experiments 468, 
we were not able to find any research that had explicitly assessed the effect of rotation in 
this way. Previous investigations have shown that severe agitation may increase platelet 
microvesicle release, for example during transport of samples 402. Certainly, there was a 
162 
 
small increase in “spontaneous” microvesicle levels following rotation but this was dwarfed 
by the numbers seen when stimulants were present, with a near 10-fold increase seen with 
ionophore stimulation. Clearly, this was not simply a case of increased background signal. 
The precise mechanism that underlies this finding is unclear and warrants further research. 
One possible explanation is that the microvesicles are being released when static but remain 
attached to their parent cells and are therefore lost during the initial centrifugation. A more 
interesting proposition is that accumulation of a local signalling factor is influencing 
microvesicle production when cells are static. A candidate molecule is nitric oxide, with 
research suggesting an inhibitory role in both neutrophils 486 and endothelial cells 487. 
 
We next sought to confirm that opsonisation was an important part of provoking a 
microvesicle response from neutrophils. We found that although non-opsonised S. aureus 
could increase microvesicle counts, it did so at reduced levels in comparison to opsonised S. 
aureus. This was consistent with previous reports 5 and supported the idea that 
opsonisation was important to the microvesicle response to burn injury. Further 
experiments showed us that using LPS or ATP in the rotating environment did not generate 
a greater yield of microvesicles. We therefore continued using A23187 as our soluble 
stimulus. 
 
We had hypothesised that the additional steps of neutrophil isolation may have contributed 
to the lack of microvesicle response seen in our initial experiments. However, the large 
increases seen following stimulation of a cell suspension suggested this was not the case. 
When we compared the two cell preparations directly, we found very similar levels of 
neutrophil microvesicles, following each stimulation. This led us to conclude that the 
neutrophil isolation method was in fact adequate for investigating microvesicles in vitro. It 
also suggested that the stimulants we were using were acting directly on the neutrophils, 
rather than via other leukocytes present in the culture. Additionally, this finding was of 
practical benefit as it meant the PBMCs, isolated simultaneously, could be used for our later 
co-culture experiments. 
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The final phase of this in vitro section investigated if a burn-relevant stimulus was capable of 
upregulating microvesicle production from primary neutrophils. We knew from previously  
published work that neutrophils would adhere to heat-killed fibroblasts and that this was 
serum-dependent 266. Heat-killed kidney cells and fibroblast also activate complement 266,470. 
Our preliminary research had confirmed that opsonised bacteria could increase microvesicle 
production significantly. We therefore hypothesised that heated cells, if opsonised, may 
have a similar effect on microvesicle production. The cells chosen were cultured from the 
HK-2 cell line, an immortalised kidney epithelial line. 
 
Before incubating heat-injured HK-2 cells with neutrophils, we first confirmed that our 
heating and opsonisation protocol resulted in detectable complement activation. Although 
complement activation is not the only means by which pathogens can be opsonised 484, 
several studies have addressed the importance that complement plays in the response to 
burn injury 6,94,266,470–473. We then introduced the opsonised heat-damaged epithelial cells 
into the neutrophil suspension discussed above. This resulted in a significant increase in the 
number of neutrophil microvesicles. Levels were also significantly higher than those seen 
after incubation with the opsonised non-heated HK-2 cells, whilst the non-opsonised heat-
damaged cells did not increase microvesicle production at all. We concluded from this that 
heat-injured cells could indeed interact directly with neutrophils, to upregulate their 
microvesicle production, in a serum-dependent process. This was a key finding and one 
which has not been demonstrated elsewhere, to our knowledge. 
 
It is important to highlight that the opsonised non-heated HK-2 cells also caused an increase 
in microvesicle production, whilst the difference between heated and non-heated counts 
was not as stark as that seen when examining complement activation alone. There are a 
number of possible explanations for this. The first is that the epithelial cells themselves may 
act as potent stimulus; although they are derived from a human cell line, the cells are not 
autologous and have been subjected to a number of different processing steps. Their viable 
state may also have increased their activating potential. Secondly, other factors present in 
serum, such as immunoglobulins, may be partly responsible for mediating the interaction 
with neutrophils, which we did not assess in the same way as complement activation. 
Thirdly, we may be witnessing a degree of saturation of the complement-mediated 
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pathway; the magnitude of response was very similar to that seen with opsonised S. aureus, 
although this may be coincidental. Finally, it may be the case that some microvesicles are 
bound with large epithelial cell fragments and therefore not accessible for analysis using the 
above protocol. 
 
Optimisation of an in vitro assay to assess inflammatory activity of neutrophil-derived 
microvesicles 
The second phase of our in vitro work was to evaluate the activity of the microvesicles we 
had generated. Our specific interest was their role in mediating endothelial dysfunction, an 
important feature of the post-burn response 475. Although previous research had 
demonstrated that leukocyte-derived microvesicles may play a part in this process 302,318–320, 
we were interested in creating a more sensitive and physiologically-relevant model. Earlier 
research conducted in our department had shown that in murine models of sepsis, 
monocytes marginate to the pulmonary vasculature, where they produce direct activation 
of the endothelium 488. In the context of burn injuries, monocyte recruitment is known to be 
an important part of wound healing and precedes infiltration of the damaged tissue 
196,197,245. We therefore hypothesised that microvesicles may exert a greater effect on 
endothelial cells in the presence of other leukocytes and that such a model may be more 
representative of the in vivo environment. 
 
Following a simple pilot experiment, which suggested that endothelial cells in co-culture 
may indeed be more responsive to stimulation, we moved onto testing the microvesicles. 
We initially evaluated neutrophil microvesicles, generated by A23187 stimulation, as this 
had consistently yielded the highest counts. By using a soluble stimulant, we also minimised 
any potential ambiguities that might be caused by residual S. aureus or epithelial cell 
fragments. Having pre-equilibrated the endothelial cells and PBMCs for one hour, we then 
performed a 16 hour incubation with the neutrophil microvesicles. 
 
The resultant endothelial E-selectin (CD62e) expression was significantly increased, with a 6-
fold increase over baseline, a finding not previously reported. In contrast, microvesicles 
from unstimulated neutrophils did not lead to a significant upregulation of E-selectin. A 
similar pattern was seen with VCAM-1 (CD106), with a 3-fold increase in expression over 
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baseline following stimulation with the A23187-generated microvesicles. This change did 
not reach statistical significance but when taken in conjunction with the E-selectin data, it 
suggested the model had potential for assaying microvesicle-endothelial interactions. 
 
The lower response seen with VCAM-1 was not the only limitation of our system. We 
focused our initial efforts on a relatively long stimulation period of 16 hours. Subsequent 
refinement of our protocols demonstrated that peak adhesion molecule expression 
occurred at 4-6 hours, consistent with information derived from cytokine stimulation 489. We 
also observed considerable variation in the expression of each adhesion molecule between 
experiments, necessitating their analysis as fold-change. This issue was diminished in 
subsequent experiments using the shorter stimulation period. 
 
Limitations notwithstanding, we were interested in using this model to test heat-generated 
microvesicles from a different cellular origin, to see if they exhibited a similar response. In 
vitro studies in our department had demonstrated that samples of human skin, when 
subjected to thermal injury, produced increased levels of microvesicles (Katbeh U, 
unpublished work). We isolated these skin-derived microvesicles and incubated them with 
the co-culture system described above. Microvesicles from thermally-damaged skin elicited 
a significant upregulation of E-selectin. In contrast, microvesicles from untreated skin did 
not lead to E-selectin upregulation. The lack of response from heated skin supernatant, 
which was microvesicle-free, argues against the observed response being mediated by 
soluble mediators. As was the case with neutrophil-derived microvesicles, the effect on 
VCAM-1 expression was less marked and did not reach statistical significance. 
 
The conclusions that can be drawn from this pilot study are limited. Further experiments 
using skin will be conducted but sample availability is unpredictable, as the donation is a 
sporadic process and relatively expensive. It should also be highlighted that due to a lack of 
specific surface marker, we were unable to quantify circulating skin microvesicles in our 
burn patient samples. However, a severe burn by definition involves widespread skin 
damage and our in vitro experiments have demonstrated a robust microvesicle increase 
after thermal skin damage. There is also growing evidence that microvesiculation is a 
universal feature of cellular life 490. Given these points, it would be surprising if skin 
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microvesicles were not prevalent in burn patients and our studies suggest they may 
contribute to endothelial dysfunction. 
 
In contrast to the upregulation of endothelial adhesion molecules demonstrated with 
neutrophil and skin microvesicles, the microvesicles isolated from burn patients exhibited a 
negative effect on endothelial activation in our co-culture assay. A number of factors need 
to be considered when interpreting this result. The first is that the microvesicles isolated 
from patients were a mixed population and would have contained platelet- and erythrocyte-
derived MV, in addition to those derived from leukocytes and endothelial cells. Secondly, 
our earlier experiments had used PBMCs and neutrophils from autologous donors, whereas 
the burn patient microvesicles were necessarily from non-autologous donors. This may have 
modulated the co-culture response. It should also be noted that to minimise the effect of 
platelets, platelet-poor plasma was used as a source of microvesicles. From earlier 
experiments, we knew that PPP contains significantly less MV than platelet-rich plasma. It is 
possible that variable effects are seen at different concentrations of MV. 
 
If the negative effect on endothelial activation is representative of in vivo activity, this 
finding would be consistent with a number of prior investigations. Neutrophil-derived MV 
have been shown to exhibit anti-inflammatory effects in vitro 336–338,340,450,452, although this 
finding is far from universal 318–320. The available information regarding the function of MV 
derived from other cells also demonstrates variability, with platelet-derived MV apparently 
capable of both upregulating 461,462,491 and downregulating inflammatory pathways 329,492. 
Separation of microvesicles by subtype from a complex medium such as plasma would be 
difficult but future experiments will aim to utilise immunomagnetic separation to delineate 
discrete phenotypes. The applicability of our results to all severely burned patients also 
needs to be assessed, as we focussed our pilot studies on those patients with the highest 
MV response. It may be the case that microvesicles from less severely injured patients are 
phenotypically, as well as quantitatively distinct. 
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Chapter 6 
Final Discussion  
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As discussed in the introductory chapter, the systemic consequences of a severe burn injury 
are secondary to a distinct and overwhelming inflammatory response. Marked oedema and 
hypovolaemia in the acute phase are followed later by prolonged hypermetabolism and 
catabolism 233,460. Despite decades of research into this phenomenon, the relationship 
between localised tissue injury and systemic inflammation remains poorly defined 493. 
Although burn care and survival has improved markedly, our ability to directly modulate the 
inflammatory response and curb its deleterious effects is limited 113,221. Identification of 
circulating mediators may facilitate novel therapeutic approaches, in addition to having 
diagnostic and prognostic utility. 
 
The systemic component of the post-burn inflammatory response has conventionally been 
linked to dysregulated cytokine release. These cytokines, such as TNF-α and IL-6,  are 
thought to spill over from sites of injury into the circulation 2,234. However, clinical evolution 
of the inflammatory response correlates poorly with systemic cytokine profiles 238 and 
evidence of a causative relationship is lacking. Indeed, significant reduction in the activity of 
locally-released mediators would be expected as a result of dilution, clearance and specific 
neutralisation mechanisms. Therefore, soluble cytokines may not be the dominant 
propagating factor in post-burn inflammation. 
 
Signalling by microvesicles represents an additional “third way” by which cells can 
communicate, bridging the classical dichotomy between soluble mediators and direct cell-
cell contact 304. They can function as unique biological ferries, capable of transporting a 
diverse range of cargo 494 and are elevated in disorders of the innate immune response, 
such as sepsis 3,330. We hypothesised that due to widespread tissue injury and inflammation, 
significant microvesicle release would follow a severe burn injury. The overall objective of 
this project was to evaluate the microvesicle profile associated with burn injury, to examine 
its relevance to the propagation of inflammation and to establish the relationship with 
disease severity. To address this aim, we developed optimised protocols to quantify 
circulating microvesicles and applied them to samples obtained from burn patients. In an 
accompanying experimental arm, we investigated microvesicle production and function in 
assays relevant to burn injury and systemic inflammation.  
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6.1 Optimisation of flow cytometric analysis of microvesicles 
 
Due to their small size, the analysis of microvesicles is challenging 349. Flow cytometry is the 
most commonly used method and is the most suitable for clinical studies, particularly as the 
cellular source of microvesicles can be determined. Our initial experiments demonstrated 
that the performance of our cytometer was consistent with other “conventional” 
cytometers, i.e. those not specifically designed to investigate sub-cellular particles. It is 
important to note, however, that smaller microvesicles are undetectable by flow 
cytometers, such that underestimation of counts is a recognised limitation in most studies. 
Although purpose-built cytometers have improved sensitivity 392, emerging technologies 
such as nanoparticle tracking may be required to give a more comprehensive picture 353. 
 
We sought to establish the optimal “threshold” parameter, used to trigger acquisition of a 
particle. This step was crucial to maximising sensitivity without overloading the cytometer, 
as complex biological fluids such as plasma contain a great number of small particles, not all 
of which are vesicles. We explored the use of cytoplasmic dyes, added directly to plasma, to 
increase sensitivity. Although our success was limited by a poor signal to noise ratio, 
presumably due to dye association with plasma lipoprotein complexes, this approach is 
worthy of further investigation. The adoption of differential detergent lysis allowed us to 
confirm the vesicular nature of particles detected by the cytometer. More recent research 
suggests alternative detergents might be used to differentiate between extracellular vesicle 
populations 495. This would be highly advantageous, because the current classification of 
extracellular vesicles relies on arbitrary size ranges and cut-offs 294 which are only loosely 
related to phenotype and difficult if not impossible to apply practically 496,497. 
 
Our demonstration of significant microvesicle loss at moderate centrifugation speeds, used 
to deplete platelets, was consistent with published research 376,378. It supported our 
selection of platelet-rich plasma for studying leukocyte- and endothelial cell-derived 
microvesicles. Analysis of platelet-poor plasma, obtained by centrifuging samples at higher 
speed, would have resulted in significantly less microvesicles being detected. Furthermore, 
the microvesicle loss may not have been uniform, with larger particles being sedimented at 
lower speeds, potentially affecting the results qualitatively as well as quantitatively.  
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6.2 Circulating microvesicles in burn patients 
 
Our clinical study was the first to demonstrate that leukocyte-derived and endothelial cell-
derived microvesicles are significantly elevated following severe burn injury. Mortality from 
burn injury was associated with higher levels of leukocyte microvesicles. This observation 
may prove to be unique among conditions that trigger a systemic inflammatory response. In 
trauma patients for example, platelet-derived microvesicles were found at reduced levels in 
non-survivors 467 and in survivors of ARDS, circulating leukocyte microvesicles were 
significantly higher 414. A rapid decline in circulating leukocyte and endothelial microvesicles 
was evident by day two post-injury, suggesting a decline in production and/or an increase in 
clearance. A similar transient elevation has been demonstrated in the context of 
meningococcal sepsis 330 and traumatic brain injury 498, indicating that microvesicles may 
have utility as markers of hyper-acute systemic inflammation. 
 
Despite the relatively low patient numbers in this pilot study, it was interesting that 
leukocyte-derived microvesicles correlated with the ABSI and BOBI burn severity scores. In 
addition to burn size and age, a common component of these scores is the presence of 
inhalation injury. As predicted by the severity scores, inhalation injury was more common in 
non-survivors. This raises the possibility that injured lungs are contributing to the elevated 
circulating pool of microvesicles found post-burn. Both circulating 414 and intra-alveolar 499 
microvesicle levels are elevated in patients with ARDS. Although our sample collection 
methods are not yet optimised, initial analysis of bronchoalveolar lavage fluid (BALF) from 
our burn patients revealed high levels of leukocyte-derived microvesicles (see appendix). 
Conversely, circulating microvesicles may also contribute to secondary lung damage, even in 
the absence of direct inhalation injury. Endothelial cell-derived microvesicles, for example, 
have been shown to induce pulmonary oedema and neutrophil recruitment in mice 500. The 
lungs may therefore be an excellent candidate for studying the role of microvesicles in the 
development of remote organ inflammation and dysfunction post-burn injury. 
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6.3 In vitro assessment of microvesicle production and activity 
 
We set out to develop assays to evaluate the activity of microvesicles derived from burn 
patients and from cell-based in vitro models of thermal injury. In our preliminary 
investigations of neutrophil microvesicles, we found that a static culture environment 
appeared to inhibit microvesicle release. In common with our other in vitro experiments, 
this was an artificial environment and may not reflect in vivo processes. However, a possible 
explanation is that a negative autocrine feedback mechanism exists, whereby local 
accumulation of mediators released from neutrophils under static conditions prevents 
microvesicle release. We do not yet know if this is a generic mechanism applicable to all 
cells. If a local signalling cascade exists that is specific to neutrophils, it might be exploitable 
pharmacologically. Our finding that neutrophil microvesicle release was enhanced by 
opsonised heat-killed cells was novel but in isolation, does not provide evidence that 
complement activation is the dominant stimulating factor in vivo. However, the results are 
noteworthy given that burn and trauma-induced complement activation is an established 
process 262–265. The complement system may mediate the direct interaction of pathogens 
and neutrophil microvesicles, as ectosomes released by human neutrophils at sites of 
inflammation express clusters of complement receptor 1 469. 
 
The second aspect of our in vitro studies was to investigate the activity of the microvesicles 
we had identified in burn patients, to establish if a role in endothelial dysfunction was 
plausible. Having demonstrated pulmonary endothelial activation by neutrophil- and skin-
derived microvesicles, we were surprised to discover a small but significant inhibitory effect 
of platelet-poor plasma derived from burn patients. The loss of a major fraction of plasma 
microvesicles by centrifugation is a concern and needs to be addressed in the future. 
However, if this inhibitory effect can be conclusively attributed to circulating microvesicles, 
it would be an important finding, considering the prevalence of immunosuppression in 
these patients. Although we have demonstrated an association between mortality and 
leukocyte-derived microvesicle levels, we have no evidence for causation as yet. These pilot 
investigations raise the possibility that microvesicles may contribute to the inappropriate 
dampening of the innate immune response , a feature of severe burn injury 279.  
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6.4 Concluding remarks 
 
The classical paradigm of intercellular communication is based on direct cell-cell contact and 
the secretion of paracrine molecules. Over the past few years, the importance of sub-
cellular vesicle exchange has become increasingly recognised 501. It may even be the case 
that a significant proportion of “soluble” molecules measured in fluids are in fact vesicle-
bound 334. Ours is the first study to demonstrate acute increases in the level of circulating 
microvesicles following thermal injury. Moreover, leukocyte-derived microvesicles were 
found to be predictive of mortality, suggesting they may have prognostic utility.  
 
The precise role of these microvesicles in mediating the post-burn inflammatory response 
remains to be elucidated. Our initial studies have provided conflicting evidence but it is 
possible that the net effect of neutrophil-derived microvesicles, the most numerous sub-
population post-burn, is to modulate the inflammatory response 502. It seems likely that 
significant heterogeneity exists even within microvesicle subtypes, with their activity also 
varying according to target cell phenotype. 
 
Our priorities for future work are as follows: 
 
1) Assess the activity of microvesicles derived from monocytes, platelets and 
endothelial cells, alone or in combination, on the endothelial-PBMC co-culture 
model 
2) Compare these actions to those of specific microvesicle populations, isolated from 
burn patient samples 
3) Increase our burn patient cohort and expand our investigations to include patients 
with inflammation secondary to major trauma 
4) Investigate longitudinal microvesicle release in burn patients, particularly in the 
context of supervening sepsis, to assess potential diagnostic utility 
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Consent Form for Volunteers 
 
Title of Project:  
 
Pilot study to evaluate gas and fluid-phase biomarkers of inflammation and oxidative stress in patients with burn 
injuries 
 
Study Identification: 
 
Initials: 
 
 
 
Participant Declaration (please INITIAL all boxes which apply) 
 
I have been given the chance to read and understand the 
information sheet relating to the above study   
 
I have been given the opportunity to ask questions and discuss 
the study                                       
 
I have been made aware of the risks/ benefits 
 
I understand that relevant sections of any data collected during 
the study may be looked at by individuals from regulatory 
authorities and/or Chelsea and Westminster Hospital NHS 
Foundation Trust/Queen Victoria Hospital NHS Foundation 
Trust/The Royal Marsden NHS Foundation Trust, where it is 
relevant to my taking part in this research. I give permission for 
these individuals to have access to my records. 
 
I agree to the storage of my samples for future use in ethically 
approved research projects 
 
I understand that I am free to withdraw from this study at any 
time 
 
 
 
Participant  
 
“I agree to take part in the above study”. 
 
Name:      Signature: 
 
Date: 
 
 
Person responsible for obtaining Informed Consent 
 
“To the best of my knowledge I have provided the above individual with sufficient information to enable them to give 
informed consent”. 
 
Name:      Signature: 
 
Date:      Position: 
 
 
Witnessed by 
 
Name:      Signature: 
 
Date:      Position 
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Chelsea & Westminster Hospital NHS Foundation Trust 
369 Fulham Road, London, SW10 9NH 
 
Queen Victoria Hospital NHS Foundation Trust 
Holtye Road, East Grinstead, RH19 3DZ 
 
The Royal Marsden NHS Foundation Trust 
Fulham Rd, London, SW3 6JJ 
 
 
VOLUNTEER INFORMATION SHEET 
 
 
08th October 2014 
Version 3.0 
 
STUDY TITLE 
 
Pilot study to evaluate gas and fluid-phase biomarkers of inflammation and oxidative 
stress in patients with burn injuries 
 
INVESTIGATORS 
 
Dr Suveer Singh, Dr Nandor Marczin, Dr John Porter, Dr Julian Giles, Dr Vimal Grover. 
 
WHAT IS THIS ALL ABOUT? 
 
Introduction 
 
This participant information sheet gives some information about a research study being 
carried out at Chelsea and Westminster Hospital, Queen Victoria Hospital and The Royal 
Marsden Hospital. It includes details on the type of information being collected and the aims 
of the study. If there is anything that you do not understand, or if you require information 
concerning this study, please ask the research staff for further information. 
 
Invitation 
 
You are being invited to take part in a research study. Before you decide whether or not to 
take part it is important for you to understand why the research is being done and what it 
will involve. Please take time to read the following information carefully and discuss it with 
friends and relatives. Ask us if there is anything that is not clear or if you would like more 
information.  
 
Thank you for taking the time to read this form. 
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WHY ARE WE DOING THIS? 
 
Purpose of the study 
 
The main aim of this study is to measure specific gases, cells and proteins in the breath and 
biological fluids of patients with burn injuries. The information obtained will be compared 
with findings from other patient groups. 
  
Explanation of project 
 
Patients with burn injuries will develop inflammation at the site of their injury. If the burn 
injury is severe enough, this inflammation may spread to other sites in the body. In some 
patients this can affect how well organs work, for example the lungs or the kidneys. This is 
why some patients need to be looked after in the Burns Intensive Care Unit. Such 
inflammation affects the levels of cells and proteins in various body fluids, such as blood and 
lung fluid. It can also affect the production of certain gases, which can be detected in 
exhaled breath. Collectively, these are known as ‘biomarkers’. Studies have identified that 
biomarkers may prove useful in the diagnosis and treatment certain conditions. To date, 
there has only been limited research to look at these biomarkers in patients with burn 
injuries. We aim to study a number of biomarkers and compare them to the overall 
condition of patients. In particular, we are interested in the gases that may be produced as 
very little is known about this aspect. In the future, the information we obtain might be 
useful for guiding patients’ treatment. 
 
Study Design 
 
We plan to conduct this study over four years from 2012 to 2016. We wish to study seven 
groups of participants and we aim to recruit a total of 200 participants to our study. 
 
The first group of patients will be patients with burn injuries, in whom we will measure lung, 
blood and urine levels of our biomarkers. 
 
The second group will be patients who have injuries to their lungs, as a result of breathing in 
smoke. 
 
The third group of will be patients who have developed a severe infection, such that they 
need to be cared for in the General Intensive Care Unit. 
 
The fourth group will be patients in the Intensive Care Unit undergoing bronchoscopy for a 
suspected chest infection 
 
The fifth group will be patients with low levels of white blood cells, who have developed a 
severe infection 
 
The sixth group will be patients undergoing outpatient bronchoscopy. 
 
The final group will be healthy volunteers. 
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WHY HAVE I BEEN CHOSEN? 
 
You have been chosen as you are a healthy volunteer. 
WHAT HAPPENS IF I TAKE PART? 
 
Procedures undertaken, side effects and possible risks  
 
1. Blood sampling 
This is performed routinely in management of severe burns, smoke inhalation, and severe 
infection.  
 
We will take blood samples from a vein in your hand or arm, up to a total of 30mls. To 
reduce the risk of infection or contamination of the samples, the skin will be thoroughly 
cleaned with antiseptic. To minimize any discomfort while performing this procedure, local 
anaesthetic can be applied to the skin before inserting a needle into the vein to draw blood. 
There is a slight risk of bruising which will subside soon. 
 
2. Breath analysis 
This is performed by one of two devices. The first is connected via plastic tubing to the 
breathing machine that supports you during surgery or while you are in intensive care. It is 
very similar to a device that we use routinely in these situations. The second uses small 
containers that store condensed fluid from the breathing machine. If you do not require 
support in intensive care or are not undergoing surgery, you will be required to blow into a 
simple mouthpiece. Your breath can then be analysed. Breath testing is very safe. We will 
perform breath testing twice but may repeat this if you become more unwell. 
 
3. Urine collection 
Most patients that we will be studying will require a urinary catheter at some point. This 
drains the bladder continuously and samples can be taken from this tube. If you do not 
require a urinary catheter as part of your standard treatment, we may ask you to provide a 
urine sample into a simple container. This non-invasive procedure is performed frequently 
as part of many medical tests. 
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Confidentiality 
 
After obtaining the samples from you, they will be anonymised by giving them encoded 
reference number. This will be linked to your details only in a secured file which is kept 
separate from your medical notes. All other personal data that identifies you with the 
sample will be discarded. 
 
Use of samples 
 
We will take samples to laboratory and we will measure levels of our biomarkers in the 
sample. The results of the study will be submitted for publication in scientific journals, and 
they can be made available to you, if you wish to know at the end of the study.  
 
If you decide to withdraw from the study after the procedure, and before submission of 
data for publication in scientific journals, we will discard those samples and data derived 
from them. 
 
All samples will be stored at the end of the study for a period of three years. 
 
Participation in the study 
 
Finally, we would like to thank you for your interest in the study, even if you have decided 
not to take part.  There is no pressure on you to participate and if you agree to participate 
you are free to withdraw at any stage without having to provide any reason. There will be 
no direct benefits to you for taking part in this study. It may allow us to establish the role of 
biomarkers in the early diagnosis of the source of infection in the future and help patients in 
similar circumstances. If you do decide to take part in the study all information relating to 
the study will be kept confidentially and you will not be identifiable in any reports of the 
study. 
 
If you have any questions or concerns following your participation in the study please do not 
hesitate to contact the research team: 
 
Dr John Porter (Tel: 020 8746 8518), Clinical Research Fellow, Chelsea & Westminster 
Hospital, 369 Fulham Road, London, SW10 9NH. 
 
Dr Suveer Singh (Tel: 020 8746 8472), Consultant Physician in Respiratory and Intensive Care 
Medicine, Chelsea & Westminster Hospital, 369 Fulham Road, London, SW10 9NH. 
 
Dr Julian Giles (Tel: 01342 414000), Consultant Anaesthetist, Queen Victoria Hospital, Holtye 
Road, East Grinstead, RH19 3DZ. 
 
Dr Vimal Grover (Tel: 020 7352 8171), Consultant Anaesthetist and Intensivist, The Royal 
Marsden Hospital, Fulham Road, London, SW3 6JJ. 
 
Thank you very much for helping with this project. 
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Consent Form for Patients 
 
Title of Project:  
 
Pilot study to evaluate gas and fluid-phase biomarkers of inflammation and oxidative stress in patients with burn 
injuries 
 
Patient Hospital Number:   Patient Study Identification: 
 
Patient Initials: 
 
 
 
Participant Declaration (please INITIAL all boxes which apply) 
 
I have been given the chance to read and understand the 
information sheet relating to the above study   
 
I have been given the opportunity to ask questions and discuss 
the study                                       
 
I have been made aware of the risks/ benefits 
 
I understand that relevant sections of any of my medical notes 
and data collected during the study may be looked at by 
individuals from regulatory authorities and/or Chelsea and 
Westminster Hospital NHS Foundation Trust/Queen Victoria 
Hospital NHS Foundation Trust/The Royal Marsden NHS 
Foundation Trust, where it is relevant to my taking part in this 
research. I give permission for these individuals to have access to 
my records. 
 
I agree to the storage of my samples for future use in ethically 
approved research projects 
 
I understand that I am free to withdraw from this study at any 
time without prejudice to my future care/ treatment 
 
 
Participant  
 
“I agree to take part in the above study”. 
 
Name:      Signature: 
 
Date: 
 
 
Person responsible for obtaining Informed Consent 
 
“To the best of my knowledge I have provided the above individual with sufficient information to enable them to give 
informed consent”. 
 
Name:      Signature: 
 
Date:      Position: 
 
 
Witnessed by 
 
Name:      Signature: 
 
Date:      Position 
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Chelsea & Westminster Hospital NHS Foundation Trust 
369 Fulham Road, London, SW10 9NH 
 
Queen Victoria Hospital NHS Foundation Trust 
Holtye Road, East Grinstead, RH19 3DZ 
 
The Royal Marsden NHS Foundation Trust 
Fulham Rd, London, SW3 6JJ 
 
 
PATIENT INFORMATION SHEET 
 
 
08th October 2014 
Version 5.0 
 
STUDY TITLE 
 
Pilot study to evaluate gas and fluid-phase biomarkers of inflammation and oxidative 
stress in patients with burn injuries 
 
INVESTIGATORS 
 
Dr Suveer Singh, Dr Nandor Marczin, Dr John Porter, Dr Julian Giles, Dr Vimal Grover. 
 
WHAT IS THIS ALL ABOUT? 
 
Introduction 
 
This participant information sheet gives some information about a research study being 
carried out at Chelsea and Westminster Hospital, Queen Victoria Hospital and The Royal 
Marsden Hospital. It includes details on the type of information being collected and the aims 
of the study. If there is anything that you do not understand, or if you require information 
concerning this study, please ask the research staff for further information. 
 
Invitation 
 
You are being invited to take part in a research study. Before you decide whether or not to 
take part it is important for you to understand why the research is being done and what it 
will involve. Please take time to read the following information carefully and discuss it with 
friends and relatives. Ask us if there is anything that is not clear or if you would like more 
information.  
 
Thank you for taking the time to read this form. 
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WHY ARE WE DOING THIS? 
 
Purpose of the study 
 
The main aim of this study is to measure specific gases, cells and proteins in the breath and 
biological fluids of patients with burn injuries. The information obtained will be compared 
with findings from other patient groups. 
  
Explanation of project 
 
Patients with burn injuries will develop inflammation at the site of their injury. If the burn 
injury is severe enough, this inflammation may spread to other sites in the body. In some 
patients this can affect how well organs work, for example the lungs or the kidneys. This is 
why some patients need to be looked after in the Burns Intensive Care Unit. Such 
inflammation affects the levels of cells and proteins in various body fluids, such as blood and 
lung fluid. It can also affect the production of certain gases, which can be detected in 
exhaled breath. Collectively, these are known as ‘biomarkers’. Studies have identified that 
biomarkers may prove useful in the diagnosis and treatment certain conditions. To date, 
there has only been limited research to look at these biomarkers in patients with burn 
injuries. We aim to study a number of biomarkers and compare them to the overall 
condition of patients. In particular, we are interested in the gases that may be produced as 
very little is known about this aspect. In the future, the information we obtain might be 
useful for guiding patients’ treatment. 
 
Study Design 
 
We plan to conduct this study over four years from 2012 to 2016. We wish to study seven 
groups of participants and we aim to recruit a total of 200 participants to our study. 
 
The first group of patients will be patients with burn injuries, in whom we will measure lung, 
blood and urine levels of our biomarkers. 
 
The second group will be patients who have injuries to their lungs, as a result of breathing in 
smoke. 
 
The third group of will be patients who have developed a severe infection, such that they 
need to be cared for in the General Intensive Care Unit. 
 
The fourth group will be patients in the Intensive Care Unit undergoing bronchoscopy for a 
suspected chest infection 
 
The fifth group will be patients with low levels of white blood cells, who have developed a 
severe infection 
 
The sixth group will be patients undergoing outpatient bronchoscopy. 
 
The final group will be healthy volunteers. 
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WHY HAVE I BEEN CHOSEN? 
 
You have been chosen as you are in the category of participants who:  
 
....................................................................................................................................... 
WHAT HAPPENS IF I TAKE PART? 
 
Procedures undertaken, side effects and possible risks  
 
1. Blood sampling 
This is performed routinely in the management of severe burns, smoke inhalation and severe 
infection. 
 
We will take blood samples from a vein in your hand or arm. At the same time we will 
remove a further 10-20mls of blood (equivalent to a tablespoon) for the purposes of our 
study. To reduce the risk of infection or contamination of the samples, the skin will be 
thoroughly cleaned with antiseptic. To minimize any discomfort while performing this 
procedure, local anaesthetic can be applied to the skin before inserting a needle into the 
vein to draw blood. There is a slight risk of bruising which will subside soon. We will take 1 
sample soon after you have been admitted and 1 further sample if you become more 
unwell. 
 
2. Breath analysis 
This is performed by one of two devices. The first is connected via plastic tubing to the 
breathing machine that supports you during surgery or while you are in intensive care. It is 
very similar to a device that we use routinely in these situations. The second uses small 
containers that store condensed fluid from the breathing machine. If you do not require 
support in intensive care or are not undergoing surgery, you will be required to blow into a 
simple mouthpiece. Your breath can then be analysed. Breath testing is very safe. We will 
perform breath testing twice but may repeat this if you become more unwell. 
 
3. Urine collection 
Most patients that we will be studying will require a urinary catheter at some point. This 
drains the bladder continuously and samples can be taken from this tube. If you do not 
require a urinary catheter as part of your standard treatment, we may ask you to provide a 
urine sample into a simple container. This non-invasive procedure is performed frequently 
as part of many medical tests. We will take 1 sample soon after you have been admitted and 
1 further sample if you become more unwell. 
 
4. Bronchoscopy 
This is performed routinely for patients suffering from severe smoke inhalation, in some 
patients with infections and in the bronchoscopy clinic. 
 
Patients who have inhaled smoke may need support from a breathing machine. Once the 
patient is asleep, a breathing tube is inserted via the mouth or nose. It is often necessary to 
look inside the lungs with a small camera (bronchoscope), inserted through the breathing 
tube. This is to look for signs of infection or objects blocking the lungs and if necessary to 
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wash the lungs out. Other patients undergo bronchoscopy for diagnosis or treatment in the 
outpatient clinic. We send some of the fluid collected for laboratory analysis. As part of our 
study, we would also send some fluid for biomarker analysis. It is not a painful procedure 
but it can cause coughing so we give drugs to minimise this. There is a risk of patients 
requiring more oxygen for a period after this procedure. For this reason, we will not perform 
it if you are requiring a very high amount of oxygen or high levels of support from the 
breathing machine. Bronchoscopy will only be performed if necessary for your treatment. 
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Confidentiality 
 
After obtaining the samples from you, they will be anonymised by giving them encoded 
reference number. This will be linked to your details only in a secured file which is kept 
separate from your medical notes. All other personal data that identifies you with the 
sample will be discarded. 
 
Use of samples 
 
We will take samples to laboratory and we will measure levels of our biomarkers in the 
sample. The results obtained will be without significance for you personally; i.e. they will not 
guide your care in hospital. The medical team responsible for you will use existing proven 
tests and treatments to manage your condition in line with existing protocols. The results of 
the study will be submitted for publication in scientific journals, and they can be made 
available to you, if you wish to know at the end of the study. If you decide to withdraw from 
the study after the procedure, and before submission of data for publication in scientific 
journals, we will discard those samples and data derived from them. All samples will be 
stored at the end of the study for a period of three years. 
 
Participation in the study 
 
Finally, we would like to thank you for your interest in the study, even if you have decided 
not to take part.  There is no pressure on you to participate and if you agree to participate 
you are free to withdraw at any stage without having to provide any reason. Whatever your 
decision it will not affect in any way the treatment you may be receiving at this hospital. 
There will be no direct benefits to you for taking part in this study. It may allow us to 
establish the role of biomarkers in the early diagnosis of the source of infection in the future 
and help patients in similar circumstances. If you do decide to take part in the study all 
information relating to the study will be kept confidentially and you will not be identifiable 
in any reports of the study. 
 
If you have any questions or concerns following your participation in the study please do not 
hesitate to contact the research team: 
 
Dr John Porter (Tel: 020 8746 58518), Clinical Research Fellow, Chelsea & Westminster 
Hospital, 369 Fulham Road, London, SW10 9NH. 
 
Dr Suveer Singh (Tel: 020 8746 8472), Consultant Physician in Respiratory and Intensive Care 
Medicine, Chelsea & Westminster Hospital, 369 Fulham Road, London, SW10 9NH. 
 
Dr Julian Giles (Tel: 01342 414000), Consultant Anaesthetist, Queen Victoria Hospital, Holtye 
Road, East Grinstead, RH19 3DZ. 
 
Dr Vimal Grover (Tel: 020 7352 8171), Consultant Anaesthetist and Intensivist, The Royal 
Marsden Hospital, Fulham Road, London, SW3 6JJ. 
 
Thank you very much for helping with this project.  
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Consultee Declaration Form 
 
Title of Project:  
 
Pilot study to evaluate gas and fluid-phase biomarkers of inflammation and oxidative stress in patients with burn 
injuries 
 
Patient Hospital Number:   Patient Study Identification: 
 
 
Consultee Declaration (please INITIAL all boxes which apply) 
 
I have been consulted about my relative/patient I represent 
participating in this research and have been given the chance to 
read and understand the information sheet relating to the above 
study   
I have been given the opportunity to ask questions and 
understand what is involved                                       
 
In my opinion he/she would have no objection to taking part 
 
I understand that relevant sections of any of his/her medical 
notes and data collected during the study may be looked at by 
individuals from regulatory authorities and/or Chelsea and 
Westminster Hospital NHS Foundation Trust/Queen Victoria 
Hospital NHS Foundation Trust/The Royal Marsden NHS 
Foundation Trust, where it is relevant to him/her taking part in 
this research. I give permission for these individuals to have 
access to his/her records 
 
I understand that I can request that he/she is withdrawn from 
the study at any time without giving a reason without his/her 
legal rights or future care/treatment being affected 
 
I agree to the storage and future use of his/her samples for 
future use in ethically approved research projects 
  
 
Relative/representative 
 
Name:      Signature: 
 
Date:      Relationship: 
 
 
Person responsible for obtaining assent 
 
“To the best of my knowledge I have provided the above individual with sufficient information to enable them to give 
informed assent”. 
 
Name:      Signature: 
 
Date:      Position: 
 
 
Witnessed by 
 
Name:      Signature: 
 
Date:      Position: 
  
231 
 
Chelsea & Westminster Hospital NHS Foundation Trust 
369 Fulham Road, London, SW10 9NH 
 
Queen Victoria Hospital NHS Foundation Trust 
Holtye Road, East Grinstead, RH19 3DZ 
 
The Royal Marsden NHS Foundation Trust 
Fulham Rd, London, SW3 6JJ 
 
 
RELATIVE/REPRESENTATIVE INFORMATION SHEET 
 
 
08th October 2014 
Version 4.0 
 
STUDY TITLE 
 
Pilot study to evaluate gas and fluid-phase biomarkers of inflammation and oxidative 
stress in patients with burn injuries 
 
INVESTIGATORS 
 
Dr Suveer Singh, Dr Nandor Marczin, Dr John Porter, Dr Julian Giles, Dr Vimal Grover. 
 
WHAT IS THIS ALL ABOUT? 
 
Introduction 
 
This participant information sheet gives some information about a research study being 
carried out at Chelsea and Westminster Hospital, Queen Victoria Hospital and The Royal 
Marsden Hospital. It includes details on the type of information being collected and the aims 
of the study. If there is anything that you do not understand, or if you require information 
concerning this study, please ask the research staff for further information.  
 
Invitation 
 
Your relative/patient you represent is being invited to take part in a research study. Before 
you decide whether or not you are happy for them to take part it is important for you to 
understand why the research is being done and what it will involve. Please take time to read 
the following information carefully and discuss it with friends and relatives. Ask us if there is 
anything that is not clear or if you would like more information.  
 
Thank you for taking the time to read this form. 
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WHY ARE WE DOING THIS? 
 
Purpose of the study 
 
The main aim of this study is to measure specific gases, cells and proteins in the breath and 
biological fluids of patients with burn injuries. The information obtained will be compared 
with findings from other patient groups. 
 
Explanation of project 
 
Patients with burn injuries will develop inflammation at the site of their injury. If the burn 
injury is severe enough, this inflammation may spread to other sites in the body. In some 
patients this can affect how well organs work, for example the lungs or the kidneys. This is 
why some patients need to be looked after in the Burns Intensive Care Unit. Such 
inflammation affects the levels of cells and proteins in various body fluids, such as blood and 
lung fluid. It can also affect the production of certain gases, which can be detected in 
exhaled breath. Collectively, these are known as ‘biomarkers’. Studies have identified that 
biomarkers may prove useful in the diagnosis and treatment certain conditions. To date, 
there has only been limited research to look at these biomarkers in patients with burn 
injuries. We aim to study a number of biomarkers and compare them to the overall severity 
of patients’ condition. In particular, we are interested in the gases that may be produced as 
very little is known about this aspect. In the future, the information we obtain might be 
useful for guiding patients’ treatment. 
 
Study Design 
 
We plan to conduct this study over four years from 2012 to 2016. We wish to study seven 
groups of participants and we aim to recruit a total of 200 participants to our study. 
 
The first group of patients will be patients with burn injuries, in whom we will measure lung, 
blood and urine levels of our biomarkers. 
 
The second group will be patients who have injuries to their lungs, as a result of breathing in 
smoke. 
 
The third group of will be patients who have developed a severe infection, such that they 
need to be cared for in the General Intensive Care Unit. 
 
The fourth group will be patients in the Intensive Care Unit undergoing bronchoscopy for a 
suspected chest infection 
 
The fifth group will be patients with low levels of white blood cells, who have developed a 
severe infection 
 
The sixth group will be patients undergoing outpatient bronchoscopy. 
 
The final group will be healthy volunteers. 
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WHY HAS MY RELATIVE/PATIENT I REPRESENT BEEN CHOSEN? 
 
They have been chosen as they are in the category of participants who:  
 
....................................................................................................................................... 
WHAT HAPPENS IF I AGREE FOR MY RELATIVE/PATIENT I REPRESENT TO TAKE PART? 
 
Procedures undertaken, side effects and possible risks  
 
1. Blood sampling 
This is performed routinely in management of severe burns, smoke inhalation, severe 
infection and before weight-loss surgery.  
 
We will take blood samples from a vein. At the same time we will remove a further 6-10mls 
of blood (equivalent to a tablespoon) for the purposes of our study. To reduce the risk of 
infection or contamination of the samples, the skin will be thoroughly cleaned with 
antiseptic. To minimize any discomfort while performing this procedure, local anaesthetic 
can be applied to the skin before inserting a needle into the vein to draw blood. There is a 
slight risk of bruising which will subside soon. We will take 1 sample soon after admission 
and 1 further sample if your relative/patient you represent becomes more unwell. 
 
2. Breath analysis 
This is performed by one of two devices. The first is connected via plastic tubing to the 
breathing machine that supports patients during surgery or while they are in intensive care. 
It is very similar to a device that we use routinely in these situations. The second uses small 
containers that store condensed fluid from the breathing machine. If your relative does not 
require support in intensive care or is not undergoing surgery, they may be asked to blow 
into a simple mouthpiece. The breath can then be analysed. Breath testing is very safe. We 
will perform breath testing twice but may repeat this if your relative/patient you represent 
becomes more unwell. 
 
3. Urine collection 
Most patients that we will be studying will require a urinary catheter at some point. This 
drains the bladder continuously and samples can be taken from this tube. If your relative 
does not require a urinary catheter as part of their standard treatment, we may ask them to 
provide a urine sample into a simple container. This non-invasive procedure is performed 
frequently as part of many medical tests. We will take 1 sample soon after admission and 1 
further sample if your relative/patient you represent becomes more unwell. 
 
4. Bronchoscopy 
This is performed routinely for patients suffering from severe smoke inhalation and in some 
patients with infections. 
 
Patients who have inhaled smoke may need support from a breathing machine. Once the 
patient is asleep, a breathing tube is inserted via the mouth or nose, or into the front of 
their neck. The breathing machine is connected to this tube. It is often necessary to look 
inside the lungs with a small camera (bronchoscope), inserted through the breathing tube. 
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This is to look for signs of infection or objects blocking the lungs and if necessary wash the 
lungs out. We send some of the fluid collected for laboratory analysis. As part of our study, 
we would also send some fluid for biomarker analysis. It is not a painful procedure but it can 
cause coughing so we give sedative drugs to minimise this. There is a risk of patients 
requiring more oxygen for a period after this procedure. For this reason, we will not perform 
it if your relative is requiring a very high amount of oxygen or high levels of support from the 
breathing machine. Bronchoscopy will only be performed if necessary for treatment. 
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Confidentiality 
 
After obtaining the samples, they will be anonymised by giving them an encoded reference 
number. This will be linked to your relative’s details only in a secured file which is kept 
separate from the medical notes.  All names and personal data that identify your relative 
with the sample will be discarded. 
 
Use of samples 
 
We will take samples to laboratory and we will measure levels of our biomarkers in the 
sample. The results obtained will be without significance for your relative personally; i.e. 
they will not guide their care in hospital. The medical team responsible for your relative will 
use proven tests and treatments in line with existing protocols. The results of the study will 
be submitted for publication in scientific journals, and they can be made available to you or 
your relative, if you wish to know at the end of the study. If you decide to withdraw from 
the study after the procedure, and before submission of data for publication in scientific 
journals, we will discard those samples and data derived from them. All samples will be 
stored at the end of the study for a period of three years. 
 
Participation in the study 
 
Finally, we would like to thank you for your interest in the study, even if you have decided 
not to agree for your relative/patient to take part.  There is no pressure on you to agree to 
participation and if you do agree you are free to change your mind at any stage without 
having to provide any reason. Whatever your decision it will not affect in any way the 
treatment your relative may be receiving at this hospital. There will be no direct benefits to 
your relative for taking part in this study. It may allow us to establish the role of biomarkers 
in the early diagnosis of infection in the future and help patients in similar circumstances. If 
you do agree for your relative to take part in the study all information relating to the study 
will be kept confidentially and you will not be identifiable in any reports of the study. 
 
If you have any questions or concerns following your participation in the study please do not 
hesitate to contact the research team: 
 
Dr John Porter (Tel: 020 8746 58518), Clinical Research Fellow, Chelsea & Westminster 
Hospital, 369 Fulham Road, London, SW10 9NH. 
 
Dr Suveer Singh (Tel: 020 8746 8472), Consultant Physician in Respiratory and Intensive Care 
Medicine, Chelsea & Westminster Hospital, 369 Fulham Road, London, SW10 9NH. 
 
Dr Julian Giles (Tel: 01342 414000), Consultant Anaesthetist, Queen Victoria Hospital, Holtye 
Road, East Grinstead, RH19 3DZ. 
 
Dr Vimal Grover (Tel: 020 7352 8171), Consultant Anaesthetist and Intensivist, The Royal 
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7.2 Permissions 
 
Figure 3.1  - “Schematic of typical flow cytometer” (chapter 3) 
From: Alina Foo 
Sent: 09 October 2015 22:16 
To: Porter, John RS R S 
Cc: Permissions 
Subject: RE: Permission for image use 
 
Dear Dr. Porter, 
 
Thank you for requesting permission. 
 
Please accept this email as your authorization to use the material as described in your 
correspondence below, and be sure to include a complete citation to the original source: 
 
Michael Brown and Carl Wittwer. Flow Cytometry: Principles and Clinical Applications in 
Hematology. Clinical Chemistry 2000; v. 46, p.1221-1229. (Reproduced with permission from 
the American Association for Clinical Chemistry). 
 
Kind regards, 
Alina 
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7.3 Microvesicles in bronchoalveolar lavage fluid sampled following inhalation injury 
 
A 
 
B 
 
 
Figure 7.1 Pilot analysis of leukocyte-derived microvesicles in bronchoalveolar lavage 
fluid (BALF) sampled from patient invasively ventilated following inhalation 
injury 
Detergent-sensitive leukocyte-derived (A) and neutrophil-derived (B) 
microvesicle populations are indicated by red boxes  
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7.4 Complement activation in response to heat treatment of kidney epithelial cells 
 
 
 
 
Figure 7.2 Analysis of complement activation following heat treatment and 
opsonisation of HK-2 kidney epithelial cells 
Heating HK-2 epithelial cells to 80⁰C prior to incubation with human serum 
leads to increased complement activation on cell surface, as demonstrated by 
increased levels of complement C3c, a stable C3-conversion product 
 
